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ABSTRACT 
Background. Many patients with mental disorders receiving treatment in mental health centres 
are using illicit drugs while a large proportion of those in addiction care programs have 
significant mental health issues. Substance use disorder and major depression are highly 
prevalent in the general population. They frequently co-exist, share common biological, 
psychological and social risk factors and affect one another in clinically significant ways. 
Comorbid substance use disorder and major depression represent a major health problem 
globally. The primary goal of this thesis is to further our understanding of the relationship 
between substance use disorders and co-occurring major depressive disorder by applying 
different epidemiological methods.  
Methods. The study designs used in this thesis were cross-sectional design (Chapters 3,4 and 5), 
population cohort design (Chapter 6) and systematic review with meta-analysis (Chapter7). 
Existing datasets from Statistics Canada were used for Chapters 3,4,5 and 6 while the systematic 
review collected data via a computerized search for original studies. Trend (Chapter 3), 
multilevel logistics regression (Chapter 4), Multinomial logistics regression (Chapter 5), Poisson 
regression (Chapter 6) and meta-analysis (Chapter 7) were done. Descriptive analysis was also 
done for all chapters. 
Results. The pooled prevalence of substance use disorder comorbid with major depression is 
3.2%. The prevalence of comorbid alcohol dependence and major depression increased from 
1996 to 2012 in females, those 30 years and older, who had a household income of less than 
$50,000 and no post-secondary graduate level education. Individuals with substance dependence 
and cannabis dependence were about three times (pooled OR (95%CI): 3.62 (95%CI 2.82-4.63)) 
and five times (pooled OR (95%CI): 5.77 (95%CI 3.8-8.77)) more likely to have comorbid major 
depression. Alcohol dependence increased the risk of persistent or recurrent major depression by 
three-fold. Comorbid substance use disorder with major depression was significantly associated 
with increased disability and suicide ideation. 
Conclusion. Given the significant overlap in comorbid substance use disorder and major 
depression, it is crucial that co-occurring disorders are managed proactively and concurrently. 
The consensus of research evidence and clinical expertise is that the treatment of comorbid 
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substance use and mental health disorders is insufficient if they are solely psychiatric focused or 
addiction focused. It is recommended that an integrated treatment approach should be adopted.  
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CHAPTER 1. INTRODUCTION 
 The nature and burden of substance use disorder and mental health 
disorders 
The Diagnostic and Statistical Manual of Mental Disorders (DSM-5), defines Substance 
Use Disorders (SUD) as “a problematic pattern of using alcohol or another substance that results 
in impairment in daily life or noticeable distress” (American Psychiatric Association, 2013). It 
refers to a habitual pattern of illicit drug or alcohol use that results in substantial problems in 
various facets of one’s life such as employment, family, financial, and physical well-being 
(Drake, Mueser, Clark, & Wallach, 1996; Substance Abuse and Mental Health Services 
Administration (US), 2016; United Nations Office on Drugs and Crime (UNODC), 2016). 
Substance use disorders may involve any number of substances such as alcohol, cannabis, 
hallucinogens, tobacco, inhalants, opioids (e. g. heroin), sedatives, hypnotics, or anxiolytics (e.g. 
valium) and stimulants (cocaine, methamphetamine) (American Psychiatric Association, 2013; 
United Nations Office on Drugs and Crime (UNODC), 2016; World Health Organization, 1992).  
Mental health disorders are illnesses that result in significant distress, behavioral/ 
psychological dysfunction, pain, disability and premature mortality (American Psychiatric 
Association, 2013; Kennedy, Lin, & Schwab, 2002; Druss, Rosenheck, & Sledge, 2000). They 
also have an economic impact in terms of absenteeism, productivity loss, joblessness and health 
costs (Stewart, Ricci, Chee, Hahn, & Morganstein, 2003; Lim, Jacobs, Ohinmaa, Schopflocher, 
& Dewa, 2008; Canadian Substance Use Costs and Harms Scientific Working Group, 2018). 
Mental health disorders result in disproportionate disability, due in part to their early age of 
onset, their chronicity, and that a minority of individuals receive treatment for their conditions 
(Canadian Centre on Substance Abuse, 2009). The single largest group of major psychiatric 
disorders are mood disorders with about 10-25% of women and 5-12% of men globally, 
developing a major depressive disorder, a type of mood disorder at some point in their life 
(Canadian Centre on Substance Abuse, 2009). 
Alcohol use was estimated to be the seventh-leading risk factor in terms of disability-
adjusted life-years (DALYs) in 2016 with an attributable DALYs increase of more than 25% 
between 1990 and 2016 (GBD 2016 Risk Factors Collaborators, 2017). It is the leading risk 
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factor in DALYs between ages 15 years and 49 years globally (GBD 2016 Risk Factors 
Collaborators, 2017). In 2012, 5.1% of the global burden of disease and injury, as measured in 
DALYs and 5.9% of all global deaths were attributable to alcohol abuse (World Health 
Organization, 2014a). In Canada in that same year, the number of persons with substance use 
disorders (6 million) over the course of a lifespan was greater than the number with mood 
disorders (3.5million) (Pearson, Janz, & Ali, 2013). Approximately 18.1% of Canadians met the 
criteria for alcohol abuse or dependence while 6.8% of Canadians identified as cannabis 
consumers in 2012 (Pearson, Janz, & Ali, 2013).1 Of all psychoactive substances under 
international control worldwide, cannabis, which is now legalized in Canada is the most 
commonly used (World Health Organization, 2016; United Nations Office on Drugs and Crime 
(UNODC), 2016). Recreational cannabis was used by approximately 181.8million individuals 
between the ages of 15 and 64 years globally in 2013 (World Health Organization, 2016; United 
Nations Office on Drugs and Crime (UNODC), 2015).  
The nature and extent of the adverse health effects of cannabis use have been under 
debate and perceived to be relatively harmless or benign when compared with other substances 
of abuse (Volkow, Baler, Compton, & Weiss, 2014; Nutt, King, Saulsbury, & Blakemore, 2007; 
Lachenmeier, 2015; George & Vaccarino, 2015). However, evidence have demonstrated the 
adverse effects of cognitive impairment and psychiatric symptoms associated with cannabis use, 
especially high frequency usage and early initiation at a very young age (United Nations Office 
on Drugs and Crime (UNODC), 2016; Lubman, Cheetham, & Yucel, 2015; Meier, et al., 2012; 
Hall, 2015; Hall & Degenhardt, 2009; Hall, 2009). The lower risk found in studies compared to 
other psychoactive substances or alcohol and tobacco does not mean ‘no risk’ because, there is a 
worrying increase in the demand for healthcare services for cannabis use disorders and 
associated health conditions (World Health Organization, 2016; United Nations Office on Drugs 
and Crime (UNODC), 2016).  
                                                 
  1 “Substance abuse refers to the harmful or hazardous use of psychoactive substances (alcohol and illicit 
drugs) while substance dependence is a cluster of behavioural, cognitive, and psychological phenomena 
(difficulties controlling its use or the strong desire to use, persisting in its use despite harmful 
consequences, higher priority given to the drug use than other activities or obligations, increased tolerance, 
physical withdrawal) that develop secondary to repeated use of the substance” (World Health Organization, 
2018). Substance use disorders (alcohol, illicit drugs) refers to substance abuse and /or dependence 
(American Psychiatric Association, 1994).  
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Individuals using substances are more likely to suffer from mood disorders and this 
association usually occurs with the more severe forms of substance use disorders and vice versa 
(Merikangas, et al., 1998; Brière, Rohde, Seeley, & Daniel Klein, 2014; Sullivan, Fiellin, & 
O'Connor, 2005; Clark, Cuthbert, Lewis-Fernandez, Narrow, & Reed, 2017; Canadian Centre on 
Substance Abuse, 2013). In other words, as the severity of either disorder increases, the 
likelihood of the other co-occurring also increases.  
 Comorbid substance use and mental health disorders 
Mental health and substance use disorders occur on a continuum and when they occur 
together, they are called concurrent disorders, multimorbidity, comorbid disorders or dual 
diagnosis (Canadian Centre on Substance Abuse, 2013; Wittchen, Perkonnig, & Reed, 1996; 
Buckley & Brown, 2006). A concurrent disorder emerges when they intersect at any point on the 
continuum, resulting in a near-endless list of possible combinations which vary, depending on 
the type and severity of the mental health problem, the substance of abuse and severity of the 
abuse. The more severe the first disorder is, the more likely it is concurrent with another disorder 
(Canadian Centre on Substance Abuse, 2013; Clark, Cuthbert, Lewis-Fernandez, Narrow, & 
Reed, 2017; Bulloch, Lavorato, Williams, & Patten, 2012).  
A large body of evidence has documented the interconnections and adverse interactions 
between mental disorders and substance use problems (Hasin, et al., 2016; Grant, et al., 2016; 
Compton, Thomas, Stinson, & Grant, 2007; Brière, Rohde, Seeley, & Daniel Klein, 2014; 
Brunette, Mueser, & Drake, 2004; George & Vaccarino, 2015; Buckley & Brown, 2006). It is 
widely recognized that addiction and mental health disorders frequently co-occur. The co-
occurrence of substance use and mental health disorders affect the clinical course of both 
disorders with respect to treatment engagement, thoughts of suicide/attempts, homelessness, 
increased risk of victimization, life expectancy and treatment outcomes (Burns, Teesson, & 
O'Neill, 2005; Burcusa & Iacono, 2007; Canadian Centre on Substance Abuse, 2009; Drake, 
Mueser, Clark, & Wallach, 1996; Spijker, et al., 2004; Boschloo, et al., 2011; Hjorthoj, et al., 
2015; Bottomley, et al., 2010; Buckley & Brown, 2006).  Compared to patients diagnosed with 
single SUD or mental health disorder, patients with co-morbid disorders have a higher risk of 
delayed diagnosis, more severe symptoms, lower compliance with treatment, poorer treatment 
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outcomes, more impairment in social functioning, increased admissions to emergency 
departments, higher prevalence of physical co-morbidity, and suicidal tendencies (Langås, Malt, 
& Opjordsmoen, 2011; Britton, et al., 2015; Borges, Benjet, Orozco, Medina-Mora, & 
Menendez, 2017; Cornelius, et al., 1995; Garcia-Toro, et al., 2013; Bulloch, Lavorato, Williams, 
& Patten, 2012; Canadian Institute for Health Information, 2013; Buckley & Brown, 2006). They 
are more often unemployed, homeless, and involved in violent episodes, or criminal behavior 
(Langås, Malt, & Opjordsmoen, 2011; Willis, Willis, Male, Henderson, & Manderscheid, 1998). 
Why is there a high overlap of substance use and mental health disorders? One theory, the 
“self-medication hypothesis”, postulates that mental health disorders lead to substance use 
disorders due to the misuse of substances to alleviate mental health symptoms. For example, 
individuals with anxiety disorders will turn to substances with depressant or calming effects to 
self-medicate their anxiety (MacDonald, Baker, Stewart, & Skinner, 2000; Khantzian, 1985; 
Maremmani, Perugi, Pacini, & Akiskal, 2006). A second theory suggests that the use of 
substances leads to the development of mental health disorders (Kushner, Abrams, & Borchardt, 
2000; American Psychiatric Association, 2000). In addition, repeated withdrawal from 
substances may trigger the development or worsening of a mental health disorder (Schuckit & 
Hesselbrock, 1994; Zvolensky, Bernstein, Yartz, McLeish, & Feldner, 2008). Another 
mechanism that might explain the overlap between substance use disorders and mental health 
disorders is the presence of an overlapping predisposition, that is, a common vulnerability 
involving genetic and /or environmental factors (Goldman, Orozi, & Ducci, 2005; Kendler, 
Prescott, Myers, & Neale, 2003; Li & Burmeister, 2009; Agrawal & Lynskey, 2014; Edvardsen, 
et al., 2008; Agrawal & Lynskey, 2008). Irrespective of the pathway that led to the comorbid 
state, once an individual has developed both, a vicious cycle may be at play where each disorder 
maintains or exacerbates the other (Canadian Centre on Substance Abuse, 2009; Stewart & 
Conrod, 2008; Stewart & Conrod, 2008b). 
This co-morbidity represents a complex interaction of genetic, biochemical, cognitive-
behavioural and environmental factors which while appearing homogenous in clinical 
presentations are often heterogeneous in etiology (Swendson & Merikangas, 2000). 
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 The burden of comorbid substance use and mental health disorder 
Evidence suggests that about 50% of individuals seeking help for addiction also have a 
mental illness while 15-20% of those seeking help for mental illness have a substance use 
disorder (Canadian Centre on Substance Abuse, 2009; RachBeisel, Scott, & Dixon, 1999; 
Canadian Institute for Health Information, 2012). Mental and Substance Use (MSU) disorders 
are primary causes of disability globally, associated with significant health, economic and social 
costs, and when left untreated these disorders can result in premature death (GBD 2016 Disease 
and Injury Incidence and Prevalence Collaborators, 2017; Hjorthoj, et al., 2015; Borges, Benjet, 
Orozco, Medina-Mora, & Menendez, 2017; Flensborg-Madsen, et al., 2009; Canadian Institute 
for Health Information, 2013). The Global Burden of Disease (GBD) study (2016) highlighted 
that the disability-adjusted life-years (DALYs) attributable to MSU disorders rose by about 47% 
between 1990 and 2016, and 12% between 2006 and 2016 (GBD 2016 DALYs and HALE 
Collaborators, 2017). The MSU were responsible for 7.4% of global DALYs and 22.9% of 
global years lived with disability (YLD) in 2010, making them the leading cause of YLDs and 
the fifth leading cause of DALYs at the time (Whiteford, et al., 2013). In 2016, across the 
lifespan and among both sexes, MSU disorders were consistently shown to be leading causes of 
YLDs worldwide (GBD 2016 DALYs and HALE Collaborators, 2017).  
Comorbid substance use and mental health disorders represent a major health problem in 
Canada. In Canada, mental health disorders account for 43% of disability and 22% of the total 
burden of disease (sum of years lived with disability and premature death) and having more than 
one disorder results in greater disability (Canadian Centre on Substance Abuse, 2009). A study 
using the Canadian Community Health Survey on Mental Health and Well Being, found that 
individuals with major depression in the previous 12 months were more likely to report 
concurrent harmful alcohol use (12.3% compared to 7% in the general population), alcohol 
dependence (5.8% compared to 2.6% in the general population), and drug dependence (3.2% 
compared to 0.8% in the general population) (Gravel & Beland, 2005). Conversely, in another 
study, individuals with SUDs in the previous 12 months were more likely to report a concurrent 
major depression - 8.8% among alcohol-dependent individuals and 16.1% in persons dependent 
on an illegal substance compared to 4.0% in the general population (Adlaf, Begin, & Sawka, 
2005). 
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In 2013, The Canadian Institute for Health Information (CIHI) found that Canadians 
15years and older with comorbid SUD and mental illness required more in-patient mental health 
services, had longer length of stays in the hospital and more re-admissions than those with an 
isolated diagnosis of either SUD or psychiatric illness (Canadian Institute for Health 
Information, 2013). The longer length of stays and increased hospital readmissions resulted in 
higher costs for the healthcare system (Canadian Institute for Health Information, 2013; Book, 
McNeil, & Simpson, 2005; Odlaug, et al., 2016; Buckley & Brown, 2006). The high rates of 
comorbid SUD and mental illness and the entanglement with physical illness, homelessness and 
marginalization poses a major challenge to the health care and social welfare systems across the 
country (O’Toole, Pollini, Gray, Bigelow, & Ford, 2007; Kamal, et al., 2007; Boyd & Kerr, 
2016). Inner-city populations, especially individuals injecting drugs, are at an increased risk of 
drug-related harm like HIV infection, Hepatitis C infection, severe bacterial infection and death 
from overdose (Kuyper, Hogg, Montaner, Schechter, & Wood, 2004; United Nations Office on 
Drugs and Crime (UNODC), 2018).  
In British Columbia, an estimated 130,000 persons met the criteria for comorbid substance 
use and mental health disorders (Patterson, Somers, McIntosh, Shiell, & Frankish, 2008). The 
Vancouver’s Downtown Eastside survey by the Vancouver Police Department showed that 50% 
of all emergency calls involved people with either mental illness or SUD demonstrating a 
marked increase in police interaction with mentally ill persons and the resultant draining of 
resources (Canadian Centre on Substance Abuse, 2009; Boyd & Kerr, 2016). The British 
Columbia Adolescent Health Survey of students in Grades 7-12 showed that the presence of 
comorbid mental health and substance use disorders increased the chances of self- harm 
compared to one disorder (McCreary Centre Society, 2012). 
Recognizing the global burden, the World Health Organization’s (WHO) World Health 
Report 2001 recommended the integration of the treatment of mental health and substance use in 
primary care (World Health Organization, 2001; Canadian Centre on Substance Abuse, 2009; 
Marel, et al., 2016; Torrens, Rossi, Martinez-Riera, Martinez-Sanvisens, & Balbuena, 2012; 
Canadian Centre on Substance Abuse, 2013b). Evidence suggests that this integration can 
enhance service delivery and offer support to clients with comorbid substance use and mental 
health disorders (Drake, Mercer-McFadden, Mueser, McHugo, & Bond, 1998; Mills, et al., 2012; 
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Marel, et al., 2016; Kelly & Daley, 2013; Torrens, Rossi, Martinez-Riera, Martinez-Sanvisens, & 
Balbuena, 2012). 
 The context of this research 
Comorbid SUDs and mental health disorders are particularly challenging to address in 
primary health care (Drake, Mueser, Clark, & Wallach, 1996; Britton, et al., 2015; Balkrishnan, 
Joish, Yang, Jayawant, & Mullins, 2008; Glasner-Edwards, et al., 2009; Stewart & O'Connor, 
2009). Over the years, the rates of professional care for mental health disorders and SUDs have 
increased yet unmet needs for care remains and a significant public health concern (Canadian 
Centre on Substance Abuse, 2009; Boyd & Kerr, 2016). 
Mainstream psychiatric and addiction research and scientific trials have largely excluded 
comorbid disorders to avoid “muddying the waters” – the uncertainty surrounding the cause of 
an effect if subjects with both disorders are included in a trial (Canadian Centre on Substance 
Abuse, 2009). Addiction research using animal models focus on a single condition or substance, 
therefore, making application to a more complex clinical condition like concurrent disorders 
difficult. Concurrent disorders are not well understood, and the management provided for them 
may be inappropriate and can be improved (Canadian Centre on Substance Abuse, 2009). 
Co-morbidity research is important because comorbidity has an impact on clinical severity 
and outcome (Swendson & Merikangas, 2000; Buckley & Brown, 2006; Kessler, Chiu, Demler, 
Merikangas, & Walters, 2005). Ineffective management of mental health problems and co-
occurring substance use disorders can lead to impaired self-care, increased morbidity and 
mortality, higher health care expenditure and decreased productivity (Drake, Mueser, Clark, & 
Wallach, 1996; Stewart & O'Connor, 2009; Canadian Institute for Health Information, 2013; 
Canadian Institute for Health Information, 2012). To develop effective interventions with 
possible changes to treatment systems, it is crucial we understand these disorders and their 
overlap (Canadian Centre on Substance Abuse, 2009; Hasin, et al., 2006). 
The primary goal of this thesis research is to further our understanding of the relationship 
between substance use disorders and co-occurring major depression (one of the most prevalent 
mental health disorders) using nationally representative Canadian population samples and by 
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synthesizing existing nationally representative primary research. This research involves the 
application of a variety of epidemiological techniques informing three levels of evidence for 
prevention interventions, program planning, and policy-making. 
This thesis aims to: 
• Demonstrate current trends in comorbid alcohol dependence with major depression in the 
Canadian population 
• Assess the risk of suicide ideation and disability associated with co-morbid substance use 
disorders with major depression in a nationally representative sample of Canadians. 
• Determine the associations between substance use disorders, overweight/obesity and co-
morbid major depressive disorder. 
• Determine the 6-year and 16-year persistence or recurrence of major depression among 
those with concurrent alcohol dependence. 
• Conduct a systematic review and meta-analysis of the existing literature assessing the 
prevalence and strength of association between co-morbid substance use disorders, 
cannabis use disorders with major depression in nationally representative population 
sample surveys. 
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CHAPTER 2. STUDY DESIGNS AND METHODS 
This thesis involves the secondary use of survey data and a review of existing literature. It 
consists of five major studies (see Table 2-1) and a concluding chapter on the overall 
implications for future research direction, program and policy development (Chapter 8). 
2.1  Chapter 3: Time trends in the prevalence of alcohol dependence and 
comorbid major depression in the Canadian population (1996/97-2012) 
Is the frequency of depression, alcohol dependence, and comorbid depression with alcohol 
dependence changing over time or have they remained static? The time trends in the prevalence 
of alcohol dependence, major depression and comorbid alcohol dependence with major 
depression were assessed in this chapter using data from four national Canadian cross-sectional 
surveys between 1996/97 to 2012. The National Population Health Survey (NPHS) 1996/97, The 
Canadian Community Health Survey, 2001 (CCHS 1.1), The Canadian Community Health 
Survey, Mental Health and Wellbeing, 2002 (CCHS 1.2) and The Canadian Community Health 
Survey, Mental Health component, 2012 (CCHS 2012:MH). As cross-sectional surveys, with 
different diagnostic criteria used over the years, the level of evidence generated is weak (Figure 
2-1) but it is the best currently available. The surveys used are large nationally representative 
samples and of high quality. 
The analyses involved age and gender standardization of prevalence estimates for alcohol 
dependence, major depression and comorbid alcohol dependence and major depression using the 
2001 census data for standardization. 
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Figure 2-1. Hierarchy of evidence 
 
2.2 Chapter 4: Co-morbid substance use and major depression: disability and 
risk of suicide in a nationally representative sample 
In this chapter, I assessed the risk of suicidal ideation and disability associated with the 
comorbid major depression with substance use disorder diagnosis compared to single diagnosis 
of either major depression or substance use disorder, or neither diagnosis. The data examined in 
this chapter was from the Canadian Community Health Survey, 2012: Mental Health Component 
(CCHS, 2012: MH).   
This survey is a cross sectional study design. Although cross sectional study designs do not 
allow for causal inference, they are analytical designs that are representative of the Canadian 
population and thus can provide very useful information on prevalence and associated risk 
factors. This survey is of high quality and a large sample size (N=25 113). 
Modified from (Griffin, Jordan, & El Gawad, 2016) 
 
 30 
 
Multilevel logistic regression models were used to assess two outcomes of interest, the risk 
of suicide and associated disability in comorbid substance use disorders and major depression. 
2.3 Chapter 5: Substance use disorder, overweight/obesity and co-morbid 
major depression 
The co-existence of obesity and substance use disorder is said to be highly prevalent and 
the relationship is inverse. Being obese or underweight are risk factors for a variety of physical 
health problems.  In this chapter, I assessed the relationship between substance use and obesity 
with underlying comorbid major depression in a national sample of Canadians. 
The Canadian Community Health Survey, 2012: Mental Health Component (CCHS, 2012: 
MH) was also used for this chapter and it has been described in the previous Section 2.2 The risk 
of overweight and obesity were assessed with underlying comorbid substance use disorders and 
major depression using multinomial regression models. 
2.4 Chapter 6: Alcohol dependence and the persistence or recurrence of major 
depression 
The National Population Health Survey was used for this chapter. This is a national 
longitudinal study of 17, 276 participants. This design is superior to cross sectional designs 
because it has temporal component to assess cause and effect. Its major drawback is the loss of 
participants due to follow-up.  
In this chapter, the persistence or recurrence of major depression was the outcome of 
interest. The 6-year and 16-year persistence or recurrence were assessed in the presence of 
concurrent alcohol dependence and other risk factors. 
In this longitudinal analysis, modified Poisson models were used to fit the data. 
2.5  Chapter 7: A systematic review and meta-analysis of comorbid substance 
use disorders, cannabis use disorders with major depression. 
This chapter is a systematic review of the associations between co-morbid substance use 
disorders, cannabis use disorders with major depression in nationally representative population-
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based surveys. This review was guided by the Preferred Reporting Items for Systematic Reviews 
and Meta-analysis (PRISMA) guidelines (Liberati, et al., 2009). This study design, a systematic 
review with meta-analysis represents the strongest and most informative source of evidence 
(Figure 2-1) for clinicians to keep up-to-date and informed policy-making. The most notable 
limitations are potential publication bias and the pooling of evidence from studies of different 
quality.  
In summary, Table 2-1 below summarizes the topics, study design and methods of analysis used 
in subsequent chapters of this thesis. 
  
 
3
2
 
Table 2-1 Summary of studies in this thesis  
Study design 
Level of evidence 
 
Title of study  Method & analysis 
Meta-analysis  
High  
 
Chapter 7 A systematic review and meta-analysis of 
comorbid substance use disorders, cannabis use 
disorders, with major depression  
 Systematic review; 
Meta-analysis; 
Prospective cohort  
Moderate 
 
Chapter 6 Alcohol dependence and the persistence or 
recurrence of major depression 
 Descriptive analysis; 
Modified Poisson regression 
Cross-sectional   
Low to medium depending 
on the specifics of the survey 
design 
Chapter 5 Substance use disorder, overweight/obesity 
and co-morbid major depression 
 Descriptive  
Multinomial regression 
 
Chapter 4 Co-morbid substance use with major 
depression: disability and risk of suicide in a nationally 
representative sample 
 Descriptive 
Multilevel logistics regression 
Time series 
 
Low to medium 
Chapter 3 Time trends in the prevalence of comorbid 
alcohol dependence and major depression in the 
Canadian population (1996/97-2012) 
 Descriptive  
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CHAPTER 3. TIME TRENDS IN THE PREVALENCE OF ALCOHOL 
DEPENDENCE AND COMORBID MAJOR DEPRESSION IN THE 
CANADIAN POPULATION (1996/97-2012) 
3.1 Introduction 
Major depression and alcohol use disorders (AUD) are among the most prevalent mental 
disorders in Canada (Pearson, Janz, & Ali, 2013) and are significant causes of disability burden 
in most regions of the world (World Health Organization, 2001). In 2016, the disability-adjusted 
live years (DALYs) and death attributed to alcohol were 4.2% and 5.2% respectively, making 
alcohol the seventh-leading cause of DALYs and death (GBD 2016 Risk Factors Collaborators, 
2017; GBD 2016 Alcohol Collaborators, 2018).  
The concurrent existence of major depression and alcohol dependence is common 
(Deykin, Levy, & Wells, 1987; Regier, et al., 1990; Grant & Harford, 1995; Grant, et al., 2015; 
Grant B. F., et al., 2004). Compared to the general population, the risk of becoming alcohol 
dependent is significantly higher in individuals diagnosed with depression and vice versa 
(Kessler, et al., 1996; Kessler, et al., 1997; Brière, Rohde, Seeley, & Daniel Klein, 2014; Britton, 
et al., 2015). Evidence from five US Epidemiological Catchment Area community surveys 
suggests that the odds of developing Major Depressive Episode (MDE) after 1 year has a dose-
dependent relationship with the baseline severity of alcohol dependence and vice versa (Gilman 
& Abraham, 2001). In their systematic review, Sullivan et al concluded that lifetime alcohol use 
disorder occurs in 30% (range 10-60%) of individuals with depression compared to 16-24% of 
the general population (Sullivan, Fiellin, & O'Connor, 2005). 
The comorbidity of alcohol dependence and depression is likely to remain a significant 
public health concern because the prevalence of both disorders has always been high in the 
younger age groups (Klerman & Weissman, 1989; Helzer, et al., 1990; Burke, Burke, Rae, & 
Regier, 1991; Blazer, Kessler, McGonagle, & Swartz, 1994; Wittchen, Nelson, & Lachner, 1998; 
Cross-National Collaborative Group, 1992; Grant, et al., 2015; Grant, et al., 2009). With the 
early onset, comes the increased risk of secondary psychiatric conditions (Christie, et al., 1988; 
Rohde, Lewinsohn, & Seeley, 1991; Giaconia, et al., 1994; Kasch & Klein, 1996; Brière, Rohde, 
Seeley, & Daniel Klein, 2014). Comorbidity also presents as a more severe disease with lower 
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levels of functioning, more suicidal behaviours, violence and polysubstance use (Swanson, 
Holzer, Ganju, & Jono, 1991; Cornelius, et al., 1995; Britton, et al., 2015; Brière, Rohde, Seeley, 
& Daniel Klein, 2014; Hjorthoj, et al., 2015; Borges, Benjet, Orozco, Medina-Mora, & 
Menendez, 2017)  leading to increased health and social service utilization. Studies on the 
relationship of alcohol dependence and major depression have focused on several areas such as, 
prevalence, strength of the association, causation (Merikangas, Leckman, Prusoof, Pauls, & 
Weissman, 1985; Schuckit, 1986; Coryell, Winokur, Keller, Scheftner, & Endicott, 1992; Grant, 
et al., 2015), and chronicity (Coryell, Winokur, Keller, Scheftner, & Endicott, 1992; Burcusa & 
Iacono, 2007). Very few studies have assessed the time trends of these conditions and most time 
trends look at these conditions independently, not the comorbidity (Grant B. F., et al., 2004; 
Patten, et al., 2015; Wiens, et al., 2017). For example, in their study on the trend of major 
depression in the Canadian population, Patten et al (2015) found that the prevalence of major 
depression is not increasing. 
Important research and public health implications come with changes in the prevalence of 
comorbid alcohol dependence and major depression. Understanding true changes in the 
prevalence of a complex disorder with both genetic and environmental influences over time may 
be crucial in interpreting research on etiology (Rice, et al., 2003). Changing prevalence would 
suggest changes in the level of environmental risk since the distribution of risk or protective 
genetic factors do not vary within a period as short as a decade (Grant B. F., et al., 2004). The 
need for focused planning in policy and prevention efforts is dependent on accurate information 
on changes in potentially vulnerable groups (Grant B. F., et al., 2004). It is important for 
projecting future services, treatment needs and understanding the impact of shifting 
demographics. The paucity of studies on time trends in the prevalence of comorbid alcohol 
dependence and major depression reflects a major gap in public health information. This present 
study is in part, designed to bridge the gap and provide some information. 
3.2 Objectives 
 This study was aimed to assess the time trends in the lifetime prevalence of alcohol 
dependence, major depression and comorbid alcohol dependence with major depression in 
Canada from 1996/1997 to 2012. 
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3.3 Methods 
3.3.1 Data Sources 
Data were from four Canadian national surveys. These surveys were selected because the 
variables major depression and alcohol dependence were both assessed to allow for comorbidity 
estimates. 
• The National Population Health Survey (NPHS)1996/97: Household Component  
The National Population Health Survey, the NPHS was conducted between June 1, 1996 and 
June 30, 1997 and had a total number of respondents of 81,804. It included household residents 
across all age groups in all provinces and excluded populations on Indian Reserves, Canadian 
Forces Bases and some remote areas in Ontario and Quebec and northern territories. The survey 
captured questions related to health status, use of health services, determinants of health and a 
range of demographic and economic information (Statistics Canada, 2015).  
• The Canadian Community Health Survey, 2001: Cycle 1.1 (CCHS 1.1) 
  The Canadian Community Health Survey, 2001 (CCHS 1.1) is a cross-sectional survey 
and the first cycle in a series designed to collect information related to health status, health care 
utilization and health determinants for the Canadian population. The sampling frame included 
persons aged 12 years or older, living in private occupied dwellings and excluded individuals 
living on Indian Reserves and on Crown Lands, Institutional residents, full-time members of the 
Canadian Armed Forces and residents of certain remote regions. Data was collected between 
September 5, 2000 and November 30, 2001. The total sample was 130,880 (Statistics Canada, 
2005). 
• Canadian Community Health Survey, 2002: Cycle 1.2, Mental Health and Well-
being (CCHS 1.2) 
The CCHS 1.2 assessed characteristics associated with the mental health of Canadians such 
as the status, determinants, and utilization. Data was collected between May 2002 and December 
2002, with a total sample of 36,984 Canadians who were 15 years or older and resident in one of 
the ten provinces. Individuals that were full-time members of the Canadian Forces were not 
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sampled. In addition, individuals who were resident in remote areas, Indian reserves, Crown 
Lands, or institutions were excluded (Statistics Canada, 2007). 
• The Canadian Community Health Survey 2012 – Mental Health Component (CCHS 
2012:MH)  
The CCHS 2012: MH is a comprehensive look at mental health with respect to who is 
affected by specific mental health disorders, positive mental health, access to and utilization of 
formal and informal mental health services and support; as well as individual functionality, 
regardless of the presence of a mental health problem (Statistics Canada, 2014). Data collection 
was between January 01, 2012 and December 31, 2012. The survey included persons aged 15 
years or more and resident in one of the ten Canadian provinces. Criteria for exclusion from the 
survey were living in certain remote areas, institutions, and reserves. In addition, full-time 
members of the Canadian Forces were not surveyed. These excluded populations make an 
estimated 3% of the target national population (Statistics Canada, 2014). The total number of 
respondents were 25,113 (Statistics Canada, 2014). 
3.3.2 Diagnostic Criteria 
The diagnosis of lifetime major depression and alcohol dependence in NPHS 96/97 and 
CCHS 2001 were derived from the World Health Organization Composite International 
Diagnostic Interview Short Form (CIDI-SF) based on the Diagnostic and Statistical Manual of 
Mental Disorders (DSM) III-R  criteria (Statistics Canada, 2005; Statistics Canada, 2015).  
The World Mental Health version of the Composite International Diagnostic Interview 
(WMH-CIDI) was used to derive the diagnosis of lifetime major depression and alcohol 
dependence in CCHS 1.2 and CCHS 2012: MH. However, in CCHS 1.2, the WMH-CIDI was 
based on both DSM-III-R and DSM-IV criteria while in CCHS 2012: MH it was based on DSM-
IV criteria (Statistics Canada, 2007; Statistics Canada, 2014). The CIDI-SF and WMH-CIDI are 
structured diagnostic tools made for comparative and easier administration of epidemiological 
surveys across populations (Kessler, Andrews, Mroczek, Ustun, & Wittchen, 1998; Kessler & 
Ustun, 2004). 
 38 
 
3.3.3 Statistical Analyses 
Analysis was done using Stata version 14.  First, age and gender standardization of all  
four datasets to get standard proportions for each age-gender strata were done using the 2001 
census data for ages 15years and older. Since age and gender are related to the outcomes, the 
standardization ensures the removal of their confounding effects and allows for comparison of 
prevalence estimates across surveys with different age structures over time. Second, a new 
variable standard weight was generated for each dataset. Next, the census proportions of each 
corresponding age-gender strata were assigned using the standard weight variable. The outcome 
variables, major depression and alcohol dependence were coded dichotomous, where the absence 
of the outcome is ‘0’ and presence is ‘100’ to give prevalence in percentages. Comorbid alcohol 
dependence with major depression was derived as a new variable by combining alcohol 
dependence and major depression and coded dichotomous (comorbid versus no diagnosis of 
either alcohol dependence or major depression, isolated major depression and isolated alcohol 
dependence). Variables for age, gender, marital status, highest level of education and total 
household income were recoded to have the same categorization and labels in all datasets.  
Age-gender-adjusted prevalence estimates and 95% confidence intervals (95% CI) for 
alcohol dependence, major depression, and comorbid alcohol dependence with major depression 
were generated using the svy: mean command with the standard weight variable on Stata. 
Prevalence estimates were calculated by age, gender, marital status, highest level of education, 
and total household income. Complex sampling methods of the surveys were accounted for with 
the survey weights provided in the datasets by Statistics Canada. Graphical display of results was 
done in Microsoft Excel. 
3.4 Results  
3.4.1 Prevalence of alcohol dependence, major depression and comorbid alcohol 
dependence and major depression 
 The survey characteristics of all datasets in this analysis and the accuracy of diagnostic 
instruments used (Kessler, Andrews, Mroczek, Ustun, & Wittchen, 1998; Kessler, et al., 2004) 
are shown in table 3-1.  Table 3-2 and figure 3-1 show the time trends in the prevalence of 
alcohol dependence, major depression and comorbid alcohol dependence with major depression 
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between 1996 and 2012. There was a steady rise in the prevalence between 1996 and 2002 and a 
decrease between 2002 and 2012.  Major depression was seen to have two-fold increase in 
prevalence from 1996 to 2012. The prevalence of major depression is about twice that of alcohol 
dependence for each year between 1996 and 2012. 
Table 3 -1. Characteristics of surveys included in the study 
Survey Age range Total Sample Size Diagnostic Criteria 
   Diagnostic instrument AUC for MDE 
NPHS 96/97 All age groups 81,804 CIDI-SF  a0.91 
CCHS 2001 12 years and older 130,880 CIDI-SF a0.91 
CCHS 1.2 (2002) 15 years and older 36,984 WMH-CIDI b0.86 
CCHS MH 2012 15 years and older 25,113 WMH-CIDI b0.86 
a – diagnostic instrument compared with gold standard DSM-III-R 
b – diagnostic instrument compared with the gold standard DSM-IV 
NPHS- National Population Health Survey: Household Component; CCHS- Canadian Community Health Survey; CCHS 1.2 – Canadian 
Community Health Survey, Mental Health and Wellbeing; CCHS MH- Canadian Community Health Survey, Mental Health Component; CIDI-
SF- World Health Organization Composite International Diagnostic Interview Short Form; WMH-CIDI - World Mental Health version of the 
Composite International Diagnostic Interview 
Table 3-2. Time trends in the lifetime prevalence of alcohol dependence, major depression and 
comorbid alcohol dependence with major depression 
Survey/year Alcohol 
dependence 
Alcohol 
dependence 
95% CI 
Major 
depression 
Major 
depression 
95% CI 
Alcohol 
dependence & 
major depression 
Alcohol dependence 
& major depression 
95% CI 
NPHS 96_97 3.50 3.21-3.78 5.51 5.16-5.87 0.56 0.44-0.68 
CCHS 2001 3.73 3.58-3.88 9.60 9.36-9.83 0.86 0.79-0.93 
CCHS 1.2 (2002) 5.40 4.73-5.35 12.13 11.63-12.62 1.06 0.89-1.22 
CCHS MH 2012 3.10 2.79-3.41 11.38 10.73-12.03 1.04 0.86-1.22 
NPHS- National Population Health Survey: Household Component; CCHS- Canadian Community Health Survey; CCHS 1.2 – Canadian 
Community Health Survey, Mental Health and Wellbeing; CCHS MH - Canadian Community Health Survey, Mental Health Component 
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Figure 3-1. Time trends in the lifetime prevalence of alcohol dependence, major depression, and  
comorbid alcohol dependence with major depression 1996/97-2012  
 
Alcdep – Alcohol Dependence; MDE – Major depression; ALCMD – comorbid alcohol dependence and major depression 
3.4.2 Prevalence of alcohol dependence 
From 1996 to 2012, alcohol dependence was most prevalent amongst the younger age 
groups, males, singles, those with some post-secondary education and lowest income level 
(Figure 3-2). The younger age groups had an increasing trend in the prevalence of alcohol 
dependence between 1996 and 2002 and a decrease between 2002 and 2012. The older age group 
and those with income less than $15,000 had a steady increase between 1996 and 2012. The 
prevalence of alcohol dependence in males was twice that of females for each year between 1996 
to 2012.  
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Figure 3-2. Time trends in the lifetime prevalence of alcohol dependence 1996/97 – 2012 by age, gender, marital status, education and 
household income 
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3.4.3 Prevalence of major depression 
From 1996 to 2012, major depression was most prevalent in individuals aged 20-59years, 
females, widowed/divorced/separated, those with some post-secondary education and lowest 
income level (Figure 3-3). Individuals with less than $80,000 annual household income and who 
were not post-secondary graduates had an increasing trend in the prevalence of major depression 
between 1996 and 2012.  
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Figure 3-3. Time trends in the lifetime prevalence of major depression 1996/97-2012 by age, gender, marital status, education and 
household income 
 
  
  
Marr/C-law/P – married/common-law/partner; wid/div/sep – widowed/divorced/separated; < secondary- less than secondary education; sec grad- secondary graduate; some post sec – some post 
secondary education; post sec grad- post secondary graduate 
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3.4.4 Prevalence of comorbid alcohol dependence and major depression 
From 1996 to 2012, comorbid alcohol dependence and major depression was most 
prevalent in the younger age groups, males, widowed/divorced/separated, those who had less 
than secondary education, and earn less than $15,000 household income (Figure 3-4). The rates 
were found to increase from 1996 to 2012 in those that were aged 30-69years, single, earned 
<$50,000 household income, had less that secondary education and were females. 
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Figure 3-4. Time trends in the lifetime prevalence of comorbid alcohol dependence with major depression 1996/97-2012 by age, gender, 
marital status, education and household income 
 
 
 
 
 
Marr/C-law/P – married/common-law/partner; wid/div/sep – widowed/divorced/separated; < secondary- less than secondary education; sec grad- secondary graduate; some post sec – some post 
secondary education; post sec grad- post secondary graduate 
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3.5 Discussion and Conclusion 
The overall prevalence of lifetime alcohol dependence in 1996 was 3.5%. In 2002, the 
prevalence rose to 5.4% and declined in 2012 to 3.1%. With regard to specific groups, alcohol 
dependence was most prevalent in males, younger age group (less than 40years), single, 
widowed/divorced/separated, or have a total household income of less than $15,000. These 
factors have been established in past studies. Men have higher rates of alcohol use disorder than 
women, those who are not married or younger age groups take more risks and have drinking 
patterns that lead to more problems (Dawson, Grant, & Chou, 1995; Grant B. F., 1997; Hasin, 
Stinson, Ogburn, & Grant, 2007; Caetano, Baruah, & Chartier, 2011; Grant B. F., et al., 2004). 
This trend analysis identified an emerging high-risk group for alcohol dependence. Individuals 
40years and older experienced an increase in the prevalence from 1996 to 2012 approaching the 
rates of the stable high-risk group (younger) in 2012.  
Lifetime prevalence of major depression increased markedly from 5.51% in 1996 to 
12.13% in 2002 and remained stable at 11.38% in 2012. This trend in major depression is 
consistent with previous studies on the same population that did not find a change in the 
prevalence between 2000 and 2012 (Patten, et al., 2015; Wiens, et al., 2017). Our analysis 
showed the age groups 60-69years and 70-79years experienced an increase in depression from 
1996/97 to 2012. This is consistent with a study that found an increase in the prevalence across 
age groups (Compton, Conway, Stinson, & Grant, 2006) and inconsistent with some studies that 
found increase in prevalence specific to a particular age-cohort at a particular point in time 
(Klerman & Weissman, 1989; Lewinsohn, Rhode, Seeley, & Fischer, 1993; Hagnell, Lanke, 
Rorsman, & Ojesjo, 1982; Cross-National Collaborative Group, 1992). Subgroup analysis also 
showed a consistent increase in major depression from 1996-2012 amongst those with total 
household income less than $80,000 and less than a graduate level education.  
Comorbid alcohol dependence with major depression had a prevalence of 0.56% in 
1996/97 and 1.06% in 2002 plateauing off at 1.04% in 2012. This trend mirrors the trend in 
major depression, unlike alcohol dependence that declined between 2002 and 2012. Comorbid 
alcohol dependence with major depression was most prevalent in males, younger age groups, 
low income, and low educational status as was the case for alcohol dependence. Despite the 
overall trend that plateaued between 2002 and 2012, the prevalence of this comorbidity had a 
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consistent increase from 1996 to 2012 in females, those 30 years and older, household income 
less than $50,000, and had no post-secondary graduate level education. It is thought that the 
elevated prevalence may result from the effect of alcohol dependence on major depression risk 
and vice versa (Bulloch, Lavorato, Williams, & Patten, 2012). Given its negative implications on 
the individuals, families, and society at large, comorbid alcohol dependence with major 
depression continue to pose a significant public health concern (Grant, et al., 2004) and have 
profound health care and economic implications. These findings underscore the need for 
prevention strategies through the life course - more prevalent in the younger age groups, 
emerging risks in the older age groups. 
Since rapid changes in the prevalence of alcohol dependence, major depression and 
comorbid alcohol dependence with major depression over such a relatively short time cannot be 
explained by genetic factors, attention should be on environmental factors that have occurred in 
that time. Exploration of changes in historical and cultural factors, marital stability, household 
composition, and labour force dynamics, psychiatric and medical comorbidity, genetic 
vulnerability, health care utilization and economic indices are necessary to begin to understand 
the increasing rates of comorbid alcohol dependence with major depression. 
Several factors may have contributed to the significant jump that occurred between 2001 
and 2002 in the prevalence of alcohol dependence, major depression and comorbid alcohol 
dependence with major depression. First, there was a change in the structured diagnostic 
instrument from CIDI-SF in 2001 to WMH-CIDI in 2002. The WMH-CIDI addressed some of 
the shortcomings of the CIDI-SF including and but not limited to subthreshold diagnosis of 
mental health disorders where array of symptoms not meeting the criteria for a diagnosis are 
included to capture individuals that would have been missed otherwise (Kessler, et al., 2004). 
This may have increased the prevalence in 2002 compared to 2001 and explains the plateau 
found between 2002 and 2012. Second, the CIDI-SF diagnostic criteria was based on DSM-III-R 
while the WMH-CIDI was derived from both DSM-III-R and DSM-IV in 2002 (CCHS 1.2) and 
DSM-IV in 2012 (CCHS 2012: MH). Despite some similarities between DSM-III-R and DSM-
IV, the kappa levels on both criteria are low partly due to the reclassification of some criteria and 
identification of undiagnosed DSM-III-R cases by DSM-IV (Schuckit, et al., 1994). In addition, 
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the CCHS 2002 and 2012 were mental health specific surveys with more details on mental health 
disorders compared to the 2001 survey which was a general population health survey. 
One of the strengths of this study is that the NPHS, CCHS, and CCHS Mental Health 
Component are large household population surveys with good response rates, and therefore, are 
generalizable to the Canadian population (Statistics Canada, 2014; Statistics Canada, 2005; 
Statistics Canada, 2015; Statistics Canada, 2007). The complex data structures of the surveys 
were accounted for using the survey weights provided. Age and gender standardization of 
prevalence using census data is another strength of this study. This analysis has some limitations. 
The diagnostic criteria for major depression and alcohol dependence differed in the surveys, 
hence, resulting in the inability to pool effects in a trend analysis. Thus, chance occurrence 
cannot be ruled out. The surveys excluded the homeless individuals and those institutionalized, 
which are population groups with a higher prevalence of substance use disorders and at a higher 
risk for comorbidity (Canadian Centre on Substance Abuse, 2009). Other populations excluded 
were individuals on reserves and other Aboriginal settlements and full-time members of the 
Canadian Forces. This study was also based on self-reported data, which could be compromised 
by recall bias and under-reporting. 
This study is among the first to examine the trends in the lifetime prevalence of comorbid 
alcohol dependence with major depression and demographic changes among individuals 15years 
and older in Canada. Our findings demonstrate that comorbid alcohol dependence with major 
depression has a high prevalence in the younger age group and continues to increase in adults 
particularly those with low income and educational status. A life course perspective is 
recommended as a prevention strategy. 
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Appendix A. Time Trend Tables 
Table A.1 Time trends in the prevalence of Alcohol dependence 1996/97-2012 
  
NPHS 96/97 (95%CI) 
 
CCHS 2001 (95%CI) 
 
CCHS 2002(95%CI) 
 
CCHS 2012(95%CI) 
Age  
15-19 years 
20-29years 
30-39years 
40-49years 
50-59years 
60-69years 
70-79years 
80 and above                         
 
7.89 (6.37-9.40) 
9.76 (8.56-10.96) 
2.9 (2.44-3.37) 
2.13 (1.59-2.67) 
0.8 (0.47-1.14) 
0.94 (0.33-1.55) 
0.1 (0.03-0.24) 
0.03 (0.02-0.08) 
 
7.67 (7.06-8.28) 
9.6 (8.96-10.25) 
3.93 (3.59-4.28) 
2.37 (2.12-2.64) 
1.31 (1.1-1.52) 
0.46 (0.33-0.58) 
0.14 (0.06-0.22) 
0.04 (0.02-0.09) 
 
9.03 (7.71-10.35) 
12.35 (11.19-13.52) 
5.8 (5.07-6.52) 
3.67 (3.01-4.34) 
1.91 (1.33-2.49) 
0.75 (0.41-1.09) 
0.1 (0.01-0.19) 
0.09 (0.02-0.20) 
 
1.52 (0.92-2.11) 
3.84 (2.97-4.71) 
3.99 (3.10-4.87) 
3.7 (2.87-4.53) 
2.86 (2.27-3.45) 
3.07 (2.25-3.88) 
0.98 (0.57-1.40) 
0.72 (0.19-1.63) 
Sex 
Male 
Female                                     
 
5.09 (4.61-5.58) 
1.95 (1.64-2.26)
 
5.55 (5.28-5.81) 
1.98 (1.83-2.12) 
 
7.8 (7.23-8.37) 
2.38 (2.11-2.64) 
 
4.14 (3.61-4.66) 
2.10 (1.76-2.44) 
Marital status 
Mar/C-law/partner 
Single 
Wid/Div/Sep 
 
2.22 (1.47-2.98) 
4.86 (4.17-5.55) 
4.53 (3.16-5.9) 
 
2.76 (1.99-3.53) 
5.37 (5.01-5.74) 
4.95 (4.02-5.88) 
 
4.20 (2.9-5.51) 
6.79 (6.11-7.47) 
6.05 (4.82-7.28) 
 
2.64 (2.08-3.20) 
5.38 (4.46-6.29) 
4.73 (2.92-6.54) 
Highest level of education 
<Secondary 
Sec Grad 
Some Post Sec 
Post Sec Grad 
 
3.32 (2.63-4.02) 
3.92 (3.20-4.64) 
4.13 (3.60-4.66) 
2.45 (1.25-3.66) 
 
4.23 (3.85-4.60) 
4.31 (3.96-4.66) 
5.05 (4.49-5.61) 
3.62 (3.17-4.07) 
 
5.80 (5.00-6.60) 
6.28 (5.48-7.08) 
6.43 (5.50-7.36) 
4.10 (3.44-4.77) 
 
4.57 (3.54-5.6) 
4.97 (3.80-6.15) 
6.11 (3.95-8.27) 
2.10 (1.80-2.40) 
Total Household Income 
<$15,000 
$15,000-29,999 
$30,000-49,999 
$50,000-79,999 
$80,000 or more 
 
5.23 (4.06-6.4) 
3.45 (2.72-4.19) 
3.50 (2.85-4.16) 
3.32 (2.73-3.90) 
4.33 (3.25-5.41) 
 
5.18 (4.56-5.79) 
4.36 (3.89-4.82) 
3.39 (.09-3.68) 
3.19 (2.93-3.45) 
4.11 (3.75-4.47) 
 
6.14 (5.02-7.26) 
4.94 (4.15-5.72) 
4.37 (3.73-5.00) 
4.81 (4.24-5.38) 
5.56 (4.85-6.28) 
 
8.45 (6.32-10.58) 
4.91 (3.74-6.08) 
3.28 (2.61-3.95) 
2.53 (1.80-3.26) 
2.50 (2.07-2.93) 
Marr/C-law/P – married/common-law/partner; wid/div/sep – widowed/divorced/separated; < secondary- less than secondary education; sec grad- 
secondary graduate; some post sec – some post secondary education; post sec grad- post secondary graduate 
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Table A.2 Time trends in the prevalence of Major depression 1996/97-2012 
  
NPHS 96/97(95%CI) 
 
CCHS 2001(95%CI) 
 
CCHS 2002(95%CI) 
 
CCHS 2012(95%CI) 
Age  
15-19 years 
20-29years 
30-39years 
40-49years 
50-59years 
60-69years 
70-79years 
80 and above                                                 
 
7.36 (5.88-8.85) 
6.6 (5.62-7.57) 
6.34 (5.51-7.17) 
6.6 (5.71-7.49) 
4.78 (3.92-5.65) 
2.79 (2.06-3.52) 
2.44 (1.61-3.27) 
2.41 (1.06-3.76) 
 
10.79 (10.0-11.58) 
12.07 (11.38-12.76) 
11.11 (10.55-11.67) 
10.64 (10.10-11.19) 
8.67 (8.09-9.25) 
6.03 (5.44-5.77) 
5.10 (4.43-5.77) 
4.17 (3.26-5.10) 
 
7.85 (6.56-9.14) 
12.77 (11.55-14.00) 
13.08 (11.93-14.23) 
15.57 (14.17-16.98) 
14.51 (13.15-15.87) 
9.96 (8.69-11.22) 
5.33 (4.38-6.29) 
5.02 (3.34-6.69) 
 
8.86 (7.08-10.64) 
11.69 (10.19-10.64) 
11.72 (10.18-13.26) 
14.51 (12.47-16.54) 
12.65 (11.12-14.19) 
10.87 (9.50-12.24) 
6.19 (4.74-7.64) 
3.60 (2.47-4.73) 
Sex 
Male 
Female                                     
 
4.12 (3.63-4.62) 
6.85 (6.34-7.36)
 
7.13 (6.82-7.43) 
11.98 (11.62-12.34) 
 
9.19 (8.52-9.86) 
14.96 (14.23-15.7) 
 
8.67 (7.85-9.48) 
13.99 (12.98-14.99) 
Marital status 
Mar/C-law/partner 
Single 
Wid/Div/Sep 
 
5.28 (3.94-6.61) 
6.5 (5.59-7.42) 
13.4 (9.31-17.48) 
 
8.25 (7.42-9.09) 
12.16 (11.44-12.88) 
16.94 (15.78-18.10) 
 
9.81 (9.17-10.44) 
14.35 (12.89-15.81) 
22.44 (19.77-25.11) 
 
9.35 (8.54-10.17) 
14.06 (12.66-15.46) 
16.52 (13.42-19.63) 
Highest level of education 
<Secondary 
Sec Grad 
Some Post Sec 
Post Sec Grad 
 
6.31 (5.41-7.20) 
5.15 (4.41-5.89) 
6.65 (5.05-6.25) 
3.94 (3.24-4.65) 
 
11.77 (11.11-12.43) 
9.47 (8.93-10.01) 
11.37 (10.48-12.26) 
8.50 (8.05-8.96) 
 
12.65 (11.29-14.0) 
11.08 (9.97-12.19) 
13.91 (12.20-15.61) 
12.44 (11.62-13.26) 
 
13.09 (10.73-15.45) 
11.55 (9.80-13.31) 
16.80 (13.33-20.27) 
10.81 (9.91-11.71) 
Total Household Income 
<$15,000 
$15,000-29,999 
$30,000-49,999 
$50,000-79,999 
$80,000 or more 
 
11.03 (9.68-12.94) 
6.99 (6.02-7.97) 
4.86 (4.21-5.50) 
4.47 (3.67-5.28) 
4.73 (3.52-5.94) 
 
16.41 (15.42-17.40) 
12.53 (11.82-13.24) 
9.81 (9.29-10.33) 
8.86 (8.34-9.38) 
7.89 (7.39-8.57) 
 
18.63 (16.81-20.45) 
13.49 (13.49-17.01) 
11.19 (11.19-13.32) 
10.26 (10.26-12.14) 
10.46 (9.33-11.60) 
 
21.23 (17.99-24.47) 
14.91 (12.82-17.00) 
11.90 (10.21-13.58) 
12.17 (10.51-13.83) 
9.52 (8.64-10.39) 
Marr/C-law/P – married/common-law/partner; wid/div/sep – widowed/divorced/separated; < secondary- less than secondary education; sec grad- 
secondary graduate; some post sec – some post secondary education; post sec grad- post secondary graduate 
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Table A.3 Time trends in the prevalence of comorbid Alcohol dependence and major 
depression 1996/97-2012 
  
NPHS 96/97(95%CI) 
 
CCHS 2001(95%CI) 
 
CCHS 2002(95%CI) 
 
CCHS 2012(95%CI) 
Age  
15-19 years 
20-29years 
30-39years 
40-49years 
50-59years 
60-69years 
70-79years 
80 and above                                                 
 
1.66 (0.82-2.51) 
1.24 (0.86-1.62) 
0.45 (0.27-0.63) 
0.49 (0.19-0.79) 
0.15 (0.01-0.3) 
-  
0.04 (0.03-010) 
-  
 
1.76 (1.45-2.07) 
2.11 (1.82-2.40) 
0.98 (0.81-1.45) 
0.55 (0.43-0.66) 
0.34 (0.22-0.46) 
0.06 (0.02-0.11) 
0.01 (0.01-0.02) 
-  
 
1.02 (0.54-1.50) 
2.48 (1.88-3.09) 
1.17 (0.84-1.50) 
1.22 (0.71-1.73) 
0.47 (0.28-0.67) 
0.18 (0.05-0.31) 
0.02 (0.02-0.06) 
0.01 (0.01-0.12) 
 
0.30 (0.08-0.52) 
1.54 (0.97-2.12) 
1.35 (0.89-1.81) 
1.49 (0.95-2.03) 
0.86 (0.54-1.17) 
0.70 (0.41-0.99) 
0.05 (0.01-0.11) 
0.08 (0.03-0.19) 
Sex 
Male 
Female                                     
 
0.6 (0.42-0.77) 
0.52 (0.35-0.68)
 
1.05 (0.93-1.16) 
0.67 (0.58-0.75) 
 
1.41 (1.19-1.71) 
0.72 (0.56-0.87) 
 
1.14 (0.87-1.41) 
0.95 (0.71-1.19) 
Marital status 
Mar/C-law/partner 
Single 
Wid/Div/Sep 
 
0.32 (0.04-0.67) 
0.74 (0.57-0.91) 
1.26 (0.66-1.86) 
 
0.75 (0.04-1.47) 
1.40 (1.18-1.61) 
1.63 (1.18-2.08) 
 
0.65 (0.46-0.84) 
1.59 (1.24-1.93) 
1.98 (1.35-2.60) 
 
0.77 (0.54-1.01) 
1.82 (1.33-2.31) 
1.62 (1.00-2.23) 
Highest level of education 
<Secondary 
Sec Grad 
Some Post Sec 
Post Sec Grad 
 
0.75 (0.37-1.14) 
0.66 (0.33-0.99) 
0.47 (0.34-0.60) 
0.19 (0.09-0.30) 
 
1.09 (0.89-1.29) 
0.91 (0.75-1.06) 
1.06 (0.82-1.30) 
0.81 (0.52-1.20) 
 
1.57 (1.15-1.99) 
1.18 (0.81-1.54) 
1.79 (1.21-2.37) 
0.71 (0.50-0.92) 
 
1.75 (1.07-2.43) 
1.84 (1.05-2.64) 
1.70 (0.89-2.51) 
0.68 (0.52-0.84) 
Total Household Income 
<$15,000 
$15,000-29,999 
$30,000-49,999 
$50,000-79,999 
$80,000 or more 
 
1.41 (0.78-2.04) 
0.95 (0.56-1.34) 
0.48 (0.25-0.72) 
0.41 (0.14-0.67) 
0.41 (0.17-0.64) 
 
1.47 (1.16-1.79) 
1.28 (1.05-1.51) 
0.84 (0.69-0.99) 
0.69 (0.56-0.82) 
0.72 (0.57-0.87) 
 
2.05 (1.38-2.73) 
1.21 (0.85-1.57) 
0.86 (0.55-1.16) 
1.00 (0.72-1.28) 
0.94 (0.54-1.34) 
 
3.70 (2.48-4.92) 
1.94 (1.09-2.8) 
1.27 (0.8-1.75) 
0.65 (0.30-1.0) 
0.75 (0.52-0.98) 
 
Marr/C-law/P – married/common-law/partner; wid/div/sep – widowed/divorced/separated; < secondary- less than secondary education; sec grad- 
secondary graduate; some post sec – some post secondary education; post sec grad- post secondary graduate 
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CHAPTER 4. CO-MORBID SUBSTANCE USE WITH MAJOR DEPRESSION: 
DISABILITY AND RISK OF SUICIDE IDEATION IN A NATIONALLY 
REPRESENTATIVE SAMPLE 
4.1 Introduction  
4.1.1 Prevalence of substance use disorders and major depression 
Substance Use Disorders (SUDs) and major depression are the two most common mental 
health disorders in North America; and they often co-exist; especially in treatment-seeking 
patients (Grant, et al., 2004; Galbaud du Fort, Newman, Boothroyd, & Bland, 1999; RachBeisel, 
Scott, & Dixon, 1999). A total of 2.8 million Canadians (10.1%) in 2012, reported symptoms 
consistent with at least one of the following mental health or substance use disorders: mood 
disorders (depression or bipolar), generalized anxiety disorders, abuse and/or dependence of 
alcohol, cannabis or other drugs (Pearson, Janz, & Ali, 2013).  
Alcohol and cannabis are among the most commonly used substances in Canada 
(Statistics Canada, 2017a; Pearson, Janz, & Ali, 2013). Correspondingly, alcohol and cannabis 
use disorders are fairly common. Globally, the harmful use of alcohol ranks among the top seven 
risk factors for disease, disability, and death (World Health Organization, 2011; Lim, et al., 
2012; World Health Organization, 2014a; GBD 2016 Risk Factors Collaborators, 2017; GBD 
2016 Alcohol Collaborators, 2018). Cannabis use has also been associated with a wide range of 
mental illness, including depression (Kessler, et al., 1996; Lev-Ran, Le Foll, McKenzie, George, 
& Rehm, 2013; Mathews, Hall, & Gartner, 2011; Volkow, Baler, Compton, & Weiss, 2014; 
Wright & Metts, 2016). Evidence from the 1990 United States (U.S.) National Comorbidity 
Survey suggests that 90% of respondents with marijuana dependence had lifetime DSM-III 
psychiatric disorders (Kessler, et al., 1996). Among people at high risk of SUDs, those with 
mental health problems are some of the most vulnerable (Shi, 2014). 
Comorbid substance use disorder (SUD) with major depression tend to occur more 
commonly among young people (de Graaf, Bijl, Smit, Vollebergh, & Spijker, 2002), is higher in 
people with drug use disorders compared to alcohol use disorders (Jane-LIopis & Matytsina, 
2006; Regier, et al., 1990) and among those with substance use dependence (the cluster of 
behavioural, cognitive, and psychological phenomena that develop secondary to repeated use of 
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substances) as opposed to abuse (the harmful or hazardous use of psychoactive substances) 
(Jane-LIopis & Matytsina, 2006; Merikangas, et al., 1998; World Health Organization, 2018). In 
patient samples, comorbid Major Depressive Disorder (MDD) in individuals with SUDs have 
been found to be associated with poorer quality of life (Saatcioglu, Yapici, & Cakmak, 2008), 
elevated rates of disability (Olfson, et al., 1997), elevated suicide risk (Glasner-Edwards, et al., 
2008; Berglund & Ojehagen, 1998; Grant & Hasin, 1999; Waller, Lyons, & Costantini-Ferrando, 
1999) and, negative treatment outcomes whether considered as comorbid diagnosis (Burns, 
Teesson, & O'Neill, 2005; Glasner-Edwards, et al., 2009) or a continuous measure of depressive 
symptoms (Dodge, Sindelar, & Sinha, 2005).  
4.1.2 Disability and comorbid substance use disorders with major depression 
In the U.S. employers lose an excess of 31 billion dollars of productive time from 
workers with depression compared to those without depression per year (Stewart, Ricci, Chee, 
Hahn, & Morganstein, 2003). High levels of disability in several domains of functioning have 
been associated with mental illness (Druss, Rosenheck, & Sledge, 2000). A study by Kennedy et 
al. (2002) found significantly higher functional impairments in work, family and social domains 
in patients with depression compared to those without depression (Kennedy, Lin, & Schwab, 
2002). Evidence from the 1998 US National Health Interview Survey showed that 35.4% of 
individuals with a mental disorder had trouble finding or keeping a job, 33.3% were unable to 
perform major activities and 5.2% were unable to work or were limited in their work due to 
mental health problems (Willis, Willis, Male, Henderson, & Manderscheid, 1998). Similar to 
other mental illnesses, SUDs also have high levels of disability.  Previous studies suggest 
considerable disability associated with major life activities and keeping or finding a job (Willis, 
Willis, Male, Henderson, & Manderscheid, 1998; Holder & Blose, 1991; Aldaf, Smart, & Walsh, 
1992). The cost of substance use (SU) in 2014 categorized as healthcare costs, lost productivity 
costs, criminal justice costs and other direct costs were $38.4 billion in Canada with 40.8% 
related to the cost of lost productivity (Canadian Substance Use Costs and Harms Scientific 
Working Group, 2018).  Four substances with the largest costs were alcohol, tobacco, opioids, 
and cannabis. Seventy percent of these costs were due to alcohol and tobacco (Canadian 
Substance Use Costs and Harms Scientific Working Group, 2018). 
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While functional disabilities associated with single mental disorders or SUDs can be 
severe, comorbidity in patients has been associated with significantly worse disabilities and to 
have a considerable impact on the Quality of Life (QoL) (Saatcioglu, Yapici, & Cakmak, 2008). 
For example, evidence from the National Comorbidity Survey showed that individuals with 
comorbidities of two or more disorders had on average four times more work days lost and three 
times more work cutback days than those with one disorder (Kessler, Foster, Saunders, & Stagg, 
1995). Individuals with comorbid disorders are more likely to be unemployed, divorced, socially 
isolated (Olfson, et al., 1997; Kessler R. C., 1995) and frequent users of health services in 
comparison to individuals diagnosed with single disorders (Burns & Tesson, 2002). 
4.1.3 Suicide risk and comorbid substance use disorders with major depression  
In 2012, approximately 804,000 completed suicides were reported worldwide. This 
translates to a yearly age-standardized rate of 11.4 suicides per 100,000 persons (World Health 
Organization, 2014b). An estimated 50% and 71% of brutal deaths in males and females 
respectively are attributed to suicides worldwide. In adolescents and young adults aged 15-25 
years old, suicide was ranked the second leading cause of mortality worldwide (World Health 
Organization, 2014b). 
SUDs increase the risk of suicide (Schneider, 2009; Beautrias, et al., 1996; Borges, 
Walters, & Kessler, 2000; Miller, et al., 2011; Petronis, Samuel, Mosckicki, & Anthony, 1990; 
Wong, Zhou, Goebert, & Hishinuma, 2013; Westman, et al., 2015; Hjorthoj, et al., 2015) with  
25 – 50% of all suicides associated SUDs and 22% attributable to AUD, meaning that every fifth 
suicide could have been prevented if alcohol was not consumed (Cavanagh, Carson, Sharpe, & 
Lawrie, 2003). Emerging evidence suggest a role of cannabis on suicidal behavior (Agrawal & 
Lynskey, 2014; Borges, et al., 2017b; Borges, Benjet, Orozco, Medina-Mora, & Menendez, 
2017a; Shalit, Shoval, Shlosberg, Feingold, & Lev-Ran, 2016), a matter of great relevance and 
considerable debate due to its high prevalence (United Nations Office on Drugs and Crime, 
2015) and actual and  proposed changes in legislation covering its use in several countries 
including Canada (Statistics Canada, 2017a; Borges, Benjet, Orozco, Medina-Mora, & 
Menendez, 2017a). 
While the lifetime risk of suicide is estimated to be 4% in patients with mood disorders 
(Bostwick & Pankraz, 2000), and 7% in people with alcohol dependence (Schneider, 2009), it 
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increases considerably with comorbidity (Cavanagh, Carson, Sharpe, & Lawrie, 2003). In high-
income countries like Canada, mental disorders were present in up to 90% of completed suicides 
(Cavanagh, Carson, Sharpe, & Lawrie, 2003). Suicidal behaviour is most commonly associated 
with depression and alcohol use disorders (World Health Organization, 2014b) and the 
combination of alcohol dependence and depression is considered the leading risk factor for 
completed suicides (Gliatto & Rai, 1999). Major depression and alcohol dependence were 
responsible for the first and second largest proportion of the suicide disability-adjusted life-years 
(DALY) that were attributable to mental and substance use disorders in 2010, respectively 
(Ferrari, et al., 2014). 
Since suicide is a sensitive and complex issue, a rare outcome and illegal in some 
countries, analytical studies on suicides are complicated and suicides are very likely to be under-
reported and misclassified (World Health Organization, 2014b; Borges, Benjet, Orozco, Medina-
Mora, & Menendez, 2017a). Key risk factors for suicides are suicide attempts and suicide 
ideation (World Health Organization, 2014b; Nock, et al., 2008). Suicide attempts and suicide 
ideation, therefore, represent surrogates for studies on suicides and associated factors (Borges et 
al., 2009). 
Several studies on comorbid SUD with psychiatric disorders have focused on prevalence 
and risk factors with very few on the impact of the comorbidity such as associated disability and 
the risk of suicide. In addition, most of the studies that have assessed the impact of comorbid 
SUD with psychiatric disorders used patient samples (Gliatto & Rai, 1999; Glasner-Edwards, et 
al., 2008; Saatcioglu, Yapici, & Cakmak, 2008). This study aims the bridge the gaps in the 
literature using a national representative sample of Canadians to assess the impact of comorbid 
SUD with major depression on disability and risk of suicide.  
4.2  Objectives 
This study aimed to first, determine the disability associated with comorbid substance use 
disorders (SUD) with depression and second, the associated risk of suicide ideation in 
comorbid SUD with depression in a nationally representative sample. 
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4.3  Methods  
4.3.1 Subjects 
Subjects were participants of the Canadian Community Health Survey (CCHS), 2012: 
Mental Health Component (CCHS 2012: MH), N= 25,113, response rate = 86.3%. The CCHS 
2012: MH provides a comprehensive look at mental health with respect to who is affected by 
specific mental health disorders, positive mental health, access to and utilization of formal and 
informal mental health services and support; as well as individual functionality, regardless of the 
presence of a mental health problem (Statistics Canada, 2014). The survey included persons aged 
15 years or more and resident in one of the ten Canadian provinces. Criteria for exclusion from 
the survey were living  in certain remote areas, institutions, and reserves. In addition, full-time 
members of the Canadian Forces were not surveyed. These excluded populations make an 
estimated 3% of the target national population (Statistics Canada, 2014). 
This secondary analysis of the CCHS, MH 2012 dataset was done using the Public Use 
Microdata Files (PUMF). Unlike the confidential microdata files (Master data files) which are 
accessible through Research Data Centres only, PUMFs are available through University 
Libraries across Canada. PUMFs are manipulated files done to make data widely available while 
still maintaining confidentiality. Such manipulations include aggregating, capping or completely 
erasing identifying variables (Statistics Canada, 2017b). 
4.3.2 Measures 
Major Depression 
The World Mental Health version of the Composite International Diagnostic Interview 
(WMH-CIDI) is a structured diagnostic interview based on symptoms and symptom severity 
associated with specific psychiatric disorders. The WMH-CIDI algorithm derived from the 
Diagnostic and Statistical Manual of Mental Disorders IV (DSM IV) was applied to the symptom 
data to define specific psychiatric diagnosis, in this case, Unipolar Major Depressive Episode 
(MDE) - lifetime and 12-month (Statistics Canada, 2014). 
Substance Use Disorder 
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The WMH-CIDI algorithms derived from DSM IV were applied to the symptom data to 
define substance use disorders (SUD), that is, substance abuse and/or dependence for alcohol 
(alcohol use disorder -AUD), cannabis (Cannabis use disorder – CUD) and other drugs excluding 
cannabis (drugs use disorder- DUD) in the data. Lifetime and 12-month SUDs were defined 
(Statistics Canada, 2014). 
World Health Organization Disability Assessment Schedule Score 2.0  
The World Health Organization Disability Assessment Schedule Score 2.0 (WHODAS 
2.0) is a “generic assessment instrument for health and disability in adult populations. It produces 
standardized disability levels and profiles across cultures and it is constructed on the conceptual 
framework of the International Classification of Functioning, Disability and Health (ICF) (World 
Health Organization, 2016). It assesses functioning based on six main domains- cognition, 
mobility, self-care, getting along, life activities and participation” (World Health Organization, 
2016). In this data, the score for total disability was derived by Statistics Canada and individuals 
were classified into two groups < 40 (lowest recordable degree of disability) versus 40 or more 
(high degree of disability) (Statistics Canada, 2014). 
Suicidal Ideation 
The risk of suicide was assessed using the proxy, suicidal thoughts (ideation). Statistics 
Canada used the WHM CIDI symptom data to develop algorithms for lifetime and 12-months 
suicidal thoughts (ideation) in the data. These algorithms classified respondents based on 
whether they ever (lifetime) thought of committing suicide or taking their own life and whether 
or not those thoughts occurred in the past 12 months (Statistics Canada, 2014). 
Other Measures  
Other variables that were included in these analyses were: sociodemographic factors - 
age, sex, marital status (married, common-law, widowed, divorced or separated, single), highest 
level of education (less than secondary education, secondary education graduate, some post 
secondary education, post secondary education graduate), total household income in Canadian 
dollars (no income or <20,000, 20,000-39,999, 40,000-59,999, 60,000-79,999, 80,000 or more), 
race (white, non-white), smoking status, personal and family history of mental health disorder, 
history of a chronic disease and childhood traumatic events. 
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4.3.3  Statistical Analysis 
All statistical analyses were carried out using STATA version 14.0. First, a new variable, 
comorbid SUD with MDE was created by merging each SUD (alcohol, cannabis, other drugs) 
variable and MDE. For each SUD, the new variable created had four levels – no diagnosis 
(neither SUD nor MDE), single diagnosis of SUD (AUD or CUD or DUD), single diagnosis of 
MDE and comorbid diagnosis of SUD with MDE. Then, participants were described by 
sociodemographic characteristics and DSM IV diagnosis. For each outcome variable (disability 
and suicide ideation), a Chi-Square test was done to depict the relationship between the DSM-IV 
diagnoses (isolated and comorbid) and the probability of having disability or suicide ideation in 
the population. 
The MCAR test on Stata version 14 was used to determine if data was missing completely at 
random (MCAR) and a justification for a complete case analysis. Data was not MCAR 
(Appendix 1). Then, Multiple imputations using chained equations was carried out following 
significant Chi Square associations between the independent variables and the missingness in the 
outcome variables (disability and risk of suicide ideation) (Appendix 1). Prior to imputation, the 
area under the receiver operating curve (ROC) was used to assess the discriminatory accuracy of 
the models to correctly classify respondents based on the outcomes. Generalized Hosmer–
Lemeshow goodness of fit was used to fit the imputation models prior to imputation. After 
estimation with the imputed data, the models were tested for equal fraction-missing-information 
to check that the between-imputation and within-imputation variances were proportional. The 
complex sampling method of the data was accounted for by using the sampling weights provided 
by Statistics Canada on the survey (svy) command in Stata.  
Multilevel logistic regression models with province of residence as the group variable were 
used to assess the two outcomes – disability and risk of suicide. Four models were constructed 
for each outcome using stepwise multivariate analyses with backward elimination of covariates. 
In step one, the first model for each outcome was constructed using the sociodemographic 
factors (age, sex, marital status, education, income, race, smoking), personal and family history 
of mental illness, history of childhood maltreatment and history of chronic disease. In step two, 
three other models were constructed for each outcome by adding the comorbid substance use 
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disorder with major depression variable (alcohol & depression- model 2, cannabis & depression 
– model 3 and other drugs except cannabis & depression – model 4) to the covariates listed in 
step one. Since the multilevel models did not allow pairwise comparison post hoc analyses for 
the variable ‘comorbid substance use disorder with major depression’ in the three comorbid 
models, comparisons were generated by changing the reference category. The odds ratio (OR) of 
all covariates in step 1 final models and step 2 final models were reported for each outcome. 
Confounding was assessed for variables eliminated from the multivariate models and re-entered 
into the models if present. Since the focus of the analysis was to understand the main effects and 
the differences between isolated substance use disorders, major depression and the comorbidities 
on the risk of suicide ideation and disability, biologically plausible interaction terms were not 
assessed. 
 
4.4 Results 
4.4.1 Participants characteristics 
Table 4-1 shows weighted percentages of the sociodemographic characteristics and 
distribution of DSM-IV diagnoses for the target population. A third of the population were 
residents of Ontario and aged 25-44 years. About half of the population were married, female, 
were post secondary graduates with total household income of $80,000 or more. Major 
depressive episode (MDE), Alcohol use disorders (AUD), Cannabis use disorders (CUD), other 
drugs excluding cannabis use disorder (DUD) had lifetime prevalence rates of 11.4%, 19%, 6.8% 
and 4.0% respectively while the lifetime comorbid diagnoses of MDE with AUD, MDE with 
CUD, MDE with DUD had prevalence rates of 3.23%, 1.73% and 1.29% respectively. About 2% 
of the population had high degree of disability (disability scroe of 40 or more). 
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Table 4-1. CCHS 2012:MH participants socio-demographic characteristics, distribution of DSM-IV 
diagnoses and WHO disability score 
 Weighted 
percentages 
95% CI 
Province of residence 
Newfoundland and Labrador 
Prince Edward 
Nova Scotia 
New Brunswick 
Quebec 
Ontario 
Manitoba 
Saskatchewan 
Alberta 
British Columbia 
 
1.55 
0.40 
2.77 
2.15 
23.81 
38.95 
3.43 
2.82 
10.95 
13.16 
 
1.45 - 1.65 
0.38 - 0.43 
2.65 - 2.90 
2.05 - 2.26 
23.0 - 24.65 
38.03 - 39.89 
3.20 - 3.68 
2.67 - 2.97 
10.44 -11.48 
12.60 - 13.75 
Age  
15 to 24 years 
25 to 44 years 
45 to 64 years 
65 years and above 
 
8.52 
36.14 
37.22 
18.13 
 
7.97 - 9.10 
34.97 - 37.32 
36.03 -38.43 
17.41 - 18.87 
Sex 
Male 
Female 
 
49.09 
50.91 
 
47.89 - 50.28 
49.72 - 52.11 
Marital status 
Married 
Common-law 
Widowed 
Divorced or Separated 
Single 
 
53.76 
11.89 
5.07 
8.67 
20.61 
 
52.58 – 54.94 
11.14 – 12.69 
4.71 – 5.45 
7.96 – 9.43 
19.70 – 21.55 
Highest level of education 
<Secondary 
Secondary grad 
Some post-secondary 
Post-secondary grad 
 
14.22 
15.70 
5.96 
64.12 
 
13.44 – 15.03 
14.09 – 16.55 
5.40 – 6.57 
62.99 – 65.24 
Race 
White 
Non-white 
 
77.63 
22.37 
 
76.53 – 78.69 
21.31 – 23.47 
Total household income (CDN$) 
No income or <20,000 
20,000-39,999 
40,000-59,999 
60,000-79,999 
80,000 or more 
 
4.16 
11.84 
18.15 
17.75 
48.10 
 
3.77 – 4.59 
11.22 – 12.48 
17.29 – 19.04 
16.85 – 18.68 
46.91 – 49.30 
No of types of childhood maltreatment 
No child abuses 
1-3 types of child abuses 
4-6 types of child abuses 
 
52.37 
40.28 
7.35 
 
51.17 – 53.56 
39.11 – 41.47 
6.76 – 7.99 
Type of smoker 
Daily 
Occasionally 
Not at all 
 
16.28 
5.37 
78.35 
 
15.42 – 17.18 
4.76 – 6.05 
77.31 – 79.36 
Family history of mental health disorder 
Yes 
No 
 
39.19 
59.85 
 
38.04 – 40.35 
58.69 – 61.00 
Personal history of mental health disorder 
Yes 
No 
 
33.46 
66.54 
 
32.38 – 34.56 
65.44 – 67.62 
12-month major depressive episode 4.54 4.10 – 4.97 
Lifetime major depressive episode 11.42 10.75 – 12.13 
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12-month alcohol use disorder1 2.85 2.49 – 3.25 
Lifetime alcohol use disorder 18.96 18.11 – 19.86 
12-month alcohol use disorder and major depression 0.42 0.31 – 0.58 
Lifetime alcohol use disorder and major depression 3.23 2.91 - 3.58 
12-month cannabis use disorder2 0.97 0.80 – 1.18 
Lifetime cannabis use disorder 6.80 6.26 – 7.39 
12-month cannabis use disorder and major depression 0.23 0.14 – 0.38 
Lifetime cannabis use disorder and major depression 1.73 1.48 – 2.01 
12-month drug use disorder3 0.59 0.47 – 0.76 
Lifetime drug use disorder (other) 4.03 3.64 – 4.47 
12-month drug use disorder and major depression 0.25 0.17 – 0.38 
Lifetime drug use disorder (other) and major depression 1.29 1.10 – 1.51 
12-month suicide ideation 3.00 2.65 – 3.40 
Lifetime suicide ideation 11.61 10.95 – 12.31 
WHO Disability Assessment Score (WHODAS) 
0 (lowest recordable degree) 
1 (40 or more – high degree) 
 
97.95 
2.05 
 
97.61 - 98.24 
1.76 - 2.39 
CCHS 2012: MH - Canadian Community Health Survey (CCHS), 2012: Mental Health Component 
< Secondary- less than secondary education; Secondary grad- secondary education graduate; Some post sec – some post secondary 
 education; Post-secondary grad – post secondary education graduate 
1Alcohol abuse or dependence; 2Cannabis abuse or dependence; 3Drugs (excluding cannabis) abuse or dependence 
4.4.2 Comorbid diagnosis and disability 
The prevalence of disability using the WHO disability assessment score for the general 
Canadian population was 2.05% (Table 4-1). Notable factors associated with an increased risk 
for disability were older age, being widowed, history of a chronic condition, and personal history 
of a mental illness (Table 4-2). Higher income and educational status were protective from 
disability (Table 4-2). 
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Table 4-2. Participants sociodemographic factors associated with disability 
  
Crude OR (95% CI) 
aAdjusted 
OR (95% CI) Statistic (p-value) 
Age 
15 to 24 years 
25 to 44 years 
45 to 64 years 
65 years and above 
 
1 
1.44 (0.67-3.06) 
3.72 (1.79-7.74)** 
4.80 (1.67-13.77)** 
 
1 
1.32 (0.75-2.32) 
2.47 (1.34-4.53)* 
2.26 (1.22-4.21)* 
0.004 
Sex 
Male 
Female 
 
1 
1.35 (1.09-1.67)* 
 
1 
1.12 (0.89-1.41) 
 
Marital Status 
Single 
Married 
Common-law 
Widowed 
Divorced or Separated 
 
1 
1.34 (1.02-1.76)* 
0.88 (0.58-1.33) 
4.14 (2.27-7.52)** 
3.19 (2.38-4.27)** 
 
1 
1.14 (0.86 -1.53) 
0.76 (0.53-1.09) 
1.69 (1.22-2.35)** 
1.46 (0.93-2.28) 
0.0005 
Educational status 
<secondary 
Secondary grad 
Some post sec 
Post-secondary grad 
 
1 
0.60 (0.41-0.89)* 
0.83 (0.46-1.53) 
0.51 (0.42-0.63)** 
 
1 
0.81 (0.56-1.17) 
1.27 (0.79-2.02) 
0.76 (0.66-0.88)** 
0.005 
Race 
White 
Non-white 
 
1 
0.83 (0.63-1.07) 
 
1 
1.30 (1.02-1.65)* 
 
Total Household Income ($) 
No income or <20,000 
20,000-39,999 
40,000-59,999 
60,000-79,999 
80,000 or more 
 
1 
0.68 (0.54-0.87)** 
0.27 (0.17-0.44)** 
0.24 (0.11-0.54)** 
0.15 (0.10-0.21)** 
 
1 
0.77 (0.59-0.99)* 
0.36 (0.21-0.63)** 
0.35 (0.13-0.95)* 
0.25 (0.16-0.42)** 
<0.0001 
Type of smoker 
Not at all 
Daily 
Occasionally 
 
1 
2.10 (1.62-2.72)** 
0.42 (0.27-0.66)** 
 
1 
1.37 (0.94-1.98) 
0.48 (0.32-0.73)** 
<0.0001 
Types of childhood maltreatment 
None 
1-3 types 
4-6 types 
 
1 
1.49 (1.04-2.13)* 
4.86 (2.89-8.19)** 
 
x 
 
History of chronic disease 
Yes 
No 
 
24.49 (15.18-39.52)** 
1 
 
13.80 (8.61-22.13)** 
1 
 
 
Family history of mental health disorder 
Yes 
No 
 
1.70 (1.16-2.48)* 
1 
 
1.45 (1.04-2.03)* 
1 
 
 
Personal history of mental illness 
Yes 
No 
 
2.96 (2.47-3.57)** 
1 
 
2.35 (1.86-2.97)** 
1 
 
 
 
a - adjusted in a multivariate model   
x – lost in multivariate analysis 
Significant values are marked in bold print  
*  p-value < =0.05 
** p-value <0.01 
0.3% of variation explained by the province of residence (p-value=0.07) 
< Secondary- less than secondary education; Secondary grad- secondary education graduate; Some post sec – some post secondary education; 
Post-secondary grad – post secondary education graduate 
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Individuals with single diagnosis of MDE only were 4 times (OR, 95%CI – 4.68, 3.46-
6.33)  more likely to have disability while the risk was 2-fold (OR, 95%CI – 2.92, 1.65-5.18) in 
single diagnosis of DUD only (Table 4.3). Compared to no diagnosis (ND), individuals with 
comorbid AUD with MDE, CUD with MDE and DUD with MDE had 4-, 6- and 9-times higher 
risk of disability respectively. Individuals with single MDE, comorbid AUD with MDE and 
DUD with MDE had significantly higher risk of disability compared to those with single SUD 
only (AUD, and DUD). 
Table 4-3. Lifetime comorbid SUD with major depression and associated disability  
OR (95%CI) 
 Ref= ND Ref = SUD Ref = MD 
Alcohol and major depression (model 1) 
ND 1 0.95 (0.60-1.50) 0.21 (0.16-0.29)** 
AUD only 1.05 (0.67-1.67) 1 0.23 (0.14-0.37)** 
MDE only 4.68 (3.46-6.33)** 4.44 (2.73-7.24)** 1 
AUD & MDE 3.97 (2.51-6.27)** 3.77 (1.87-7.60)** 0.85 (0.45-1.61) 
Cannabis and major depression (model 2) 
ND 1 0.58 (0.20-1.65) 0.22 (0.18-0.25)** 
CUD only 1.72 (0.61-4.91) 1 0.37 (0.14-0.99)* 
MDE only 4.64 (3.94-5.46)** 2.69 (1.00-7.20)* 1 
CUD & MDE 5.97 (3.08-11.61)** 3.46 (0.88-13.93) 1.29 (0.68-2.43) 
Other drugs (excluding cannabis) and major depression (model 3) 
ND 1 0.34 (0.19-0.61)** 0.21 (0.19-0.24)** 
DUD only 2.92 (1.65-5.18)** 1 0.61 (0.34-1.10) 
MDE only 4.79 (4.24-5.40)** 1.64 (0.90-2.98) 1 
DUD & MDE 8.54 (3.89-18.76)** 2.92 (1.00-8.50)* 1.78 (0.82-3.40) 
Significant values are marked in bold print  
*  p-value < =0.05 
** p-value <0.01 
1 – reference category 
Models were adjusted for age, gender, marital status, highest level of education, race, smoking status, history of any mental health disorder, family 
history of mental health disorder in multivariate analyses 
Variation explained by the province of residence: model 1 = 0.5% (p-value=0.08); model 2 = 0.4% (p-value=0.1); model 3 = 0.5% 9 (p-value=0.1) 
ND – no diagnosis; AUD - Alcohol use disorders is defined DSM-IV Alcohol Abuse /or Dependence diagnoses.; CUD - Cannabis use disorders is 
defined DSM-IV Cannabis Abuse /or Dependence diagnoses.; DUD - Drug use disorders is defined as DSM-IV diagnoses of drug abuse/or 
dependence diagnoses on opiates, sedatives, tranquilizers, amphetamines hallucinogens, heroin, cocaine, inhalants, and/or other drug except 
cannabis.; MDE - Major Depression is defined DSM-IV diagnosis of major depressive episode. SUD – AUD (model 1), CUD (model 2) and DUD 
(model 3) 
Disability was assessed with the World Health Organization Disability Assessment Schedule (WHODAS) 2.0 score (40 or more versus <40) 
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4.4.3 Comorbid diagnosis and suicide ideation 
The lifetime and 12-month prevalence of suicide ideation were 11.61% and 3.0% 
respectively (Table 4-1). Table 4-4 shows factors associated with suicidal ideation. The risk of 
suicidal thoughts is increased in those with a history of chronic health condition, childhood 
maltreatment, family and personal history of mental illness. Older age and being married or 
common-law, being a graduate (secondary or post secondary) were protective from suicidal 
ideation. 
Table 4-4. Participants sociodemographic factors associated with 12-month suicide ideation  
Crude OR (95% CI) aAdjusted 
OR (95% CI) Statistic (p-value) 
Age 
15 to 24 years 
25 to 44 years 
45 to 64 years 
65 years and above 
 
1 
0.63 (0.50-0.80)** 
0.47 (0.42-0.53)** 
0.22 (0.18-0.27)** 
 
1 
0.61 (0.50-0.75)** 
0.39 (0.32-0.49)** 
0.21 (0.16-0.27)** 
<0.0001 
Sex 
Male 
Female 
 
1 
1.08 (0.96-1.22) 
 
1 
1.08 (0.92-1.27) 
 
Marital Status 
Single 
Married 
Common-law 
Widowed 
Divorced or Separated 
 
1 
0.37 (0.33-0.41)** 
0.51 (0.26-1.00) 
0.36 (0.22-0.60)** 
0.89 (0.73-1.08) 
 
1 
0.72 (0.64-0.81)** 
0.56 (0.35-0.89)* 
0.96 (0.56-1.64) 
1.02 (0.82-1.28) 
0.0003 
Educational status 
<secondary 
Secondary grad 
Some post sec 
Post-secondary grad 
 
1 
0.67 (0.52-0.87)** 
0.95 (0.65-1.39) 
0.58 (0.50-0.68)** 
 
1 
0.64 (0.46-0.90)* 
0.60 (0.34-1.04) 
0.69 (0.52-0.91)* 
0.05 
 
Race 
White 
Non-white 
 
1 
1.13 (0.88-1.45) 
 
1 
1.34 (1.12-1.61)** 
 
Total Household Income ($) 
No income or <20,000 
20,000-39,999 
40,000-59,999 
60,000-79,999 
80,000 or more 
 
1 
0.69 (0.44-1.10) 
0.48 (0.29-0.80)* 
0.44 (0.29-0.65)** 
0.30 (0.22-0.40)** 
 
1 
0.95 (0.64-1.42) 
0.81 (0.52-1.27) 
0.72 (0.46-1.13) 
0.51 (0.40-0.67)** 
<0.0001 
Type of smoker 
Not at all 
Daily 
Occasionally 
 
1 
2.38 (2.09-2.72)** 
2.36 (1.48-3.76)** 
 
1 
1.19 (1.01-1.40)* 
1.43 (0.96-2.13) 
0.04 
Types of childhood maltreatment 
None 
1-3 types 
4-6 types 
 
1 
2.66 (1.94-3.64)** 
8.08 (6.08-10.77)** 
 
1 
1.80 (1.21-2.68)* 
3.05 (2.29-4.06)** 
<0.0001 
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History of chronic disease 
Yes 
No 
 
3.05 (2.60-3.58)** 
1 
 
2.47 (2.02-3.03)** 
1 
 
Family history of mental health disorder 
Yes 
No 
 
2.70 (2.50-2.91)** 
1 
 
1.62 (1.38-1.89)** 
1 
 
Personal history of mental illness 
Yes 
No 
 
7.06 (5.61-8.88)** 
1 
 
4.41 (3.42-5.69)** 
1 
 
a – adjusted in a multivariate model 
Significant values are marked in bold print  
*  p-value < =0.05 
** p-value <0.01 
Variation explained by the Province of residence is 0.001% (p-value=0.7) 
< Secondary- less than secondary education; Secondary grad- secondary education graduate; Some post sec – some post secondary 
education; Post-secondary grad – post secondary education graduate 
Compared to those with no diagnosis (Table 4-5), individuals with comorbid 
diagnosis of AUD with MDE, CUD with MDE, DUD with MDE were 9 to 16 times more 
likely to have suicide ideation (OR 95% CI -  9.02, 5.61-14.49; 11.27, 7.57-16.78; 16.19, 
11.10-23.63 respectively). Individuals with comorbid diagnosis of AUD with MDE, CUD 
with MDE and DUD with MDE had about six to eight-fold increase in the risk of suicide 
when compared with individuals with single SUD only (OR 95% CI -  5.58, 4.28-7.27; 
8.11, 5.01-13.12; 6.63, 5.10-8.64 respectively). A single diagnosis of MDE gave about 7-
fold increase in the risk of suicide ideation when compared with no diagnosis, and three 
to five-fold increase when compared with a single diagnosis of DUD, AUD and CUD 
(OR 95% CI -  2.92, 2.18-3.91; 4.08, 2.10-7.93; 5.16, 3.75-7.09) respectively. A single 
diagnosis of DUD only gave a 2-fold increase in the risk of suicide ideation compared to 
individuals with no diagnosis.  
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Table 4-5. DSM-IV diagnoses and the risk of 12-month suicide ideation  
OR (95%CI) 
 Ref= ND Ref = SUD Ref = MD 
Alcohol and major depression (model 1) 
ND 1 0.62 (0.38-1.02) 0.15 (0.11-0.22)** 
AUD only 1.62 (0.98-2.66) 1 0.25 (0.13-0.48)** 
MDE only 6.59 (4.58-9.47)** 4.08 (2.10-7.93)** 1 
AUD & MDE 9.02 (5.61-14.49)** 5.58 (4.28-7.27)** 1.37 (0.80-2.35) 
Cannabis and major depression (model 2) 
ND 1 0.72 (0.51-1.01) 0.14 (0.09-0.22)** 
CUD only 1.39 (0.99-1.96) 1 0.19 (0.14-0.27)** 
MDE only 7.17 (4.49-11.46)** 5.16 (3.75-7.09)** 1 
CUD &MDE 11.27 (7.57-16.78)** 8.11 (5.01-13.12)** 1.57 (0.86-2.88) 
Other drugs (excluding cannabis) and major depression (model 3) 
ND 1 0.41 (0.28-0.60)** 0.14 (0.09-0.21)** 
DUD only 2.44 (1.66-3.59)** 1 0.34 (0.26-0.46)** 
MDE only 7.13 (4.76-10.68)** 2.92 (2.18-3.91)** 1 
DUD &MDE 16.19 (11.10-23.63)** 6.63 (5.10-8.64)** 2.28 (1.47-3.53)** 
Significant values are marked in bold print  
*  p-value < =0.05 
** p-value <0.01 
1 – reference category 
Models were adjusted for age, gender, marital status, highest level of education, race, smoking status, history of any mental health disorder, family 
history of mental health disorder in multivariate analyses 
Variation explained by the Province of residence: model 1=0.01% (p-value=0.6);  model 2=0.01% (p-value=0.4); model 3=0.01% (p-value=0.4) 
ND – no diagnosis; AUD - Alcohol use disorders is defined DSM-IV Alcohol Abuse /or Dependence diagnoses.; CUD - Cannabis use disorders is 
defined DSM-IV Cannabis Abuse /or Dependence diagnoses.; DUD - Drug use disorders is defined as DSM-IV diagnoses of drug abuse/or 
dependence diagnoses on opiates, sedatives, tranquilizers, amphetamines hallucinogens, heroin, cocaine, inhalants, and/or other drug except 
cannabis.; MDE - Major Depression is defined DSM-IV diagnosis of major depressive episode. SUD – AUD (model 1), CUD (model 2) and DUD 
(model 3) 
The relationship between DSM-IV diagnosis and the probability of suicide ideation and 
disability in the population is shown in figure 4-1. The probability of suicide ideation and 
disability is <10% and <2% respectively in individuals with no diagnosis of either SUD (AUD, 
CUD or DUD) or MDE. There is 18-34% and 2-4% probability of suicide ideation and disability 
respectively with isolated diagnosis of a SUD. With a diagnosis of comorbid SUD with MDE, 
the probability of the suicide ideation and disability range from 60-80% and 11-17% 
respectively.  
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Figure 4-1. Relationship between DSM-IV diagnosis and the probability of suicide ideation and 
disability  
 
 AUD - Alcohol use disorder, defined DSM-IV Alcohol Abuse /or Dependence diagnoses.; CUD - Cannabis use disorder, defined DSM-IV 
Cannabis Abuse /or Dependence diagnoses; DUD - Drug use disorder, defined as DSM-IV diagnoses of drug abuse/or dependence diagnoses on 
opiates, sedatives, tranquilizers, amphetamines hallucinogens, heroin, cocaine, inhalants, and/or other drug except cannabis.; MDE - Major 
depressive episode, defined DSM-IV diagnosis of major depressive episode.  
4.5 Discussion 
4.5.1 Prevalence and associations of comorbid diagnosis 
The past 12-month prevalence of AUD, CUD, DUD, and MDE were 2.9%, 0.97%, 0.6% 
and 4.5% respectively. This prevalence of MDE, which is about twice that of AUD, is consistent 
with the findings from a previous Canadian survey on the same population (Currie, et al., 2005). 
A much higher prevalence was found for depression (Hasin, Goodwin, Stinson, & Grant, 2005), 
alcohol use disorder (Grant, et al., 2015; Grant, et al., 2004), cannabis and drugs use disorder 
(Grant, et al., 2004) in the US compared to our study. Prevalence of comorbid diagnosis of SUD 
with MDE in our study was much lower than those found in the US (Grant, et al., 2004). These 
variations in the prevalence of SUDs, MDE and comorbid SUD with MDE could be due to 
different population characteristics, research methodologies, and diagnostic criteria.  
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4.5.2 Comorbid SUD with MDE and disability  
  Our study showed a gradual increase in the probability of disability in the population as 
one moves from ‘no diagnosis’ to single diagnosis of a SUD, a single diagnosis of MDE through 
comorbid diagnosis of SUD with MDE. The risk of disability was high in individuals with single 
diagnosis of DUD or MDE and comorbid diagnosis of SUD with MDE in our study. Our study 
showed a significantly higher odds of disability in comorbid AUD with MDE (OR, 95%CI - 
3.77, 1.87-7.60) and comorbid DUD with MDE (OR, 95%CI - 2.92, 1.00-8.50) compared to 
single diagnosis of AUD and DUD respectively. This was consistent with other studies that 
found increased social, occupational and functional disability as well as healthcare utilization 
amongst individuals with comorbid substance use and psychiatric disorders (Wilk, West, Rae, & 
Regier, 2006; Olfson, et al., 1997; Kessler, et al., 1996; Kessler, Foster, Saunders, & Stagg, 
1995; Kessler R. , 2004; Burns, Teesson, & O'Neill, 2005). This finding could be explained by 
the synergistic interaction of the pathological effects of comorbid conditions.  
Major depression was found to have an associated increased risk of disability compared 
to isolated AUD or CUD. However, comorbid SUD (AUD, CUD, DUD) with MDE were not 
significantly associated with disability when compared with isolated MDE. Two possible 
explanations could be responsible for these findings. Firstly, it could be that the substance use by 
individuals with comorbid diagnosis was seen secondary to self-medication for the mood 
disorder, hence, the substance use disorders are less severe with less effect on functioning (Wilk, 
West, Rae, & Regier, 2006). Secondly, since pharmacological therapy is an integral part of the 
treatment of mood disorders, those with comorbid diagnosis are more likely to be on 
pharmacological agents that may lessen the effect of substance use disorders on patient 
functioning (Wilk, West, Rae, & Regier, 2006).  
Disability is known to be significantly associated with poorer quality of life (Üstün, et al., 
2010; Thomas, Nisha, & Varghese, 2016; Tharoor, NarasimhanaSharma, & Chauhan, 2007). 
Therefore, the increased disability associated with comorbid SUD with MDE found in our study 
provides further evidence of a lower quality of life by individuals with the comorbidity 
(Saatcioglu, Yapici, & Cakmak, 2008). 
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4.5.3 Comorbid SUD with MDE and risk of suicide ideation 
Findings from our study showed a gradual increase from ‘no diagnosis’ to comorbid 
diagnosis of SUD with MDE in the probability of having suicidal thoughts in the population. Our 
study also showed an increased risk of suicidal thoughts in individuals with comorbid SUD with 
MDE and sole diagnosis of MDE or DUD, consistent with previous studies (Currie, et al., 2005; 
Sher, et al., 2008; Cornelius, et al., 1995). This also supports other studies that demonstrated 
AUDs and major depression as the most commonly diagnosed major pathological disorders in 
persons who commit suicide (Fawcett, Clark, & Busch, 1993; Rudd, Dahm, & Rajab, 1993; 
Henriksson, et al., 1993).  
When compared with individuals with no diagnosis, the risk of suicide ideation 
associated with comorbid SUD with MDE (OR, 95%CI: AUD/MDE - 9.02 , 5.61-14.49;  
CUD/MDE- 11.27, 7.57-16.78; DUD/MDE -16.19, 11.10-23.63) was much higher than the risk 
associated with single diagnosis of MDE (OR, 95%CI - 7.13, 4.76-10.68). Comorbid SUD with 
MDE significantly increased the odds of suicide ideation when compared with the sole diagnosis 
of AUD (OR, 95%CI -5.58, 4.28-7.27), CUD (OR, 95%CI - 8.11, 5.01-13.12), DUD (OR, 
95%CI- 6.63, 5.10-8.64) and MDE (OR, 95%CI - 2.28, 1.47-3.53). These findings were 
consistent with previous findings of a disproportionate increase in suicide ideation with 
comorbid AUD with MDE (Barraclough, Bunch, Nelson, & Sainsbury, 1974; Cornelius J. R., et 
al., 1995; Britton, et al., 2015; Brière, Rohde, Seeley, & Daniel Klein, 2014). In addition, when 
compared with the single diagnosis of SUD, a single diagnosis of MDE had a two to five-fold 
increase in the risk of suicide ideation, also consistent with previous findings where primary 
major depression without secondary AUD conferred a prospective risk of suicide attempts on the 
population (Britton, et al., 2015). 
This associated increased risk of suicide ideation in comorbid SUD with MDE can be 
explained by depression mediating the effect of SUD on suicide or SUD being the consequence 
of MDE. Studies suggest that suicidal behaviour, aggression, and alcoholism have been linked to 
abnormal serotonergic function (Mann & Malone, 1997; Mann, Brent, & Arango, 2001); and this 
has been proposed to mediate an individual’s genetic and developmental predispositions (Mann, 
Waternaux, Haas, & Malone, 1999). In addition, studies on humans and animals alike have 
shown that increased uninhibited psychopathology, substance abuse, and impulsive aggression 
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were secondary to serotonin abnormalities (Crabbe, et al., 1996; Saudou, et al., 1994; Mann, 
Brent, & Arango, 2001). 
Consistent with previous studies, drug use disorders had significant association with 
suicide ideation (Schneider, 2009; Borges, Walters, & Kessler, 2000; Miller, et al., 2011; 
Petronis, Samuel, Mosckicki, & Anthony, 1990; Borges, Benjet, Orozco, Medina-Mora, & 
Menendez, 2017a). Inconsistent with previous reports, our study did not find an increased risk of 
suicide ideation in AUD and CUD only (Sher, et al., 2008; Flensborg-Madsen, et al., 2009; 
Borges, Benjet, Orozco, Medina-Mora, & Menendez, 2017a; Shalit, Shoval, Shlosberg, 
Feingold, & Lev-Ran, 2016) after controlling for sociodemographic factors and family history of 
mental illness. This we attributed to the DSM IV substance use disorder criteria, that is the 
presence of DSM IV substance abuse or DSM IV substance dependence without an indication of 
severity as seen in DSM V.  This finding was however, consistent with a previous finding of no 
association in low to moderate severity of cannabis use (Shalit, Shoval, Shlosberg, Feingold, & 
Lev-Ran, 2016).  
4.5.4 Strengths and limitations 
A strength of this analysis is that it was based on a nationally representative sample of the 
Canadian population which provides insight into these comorbidities among individuals 
irrespective of their health-seeking behaviors. Another strength was that the diagnoses of 
substance use disorders and major depressive episodes were derived from DSM IV criteria using 
a structured diagnostic interview and algorithm (WMH-CIDI).  This study included different 
comparison groups of SUD and MDE highlighting the actual effects of comorbid associations. 
Missing values were accounted for using multiple imputations and the complex data structure 
was accounted for with multilevel random effects models and survey weights, enabling 
generalizability. Limitations of this study include the cross-sectional study design which does not 
allow for causal inference. Further studies would be required to assess causality. Individuals 
living on reserves and other Aboriginal settlements, in institutions and full-time members of the 
Canadian Forces which make up about 3% of the total population were excluded from the data. 
Therefore, our analysis may have underestimated the true strength of associations of interest. 
This study was based on self-reported data, thus could be compromised by recall bias and under-
reporting. 
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4.6  Conclusion 
In conclusion, this study does provide further evidence of associated risk of disability and the 
risk of suicide ideation among persons who have comorbid alcohol use disorders, cannabis use 
disorders, drug use disorders with major depression. Effective integration of mental health and 
addictions services may contribute to better treatment outcomes. 
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Appendix A.  Missing values analysis 
Table A.1 Summary of missing values 
Variables Observed Missing Imputed Total 
Marital status 25,045 68 68 25113 
Educational status 25,002 111 111 25113 
Race 25,012 101 101 25113 
Income 25,099 14 14 25113 
12-month CUD 24,910 203 203 25113 
Lifetime CUD 24,905 208 208 25113 
12-month DUD 24,833 280 280 25113 
Lifetime DUD 24,828 285 285 25113 
12-month AUD 24,737 376 376 25113 
Lifetime AUD 24,719 394 394 25113 
12-month MDE 24,954 159 159 25113 
Lifetime MDE 24,951 162 162 25113 
12-month suicide ideation 25038 75 75 25113 
Lifetime suicide ideation 25040 73 73 25113 
WHO disability assessment score 24974 319 319 25113 
Childhood maltreatment 22562 2551 2551 25113 
Smoking status 25,097 16 16 25113 
Family history of mental illness 24,832 281 281 25113 
Personal history of mental illness 24,373 740 740 25113 
History chronic condition 25086 27 27 25113 
CUD- cannabis us disorder; AUD- alcohol use disorder; DUD – other drugs (excluding cannabis) use disorder; MDE – major 
depressive episode; WHO – World health Organization 
 
 
Test for Missing Completely At Random (MCAR) 
Little's MCAR test: Prob > chi-square   = 0.0000 
Data is not MCAR. 
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Table A.2 Association of predictor variables and missingness in 12-month suicide ideation 
Variables Chi square p-value 
Province of residence 0.10 
Age  0.55 
Sex 0.46 
Marital status 0.36 
Educational status 0.05 
Race 0.58 
Income 0.003 
12-month CUD 0.33 
Lifetime CUD 0.08 
12-month DUD 0.48 
Lifetime DUD 0.27 
12-month AUD 0.15 
Lifetime AUD 0.001 
12-month MDE 0.96 
Lifetime MDE 0.67 
Smoking status 0.47 
Childhood maltreatment 0.31 
Family history of mental illness <0.0001 
Personal history of mental illness 0.95 
History of a chronic condition 0.07 
CUD- cannabis us disorder; AUD- alcohol use disorder; DUD – other drugs (excluding cannabis) use disorder;  
MDE – major depressive episode 
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Table A.3  Association of predictor variables and missingness in WHO disability 
assessment score 
Variables Chi square p-value 
Province of residence 0.20 
Age  <0.0001 
Sex <0.0001 
Marital status <0.0001 
Educational status <0.0001 
Race 0.82 
Income <0.0001 
Body mass index 0.76 
12-month CUD 0.04 
Lifetime CUD 0.52 
12-month DUD 0.43 
Lifetime DUD 0.41 
12-month AUD 0.09 
Lifetime AUD 0.05 
12-month MDE <0.0001 
Lifetime MDE 0.04 
Smoking status 0.08 
Childhood maltreatment 0.16 
Family history of mental illness <0.0001 
Personal history of mental illness 0.63 
Has a chronic condition <0.0001 
WHO- World Health Organization; CUD- cannabis us disorder; AUD- alcohol use disorder; DUD – other drugs (excluding 
cannabis) use disorder; MDE – major depressive episode 
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CHAPTER 5. SUBSTANCE USE DISORDER, OVERWEIGHT/OBESITY AND 
CO-MORBID MAJOR DEPRESSION 
5.1  Introduction 
Obesity/overweight and substance use disorders (SUDs) are major risk factors in the global 
burden of disease (Pasch, Velazquez, Cance, Moe, & Lytle, 2012). They are significant public 
health problems associated with increased health risks, morbidity, mortality, medical costs and 
reduced life expectancy (Bertakis & Azari, 2005; McGinnis & Foege, 1999; Must, et al., 1999; 
N’Goran, et al., 2015). Psychiatric disorders also contribute immensely to global disease burden 
(Kessler, Chiu, Delmer, Merikangas, & Walters, 2005; Greenberg, et al., 1999), and frequently 
co-occur with both obesity (Simon, et al., 2006) and substance use disorders (Kessler, Chiu, 
Delmer, Merikangas, & Walters, 2005; Grant, et al., 2004; Hasin, Goodwin, Stinson, & Grant, 
2005) with major depression having an increased likelihood for this association.  Despite this 
comorbidity with psychiatric disorders, an inverse relationship is said to exist between obesity 
and SUD (Gruchow, Sobocinski, Barboriak, & Scheller, 1985; Lahti-Koski, Pietinen, 
Heliovaara, & Vartiainen, 2002; Liu, Serdula, Williamson, Mokdad, & Byers, 1994; Kleiner, et 
al., 2004; Gearhardt & Corbin, 2009; Warren, Frost-Pineda, & Gold, 2005; Pickering, et al., 
2011). 
Several mechanisms have been suggested to explain the association between body mass 
index (BMI) and substance use. One mechanism is the ‘coping model’. Here, it is suggested that 
to cope with the negative social and emotional consequences of their excess weight, individuals 
problematically use substances (Pasch, Velazquez, Cance, Moe, & Lytle, 2012). Those who are 
overweight/obese may also use substances as a weight control strategy in the ‘weight control 
model’ (Pasch, Velazquez, Cance, Moe, & Lytle, 2012). In another mechanism, some substances 
may increase the risk of future weight gain especially alcohol and cannabis, in the ‘weight gain 
model’ (Pasch, Velazquez, Cance, Moe, & Lytle, 2012). Alcohol may affect the energy balance 
and cannabis has been linked to increased appetite and decreased inhibitions. This can lead to 
increased calorie intake and dulling of the incentive to physical activity (Pasch, Velazquez, 
Cance, Moe, & Lytle, 2012). Finally, it is suggested that food intake and substance use both 
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compete for the same neural reward sites in the brain and as such, a higher BMI is most likely to 
be associated with lower substance use (Blüml, et al., 2012). 
Some literature support the hypothesis that common neural substrates underlie both food and 
illicit drug consumption (Kalivas & Volkow, 2005; Trinko, Sears, Guarnieri, & DiLeone, 2007; 
Volkow, Wang, Fowler, & Telang, 2008; Volkow & Wise, 2005). The hypothesized 
neurobiological pathways responsible for the regulation of food intake and substance use are the 
mesolimbic and mesocortical dopaminergic reward-motivation circuits and endogenous opioid 
systems (Volkow & Wise, 2005; Trinko, Sears, Guarnieri, & DiLeone, 2007; Wang, Volkow, 
Thanos, & Fowler, 2004; Di Chiara & Imperato, 1988; MacDonald, Billington, & Levine, 2004). 
A disorder in the reward homeostasis and/or a deficit in the neural reward circuits are thought to 
be the mechanisms through which obesity and substance use disorder occur (Johnson & Kenny, 
2010). Evidence from neuro-functional imaging studies showed low levels of dopamine D2 in 
drug-addicted subjects (Volkow, Fowler, & Wang, 2004) and in obese patients with an inverse 
relationship between BMI and dopamine D2 receptor levels (Wang, et al., 2001). In addition, 
genome scan studies reported that different consumption phenotypes, that is food or drug abuse, 
have common genetic determinants (Ehlers & Wilhelmsen, 2007). 
Several large epidemiological studies show the inverse relationship between substance use 
and BMI (Gearhardt & Corbin, 2009; Kleiner, et al., 2004; Duncan, et al., 2009; Breslow & 
Smothers, 2005; Blüml, et al., 2012) but these results are not unanimous as other studies could 
not find this inverse association (Arif & Rohrer, 2005; Barry & Petry, 2009; Pickering, Grant, 
Chou, & Compton, 2007; Petry, Barry, & Pietrzak, 2008; McLaren, Beck, Patten, Fick, & Adair, 
2008). However, most of these studies were cross-sectional and lack the ability to determine 
causality since cross-sectional study designs do not have the temporality criterion; an important 
determinant of causality (Hill A. B., 1965). Even though some studies found no association 
(Mather, Cox, Enns, & Sareen, 2009; Petry, Barry, & Pietrzak, 2008) or a positive relationship 
(McLaren, Beck, Patten, Fick, & Adair, 2008) between obesity and SUD, in their longitudinal 
study, Pickering et al., (2011) found that persons who were overweight or obese had a reduced 
likelihood of having alcohol or SUDs after 3 years. Thus, with the excess consumption of one 
substance (e.g., drug abuse), the reward system is activated and the desire for and use of the 
other substance (e.g., food) may be blocked or reduced (Gearhardt, Harrison, & McKee, 2012). 
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Few studies have been done to examine the association between obesity and substance use 
with underlying major depression and none in Canada. Studying the association between obesity 
and SUD with depression is important since depression may encourage the excessive 
consumption of food and addictive substances (Gearhardt, Harrison, & McKee, 2012). Major 
depression may increase the likelihood of either obesity or SUDs, but does it alter the 
relationship between obesity and SUDs? This forms the basis for the hypothesis, that major 
depression could alter the inverse relationship between obesity and SUDs. 
5.2 Objective 
This study was aimed to examine the associations between substance use disorders and 
overweight/obesity, and the effect major depression has on this relationship. 
5.3  Methods  
5.3.1 Subjects 
Data for these analyses came from the Canadian Community Health Survey (CCHS), 
2012: Mental Health Component (CCHS 2012: MH) (Statistics Canada, 2014). Briefly, it is a 
cross sectional survey of persons aged 15 years or more and resident in one of the ten Canadian 
provinces. Criteria for exclusion from the survey were living  in certain remote areas, 
institutions, and reserves. In addition, full-time members of the Canadian Forces were not 
surveyed. These excluded populations make an estimated 3% of the target national population 
(Statistics Canada, 2014). The CCHS 2012: MH is a comprehensive look at mental health with 
respect to who is affected by specific mental health disorders, positive mental health, access to 
and utilization of formal and informal mental health services and support; as well as individual 
functionality, regardless of the presence of a mental health problem (Statistics Canada, 2014). 
The data was collected by Statistics Canada between January and December of 2012, (N = 
25,113) with a response rate of 86.3%.  
The current analysis was conducted for the cohort of individuals who met the inclusion 
criteria for deriving Body Mass Index (BMI) in the data, N= 22,881 (Figure 5-1). Inclusion 
criteria for BMI in the data was adult respondents aged 20 and over and not pregnant. Female 
respondents who were between ages 18 to 49 years and were pregnant or did not respond to the 
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pregnancy question were excluded from the BMI data. In addition, the BMI data was suppressed 
for individuals 15-19year old since BMI classification for less than 18 is different from adults 
(Statistics Canada, 2014).  
This secondary analysis of the CCHS 2012: MH dataset was done using the Public Use 
Microdata Files (PUMF). Unlike the confidential microdata files (Master data files) which are 
accessible through Research Data Centres only, the PUMF is manipulated by aggregating, 
capping, or completely erasing variables that are considered personal identifiers to allow for 
accessibility through University libraries while maintaining confidentiality (Statistics Canada, 
2017). 
Figure 5-1. Cohort sample derivation 
 
*Excluded from the analysis 
5.3.2 Major Depression 
Unipolar Major Depressive Episode (MDE) was defined using the World Mental Health 
version of the Composite International Diagnostic Interview (WMH-CIDI) algorithm derived 
from the Diagnostic and Statistical Manual of Mental Disorders IV (DSM IV). This analysis was 
based on both the 12-month and lifetime MDE (Statistics Canada, 2014). 
Original CCHS 2012: MH sample
n=25,113
Final cohort n=22,881 
Individuals 20 years and older 
Individuals not pregnant
Excluded from the BMI data n=2,232*
Individuals aged  15-19years 
Individuals pregnant 
Individuals who did not respond to the 
pregnancy question
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5.3.3 Substance Use Disorder (SUD) 
The WMH-CIDI algorithms derived from DSM IV were used to define substance abuse 
or dependence for alcohol (alcohol use disorder -AUD), cannabis (cannabis use disorder – CUD) 
and other drugs excluding cannabis (drugs use disorder- DUD) in the data (Statistics Canada 
2014). This analysis was based on symptoms of abuse or dependence reported in the last 12-
months and lifetime (Statistics Canada, 2014). 
5.3.4 Body Mass Index (BMI) 
Body Mass Index was derived from self-reported weight and height in the survey data 
and was classified as: underweight (<18.5), normal weight (18.5 – 24.9), over-weight (25.0 – 
29.9) and obese (>= 30.0) for adults 20years and over using the international standard (Statistics 
Canada, 2014).  Female respondents aged 18 to 49 who were pregnant or did not answer the 
pregnancy question were excluded from the BMI data (Statistics Canada, 2014).  
5.3.5 Other measures 
Demographic information was obtained for: age, sex, gender, marital status, (married, 
common-law, widowed, divorced or separated, single), highest level of education (less than 
secondary education, secondary education graduate, some post secondary education, post 
secondary education graduate), total household income in Canadian dollars (no income or 
<20,000, 20,000-39,999, 40,000-59,999, 60,000-79,999, 80,000 or more), race (white, non-
white), smoking status, personal and family history of mental health disorder. 
5.3.6 Statistical Analyses 
First, by merging each SUD (alcohol, cannabis, other drugs) variable and MDE, a new 
variable, comorbid SUD with MDE was created. For each SUD, the new variable created had 
four levels – no diagnosis (neither SUD nor MDE), single diagnosis of SUD (AUD or CUD or 
DUD), single diagnosis of MDE and comorbid diagnosis of SUD with MDE. Second, 
participants were described according to the BMI category. Third, analyses to examine the 
sociodemographic and other risk factors of BMI was done. The main associations between major 
depression, SUDs (alcohol, cannabis only and other drugs excluding cannabis) on BMI category 
were also done. Then, the comorbid associations, that is, SUDs with MDE on BMI category 
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were assessed. These associations were assessed using multinomial logistic regression models in 
STATA version 14 after a failed proportional odds assumption test (the Brant test). In these 
analyses, individuals with normal weight BMI category were the reference category.  
Missing values were assessed using MCAR test on Stata 14 to determine if data was missing 
completely at random (MCAR) and a justification for a complete case analysis. Data was not 
MCAR (Appendix 1). Multiple imputations using chained equations was then carried out 
following significant Chi Square associations between the independent variables and the 
missingness in the outcome variable (BMI) (Appendix 1). Generalized Hosmer–Lemeshow 
goodness of fit was used to fit the outcome models and imputation models prior to imputation. 
After estimation with the imputed data, the models were tested for equal fraction-missing-
information to check that the between-imputation and within-imputation variances were 
proportional. The complex sampling method of the data was accounted for by using the sampling 
weights provided by Statistics Canada on the survey (svy) command in Stata.  
Four models (AUD, CUD, DUD and MDE) were assessed for the main associations with 
BMI while three models (alcohol and depression, cannabis and depression, other drugs excluding 
cannabis and depression) were examined for the comorbid associations between SUD and MDE 
on BMI. Using a stepwise multinomial logistic regression analysis with backward elimination of 
covariates, multivariate models were built with the addition of sociodemographic factors and 
other risk factors as covariates. Since the multinomial models of multiply data did not allow 
pairwise comparison post hoc analyses, comparisons of different levels of the comorbid variable 
were generated by changing the reference category. The relative risk ratios (RRR) of the risk 
factors of BMI , the main associations and comorbid models were reported. Confounding was 
assessed for variables eliminated from the multivariate models and re-entered into the models if 
present. Since the focus of the analysis was to understand the main effects and the differences 
between isolated substance use disorders, major depression and the comorbidities on the risk of 
overweight/obesity, biologically plausible interaction terms were not assessed. 
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5.4 Results  
5.4.1 Participant characteristics  
Table 5-1 below shows the participants sociodemographic distributions in relation to their 
BMI status. About a fifth of the population was obese while a third was overweight. Obese 
participants were more likely to be middle-aged, more likely to be married, more likely to be a 
post-secondary graduate and white. 
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Table 5-1. CCHS 2012: MH participants characteristics by BMI 
 Underweight % 
(95%CI) 
Normal  weight 
% (95%CI) 
Overweight  
% (95%CI) 
Obese 
% (95%CI) 
Total 
% (95%CI) 
Age 
20 to 24 years 
25 to 44 years 
45 to 64 years 
65 years and above 
 
0.5 (0.3-0.6) 
0.9 (0.7-1.1) 
0.5 (0.4-0.6) 
0.4 (0.3-0.6) 
 
5.3 (4.8-5.7) 
17.1 (16.1-18.0) 
14.7 (13.8-15.7) 
7.6 (7.1-8.0) 
 
1.6 (1.4-1.9) 
11.2 (10.4-12.0) 
13.8 (13.0-14.6) 
7.0 (6.6-7.5) 
 
1.0 (0.8-1.1) 
6.3 (5.8-6.9) 
8.6 (7.9-9.3) 
3.7 (3.3-4.0) 
 
8.3 (7.8-8.9) 
35.5 (34.3-36.6) 
37.5 (36.4-38.7) 
18.7 (18.0-19.4) 
Sex 
Male 
Female 
 
0.7 (0.5-0.8) 
1.6 (1.4-1.9) 
 
19.5 (18.5-20.5) 
25.1 (24.1-26.2) 
 
19.9 (19.1-20.9) 
13.6 (12.4-14.4) 
 
10.1 (9.4-10.8) 
9.4 (8.7-10.1) 
 
50.2 (49.0-51.4) 
49.8 (48.6-51.0) 
Marital status 
Married 
Common law 
Widowed 
Divorced/Separated 
Single 
 
0.8 (0.6-0.9) 
0.3 (0.2-0.5) 
0.2 (0.1-0.4) 
0.2 (0.1-0.3) 
0.8 (0.6-1.0) 
 
22.2 (21.2-23.2) 
5.4 (5.0-6.0) 
2.2 (2.0-2.4) 
3.9 (3.4-4.5) 
10.9-10.2-11.7) 
 
19.4 (18.5-20.3) 
3.7 (3.2-4.2) 
1.6 (1.5-1.8) 
3.3 (2.9-3.8) 
5.4 (5.1-6.1) 
 
11.3 (10.6-12.1) 
2.2 (1.9-2.5) 
1.2 (1.0-1.4) 
1.4 (1.2-1.6) 
3.5 (3.1-3.9) 
 
53.7 (52.5-54.8) 
11.6 (10.9-12.4) 
5.2 (4.9-5.6) 
8.8 (8.1-9.6) 
20.7 (19.8-21.7) 
Highest level of education 
< secondary 
Secondary grad 
Some post sec 
Post-secondary grad 
 
0.4 (0.3-0.5) 
0.4 (0.3-0.6) 
0.2 (0.1-0.3) 
1.3 (1.1-1.5) 
 
5.5 (5.0-6.1) 
6.3 (5.8-6.8) 
2.8 (2.4-3.2) 
30.1 (29.0-31.2) 
 
5.1 (4.7-5.6) 
5.6 (5.1-6.1) 
1.8 (1.5-2.2) 
21.1 (20.2-22.1) 
 
3.6 (3.3-4.1) 
3.3 (2.9-3.8) 
1.2 (1.0-1.5) 
11.4 (10.7-12.1) 
 
14.6 (13.8-15.4) 
15.6 (14.8-16.4) 
6.0 (5.5-6.6) 
63.9 (62.7-65.0) 
Race 
White 
Non-white 
 
1.5 (1.3-1.7) 
0.8 (0.6-1.0) 
 
32.7 (31.6-33.8) 
11.9 (11.0-12.8) 
 
26.6 (25.7-27.7) 
7.0 (6.3-7.7) 
 
17.0 (16.2-17.9) 
2.6 (2.3-3.0) 
 
77.8 (76.7-78.8) 
22.2 (21.2-23.3) 
Total household income 
<$20,000 or no income 
$20,000-39,999 
$40,000-59,999 
$60,000-79,999 
$80,000 or more 
 
0.2 (0.1-0.3) 
0.4 (0.3-0.5) 
0.6 (0.5-0.8) 
0.4 (0.3-0.5) 
0.7 (0.6-0.9) 
 
2.1 (1.8-2.5) 
5.4 (5.0-5.9) 
8.3 (7.7-9.0) 
7.8 (7.2-8.5) 
21.0 (20.0-22.1) 
 
1.3 (1.1-1.5) 
4.1 (3.7-4.5) 
5.9 (5.4-6.5) 
5.9 (5.4-6.4) 
16.4 (15.6-17.4) 
 
0.8 (0.7-1.0) 
2.5 (2.2-2.8) 
3.6 (3.3-4.0) 
3.5 (3.1-4.0) 
9.0 (8.4-9.8) 
 
4.5 (4.1-4.9) 
12.3 (11.7-13.0) 
18.4 (17.6-19.3) 
17.6 (16.7-18.5) 
47.2 (46.0-48.4) 
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CCHS 2012:MH - Canadian Community Health Survey (CCHS), 2012: Mental Health Component 
< Secondary- less than secondary education; Secondary grad- secondary education graduate; Some post sec – some post secondary education; Post-secondary grad – post 
seconadary education graduate 
 
 
 
 
 
 
 
 
 
 
 
 
 
Type of smoker 
Daily 
Occasionally 
Not at all 
 
0.6 (0.5-0.8) 
0.1 (0.06-0.2) 
0.6 (1.4-1.9) 
 
7.4 (6.9-8.0) 
2.8 (2.3-3.3) 
34.4 (33.3-35.6) 
 
5.4 (4.8-6.0) 
1.8 (1.5-2.2) 
26.4 (25.4-27.4) 
 
3.1 (2.7-3.5) 
0.8 (0.7-1.0) 
15.7 (14.9-16.5) 
 
16.4 (15.6-17.3) 
5.5 (4.9-6.2) 
78.1 (77.1-79.1) 
History of mental health disorder 
Yes 
No 
 
0.7 (0.6-0.9) 
1.5 (1.3-1.8) 
 
14.2 (13.4-15.0) 
30.4 (29.2-31.5) 
 
12.0 (11.3-12.7) 
21.7 (20.7-22.7) 
 
7.4 (6.9-8.0) 
12.2 (11.4-13.0) 
 
34.2 (33.2-35.3) 
65.8 (64.7-66.8) 
Family history of mental health disorder 
Yes 
No 
 
0.8 (0.7-0.9) 
1.5 (1.3-1.8) 
 
17.1 (16.2-18.1) 
27.4 (26.3-28.5) 
 
12.7 (12.0-13.4) 
21.0 (20.0-22.0) 
 
8.4 (7.8-9.0) 
11.2 (10.5-11.9) 
 
39.0 (37.8-40.1) 
61.0 (60.0-62.2) 
All participants 2.3 (2.0-2.6) 44.6 (43.4-45.8) 33.6 (32.5-34.7) 19.5 (18.6-20.4) 1 
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Table 5-2. CCHS 2012: MH participants distribution of DSM-IV diagnoses by BMI categories 
 
Underweight  
(95% CI) 
Normal weight 
% (95% CI) 
Overweight 
% (95% CI) 
Obesity    
% (95% CI) 
Total 
% (95% CI) 
aAlcohol use disorders 
12month 
Lifetime 
 
0.05 (0.03-0.1) 
0.3 (0.25-0.5) 
 
1.3 (1.1-1.6) 
7.4 (6.9-7.9) 
 
1.0 (0.8-1.3) 
7.3 (6.7-7.9) 
 
0.5 (0.3-0.8) 
4.1 (3.7-4.5) 
 
2.9 (2.5-3.3) 
19.1 (18.3-20.0) 
bCannabis use disorders 
12month 
Lifetime 
 
0.06 (0.03-0.1) 
0.2 (0.1-0.3) 
 
0.5 (0.4-0.7) 
3.1 (2.7-3.6) 
 
0.3 (0.2-0.4) 
2.2 (1.9-2.5) 
 
0.1 (0.07-0.2) 
1.3 (1.1-1.6) 
 
1.0 (0.8-1.2) 
6.8 (6.3-7.4) 
cOther drugs (excluding cannabis) use disorders 
12month 
Lifetime 
 
0.001 (0.0005-0.0011) 
0.1 (0.06-0.2) 
 
0.4 (0.3-0.5) 
1.7 (1.5-2.0) 
 
0.1 (0.07-0.2) 
1.4 (1.2-1.7) 
 
0.2 (0.1-0.3) 
0.9 (0.7-1.2) 
 
0.6 (0.5-0.8) 
4.1 (3.7-4.6) 
dMajor depression 
12month 
Lifetime 
 
0.14 (0.1-0.2) 
0.3 (0.2-0.4) 
 
2.2 (1.9-2.5) 
5.0 (4.5-5.5) 
 
1.3 (1.1-1.5) 
3.7 (3.3-4.1) 
 
1.0 (0.9-1.2) 
2.6 (2.3-3.0) 
 
4.6 (4.2-5.1) 
11.6 (10.9-12.3) 
Alcohol use disorder and major depression 
12month 
Lifetime 
 
0.009 (0.003-0.02) 
0.1 (0.05-0.2) 
 
0.2 (0.17-0.4) 
1.4 (1.2-1.6) 
 
0.1 (0.05-0.2) 
1.2 (1.0-1.4) 
 
0.1 (0.05-0.2) 
0.7 (0.6-0.9) 
 
0.5 (0.3-0.6) 
3.4 (3.1-3.8) 
Cannabis use disorder and major depression 
12month 
Lifetime  
 
0.002 (0.0003-0.003) 
0.04 (0.008-0.2) 
 
0.2 (0.09-0.3) 
0.7 (0.5-0.8) 
 
0.01 (0.004-0.03) 
0.5 (0.4-0.7) 
 
0.05 (0.02-0.2) 
0.4 (0.3-0.6) 
 
0.2 (0.1-0.4) 
1.7 (1.4-2.0) 
Other drugs use disorder & major depression 
12month 
Lifetime 
 
0.003 (0.0001-0.004) 
0.02 (0.006-0.04) 
 
0.1 (0.09-0.2) 
0.5 (0.4-0.7) 
 
0.03 (0.01-0.06) 
0.4 (0.3-0.5) 
 
0.1 (0.05-0.2) 
0.4 (0.3-0.5) 
 
0.3 (0.2-0.4) 
1.3 (1.1-1.6) 
aAlcohol use disorders is defined DSM-IV Alcohol Abuse /or Dependence diagnoses (past 12months and lifetime). 
bCannabis use disorders is defined DSM-IV Cannabis Abuse /or Dependence diagnoses (past 12months and lifetime). 
cDrug use disorders is defined as DSM-IV diagnoses of drug abuse/or dependence diagnoses on opiates, sedatives, tranquilizers, amphetamines hallucinogens, heroin, cocaine, 
inhalants, and/or other drugs except cannabis (past 12months and lifetime) 
dMajor Depression is defined DSM-IV diagnosis of major depressive episode (past 12 months or lifetime). 
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Table 5-2 shows the distribution of DSM-IV diagnoses by BMI categories. Participants 
were more likely to have major depression and alcohol use disorders. Lifetime AUD and MDE 
were found in 19.1% and 11.5% of individuals respectively while lifetime concurrent AUD and 
MDE was found in 3.4% of the population.  
The associated risk of being overweight and obese was significantly higher across the age 
groups compared to the youngest age group (Table 5-3). Compared to single participants, 
individuals that were married, divorced or separated had increased risk of being overweight. A 
history of mental health disorder was shown to increase the risk of overweight and obesity. 
Participants had reduced risk of overweight or obesity if they were females, had higher level of 
education and were daily smokers. In contrast, being female or a daily smoker increased the risk 
of being underweight among the participants.    
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Table 5-3. Participants sociodemographic factors and the risk of overweight/obesity 
 Crude RRR (95%CI) aAdjusted RRR (95%CI) 
 Underweight vs 
normal weight  
Overweight vs 
normal weight  
Obese vs normal 
weight 
Underweight vs 
normal weight  
Overweight vs 
normal weight  
Obese vs normal 
weight 
Statistic (p-
value) 
Age 
20 to 24 years 
25 to 44 years 
45 to 64 years 
65 years and above 
 
1 
0.62 (0.43– 0.89)* 
0.39 (0.25-0.60)** 
0.69 (0.46-1.01) 
 
1 
2.09 (1.73-2.58)** 
2.96 (2.45-3.58)** 
2.95 (2.45-3.54)** 
 
1 
2.01 (1.61-2.53)** 
3.13 (2.50-3.92)** 
2.62 (2.09-3.29)** 
 
1 
0.81 (0.51-1.28) 
0.57 (0.33-0.97)* 
0.88 (0.53-1.49) 
 
1 
1.99 (1.61-2.47)** 
2.58 (2.06-3.23)** 
2.46 (1.94-3.13)** 
 
1 
2.18 (1.68-2.83)** 
2.92 (2.24-3.80)** 
1.96 (1.47-2.30)** 
<0.0001 
Sex 
Male 
Female 
 
1 
1.91(1.40-2.61)** 
 
1 
0.53 (0.48-0.60)** 
 
1 
0.73 (0.64-0.82)** 
 
1 
2.00 (1.46-2.73)** 
 
1 
0.51 (0.46-0.58)** 
 
1 
0.71 (0.62-0.81)** 
 
Marital status 
Married 
Common law 
Widowed 
Divorced/Separated 
Single 
 
0.48 (0.35-0.67)** 
0.86 (0.56-1.33) 
1.42 (0.88-2.29) 
0.66 (0.37-1.16) 
1 
 
1.71 (1.49-1.95)** 
1.32 (1.08-1.62)** 
1.41 (1.17-1.71)** 
1.67 (1.33-2.11)** 
1 
 
1.58 (1.35-1.86)** 
1.24 (1.00-1.55) 
1.60(1.26-2.04)** 
1.12 (0.89-1.41) 
1 
 
0.60 (0.39-0.91)* 
1.00 (0.62-1.61) 
1.33 (0.74-2.38) 
0.75 (0.41-1.37) 
1 
 
1.31 (1.11-1.55)** 
1.09 (0.88-1.34) 
1.12 (0.89-1.42) 
1.38 (1.07-1.78)* 
1 
 
1.19 (0.99-1.44) 
0.93 (0.73-1.17) 
1.19 (0.90-1.58) 
0.84 (0.66-1.07) 
1 
<0.0001 
Highest level of education 
< Secondary 
Secondary grad 
Some post sec 
Post-secondary grad 
 
1 
1.05 (0.66-1.67) 
1.19 (0.72-1.97) 
0.67 (0.46-0.95)* 
 
1 
0.94 (0.78-1.13) 
0.70 (0.53-0.92)* 
0.75 (0.64-0.88)** 
 
1 
0.80 (0.64-0.99) 
0.67 (0.49-0.90)** 
0.57 (0.48-0.68)** 
 
1 
1.17 (0.71-1.93) 
1.17 (0.67-2.04) 
0.82 (0.57-1.19) 
 
1 
1.04 (0.85-1.27) 
0.86 (0.64-1.17) 
0.77 (0.65-0.92)** 
 
1 
0.80 (0.64-1.01) 
0.75 (0.55-1.02) 
0.54 (0.45-0.66)** 
<0.0001 
Total Houshold income 
Less than $20,000  
$20,000 – 39,999 
$40,000 – 59,999 
$60,000 – 79,999 
$80,000 or more 
 
1 
0.71 (0.41-1.24) 
0.74 (0.43-1.30) 
0.54 (0.30-0.97)* 
0.37 (0.22-0.65)** 
 
1 
1.25 (0.98-1.60) 
1.18 (0.93-1.50) 
1.24 (0.98-1.58) 
1.29 (1.03-1.60)* 
 
1 
1.18 (0.88-1.58) 
1.13 (0.85-1.50) 
1.17 (0.87-1.58) 
1.11 (0.84-1.45) 
 
x 
 
 
x 
 
x 
 
x 
Race 
Non-white 
White 
 
1 
0.70 (0.50-0.98)* 
 
1 
1.39 (1.21-1.60)** 
 
1 
2.37 (1.99-2.82)** 
 
1 
0.63 (0.45-0.89)** 
 
1 
1.29 (1.11-1.50)** 
 
1 
2.24 (1.86-2.70)** 
 
Type of smoker 
Daily 
Occasionally 
Not at all 
 
1.70 (1.25-2.33)** 
0.78 (0.45-1.33) 
1 
 
0.95 (0.81-1.10) 
0.86 (0.65-1.13) 
1 
 
0.90 (0.77-1.06) 
0.65 (0.48-0.88)** 
1 
 
1.77 (1.29-2.43)** 
0.69 (0.40-1.19) 
1 
 
0.84 (0.72-0.99)* 
0.93 (0.69-1.26) 
1 
 
0.75 (0.63-0.89)** 
0.73 (0.52-1.01) 
1 
<0.0001 
History of mental health 
disorder 
Yes 
 
 
1.03 (0.78-1.36) 
 
 
1.19 (1.06-1.33)** 
 
 
1.31 (1.15-1.48)** 
 
 
1.01 (0.75-1.36) 
 
 
1.15 (1.02-1.29)* 
 
 
1.23 (1.07-1.41)** 
 
  
 
9
9
 
No 1 1 1 1 1 
Family history of mental 
health disorder 
Yes 
No 
 
 
0.81 (0.62-1.05) 
1 
 
 
0.97 (0.87-1.09) 
1 
 
 
1.20 (1.06-1.36)** 
1 
 
 
x 
 
 
x 
 
 
x 
 
 
x 
a – adjusted in a multivariate model 
Significant values are marked in bold print  
*  p-value < =0.05 
** p-value <0.01 
x – lost in multivariate model 
< Secondary- less than secondary education; Secondary grad- secondary education graduate; Some post sec – some post secondary education; Post-secondary grad – post 
seconadary education graduate 
  
  
 
1
0
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5.4.2 DSM IV diagnoses and BMI status 
 
Table 5-4. DSM-IV diagnoses and the risk of overweight/obesity 
 
Crude models RRR (95%CI) a
Adjusted models RRR (95%CI) 
 Underweight vs 
normal weight 
Overweight vs normal 
weight 
Obese vs normal 
weight 
Underweight vs 
normal weight 
Overweight vs normal 
weight 
Obese vs normal 
weight 
AUD (Model 1) 
12month 
Lifetime  
 
0.81 (0.42-1.58) 
0.90 (0.62-1.31) 
 
1.02 (0.77-1.35) 
1.42 (1.25-1.61)** 
 
0.84 (0.53-1.34) 
1.35 (1.17-1.56)** 
 
0.71 (0.35-1.44) 
0.92 (0.63-1.34) 
 
1.03 (0.82-1.46) 
1.23 (1.08-1.41)** 
 
0.90 (0.56-1.44) 
1.21 (1.03-1.41)* 
CUD (model 2) 
12months 
Lifetime 
 
2.27 (1.02-5.06)* 
1.15 (0.67-1.97) 
 
0.52 (0.46-1.01) 
0.92 (0.76-1.12) 
 
0.52 (0.27-1.00) 
0.95 (0.75-1.20) 
 
2.01 (0.83-4.86) 
1.04 (0.59-1.85) 
 
0.77 (0.50-1.19) 
0.79 (0.63-0.99)* 
 
0.60 (0.30-1.19) 
0.80 (0.61-1.04) 
DUD (model 3) 
12months 
Lifetime 
 
0.003 (0.002-0.01)** 
1.09 (0.64-1.88) 
 
0.42 (0.25-0.71)** 
1.08 (0.85-1.38) 
 
1.03 (0.54-1.96) 
1.22 (0.91-1.63) 
 
0.004 (0.001-0.01)** 
0.90 (0.49-1.64) 
 
0.44 (0.27-0.74)* 
0.98 (0.75-1.27) 
 
1.16 (0.60-2.24) 
1.05 (0.77-1.43) 
MDE (model 4) 
12months 
Lifetime 
 
1.30 (0.82-2.07) 
1.14 (0.77-1.67) 
 
0.77 (0.61-0.97)* 
0.98 (0.84-1.14) 
 
1.09 (0.86-1.39) 
1.23 (1.04-1.47)* 
 
0.98 (0.61-1.57) 
1.00 (0.67-1.48) 
 
0.90 (0.71-1.16) 
1.10 (0.94-1.30) 
 
1.24 (0.97-1.59) 
1.30 (1.08-1.56)** 
Significant values are marked in bold print  
*  p-value < =0.05 
** p-value <0.01 
a
Adjusted for age, gender, marital status, highest level of education, race, smoking status, history of any mental health disorder, family history of mental health disorder in multivariate models 
AUD - Alcohol use disorders is defined DSM-IV Alcohol Abuse /or Dependence diagnoses  
CUD - Cannabis use disorders is defined DSM-IV Cannabis Abuse /or Dependence diagnoses (lifetime). 
DUD - Drug use disorders is defined as DSM-IV diagnoses of drug abuse/or dependence diagnoses on opiates, sedatives, tranquilizers, amphetamines hallucinogens, heroin, cocaine, 
inhalants, and/or other drugs except cannabis (lifetime) 
MDE - Major Depression is defined DSM-IV diagnosis of major depressive episode (lifetime). 
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The main associations between BMI and substance use disorders or major depression are 
shown in Table 5-4. Lifetime major depression is associated with a higher risk of being obese 
compared with normal weight. Individuals with lifetime alcohol use disorder had higher risk of 
being overweight or obese compared to normal weight. Lifetime CUD and 12-month DUD were 
associated with decreased risk of overweight, hence inversely proportional. 
Table 5-5 shows the lifetime diagnosis of comorbid SUD with major depression 
predicting obesity and overweight. Here, the comparison groups are either no diagnosis (ND), 
isolated diagnosis of SUD (AUD, CUD, DUD) or MDE (without the other) and comorbid SUD 
with MDE. Adults with co-morbid AUD or DUD with major depression had significantly higher 
associated risk of being obese compared to ND. Isolated diagnosis of CUD without co-occurring 
major depression was found to reduce the risk of overweight and obesity by about 30% 
compared to ND. Compared to isolated diagnosis of CUD or DUD, individuals with comorbid 
SUD (CUD or DUD) with MD had about 2 times higher risk of being obese. 
  
 
1
0
2
 
Table 5-5. Lifetime comorbid SUD with major depression predicting overweight/obesity 
 
Underweight vs normal weight RRR (95%CI) Overweight vs normal weight RRR (95%CI) Obese vs normal weight RRR (95%CI) 
 Ref= ND Ref = SUD Ref = MD Ref = ND Ref = SUD Ref = MD Ref = ND Ref = SUD  Ref = MD 
 
       Alcohol and major depression (model 1) 
ND 1 1.22 (0.82-1.82) 1.14 (0.78-1.67) 1 0.81 (0.70-0.94)** 0.92 (0.76-1.12) 1 0.82 (0.69-0.97)* 0.76 (0.61-0.94)* 
AUD only 0.82 (0.55-1.22) 1 0.93 (0.56-1.55) 1.24 (1.07-1.43)** 1 1.14 (0.91-1.42) 1.22 (1.03-1.46)* 1 0.93 (0.71-1.20) 
MDE only 0.88 (0.60-1.28) 1.07 (0.64-1.78) 1 1.09 (0.90-1.32) 0.88 (0.70-1.10) 1 1.32 (1.06-1.65)* 1.08 (0.84-1.40) 1 
AUD & MDE 1.16 (0.51-2.65) 1.42 (0.58-3.46) 1.33 (0.56-3.14) 1.23 (0.94-1.62) 1.00 (0.75-1.33) 1.13 (0.83-1.55) 1.38(1.02-1.86)* 1.13 (0.82-1.55) 1.04 (0.73-1.48) 
 
     Cannabis and major depression (model 2) 
ND 1 0.93 (0.49-1.76) 1.04 (0.62-1.73) 1 1.41 (1.09-1.84)** 1.10 (0.89-1.35) 1 1.54 (1.12-2.10)** 1.00 (0.79-1.26) 
CUD only 1.07 (0.57-2.04) 1 1.11 (0.59-2.10) 0.71 (0.54-0.92)** 1 0.78 (0.59-1.03) 0.65 (0.48-0.89) 1 0.65 (0.46-0.92)** 
MDE only 0.97 (0.58-1.62) 0.90 (0.48-1.69) 1 0.91 (0.74-1.12) 1.29 (0.97-1.70) 1 1.00 (0.79-1.26) 1.53 (1.09-2.16)* 1 
CUD & MDE 1.01 (0.20-5.17) 0.94 (0.17 -5.18) 1.05 (0.21-5.26) 1.01 (0.67-1.56) 1.44 (0.91-2.28) 1.11 (0.72-1.73) 1.40 (0.88-2.20) 2.14 (1.28-3.59)** 1.40 (0.87-2.23) 
 
      Drugs (excluding cannabis) and major depression (model 3) 
ND 1 0.81 (0.44-1.49) 0.91 (0.60-1.38) 1 0.92 (0.67-1.26) 0.89 (0.75-1.06) 1 1.03 (0.70-1.53) 0.81 (0.67-0.99)* 
DUD only 1.24 (0.67-2.29) 1 1.13 (0.54-2.35) 1.09 (0.79-1.49) 1 0.97 (0.68-1.37) 0.97 (0.65-1.43) 1 0.79 (0.52-1.21) 
MDE only 1.10 (0.72-1.67) 0.89 (0.43-1.85) 1 1.12 (0.94-1.34) 1.03 (0.73-1.46) 1 1.23 (1.01-1.50)* 1.27 (0.83-1.94) 1 
DUD & MDE 0.42 (0.14-1.23) 0.34 (0.10-1.13) 0.38 (0.12-1.20) 1.04 (0.70-1.53) 0.95 (0.59-1.55) 0.92 (0.61-1.39) 1.86 (1.21-2.85)** 1.92 (1.09-3.38)* 1.52 (0.96-2.39) 
Significant values are marked in bold print  
*  p-value < =0.05 
** p-value <0.01 
1 – reference category 
Models adjusted for age, gender, marital status, highest level of education, race, smoking status, history of any mental health disorder, family history of mental health disorder in multivariate models 
ND – no diagnosis; AUD - Alcohol use disorders is defined DSM-IV Alcohol Abuse /or Dependence diagnoses.; CUD - Cannabis use disorders is defined DSM-IV Cannabis Abuse /or Dependence 
diagnoses.; DUD - Drug use disorders is defined as DSM-IV diagnoses of drug abuse/or dependence diagnoses on opiates, sedatives, tranquilizers, amphetamines hallucinogens, heroin, cocaine, 
inhalants, and/or other drugs except cannabis.; MDE - Major Depression is defined DSM-IV diagnosis of major depressive episode. SUD – AUD (model 1), CUD (model 2) and DUD (model 3)
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5.5 Discussion and Conclusion 
This study examined the relationship between overweight/obesity and substance use 
disorders with underlying major depression. The inverse relationship between BMI and 
substance use found in previous studies (Gruchow, Sobocinski, Barboriak, & Scheller, 1985; 
Lahti-Koski, Pietinen, Heliovaara, & Vartiainen, 2002; Liu, Serdula, Williamson, Mokdad, & 
Byers, 1994; Kleiner, et al., 2004; Gearhardt & Corbin, 2009; Warren, Frost-Pineda, & Gold, 
2005; Pickering, et al., 2011; Gearhardt, Harrison, & McKee, 2012; Le Strat & Le Foll, 2011) 
continued to exist for cannabis use disorder and drug use disorders in our study.  
This could be explained by the hypothesis that food and drug intake may be regulated by the 
same neurobiological pathways (dopaminergic reward system and endogenous opioid system), 
competing for the same target brain site, hence inversely related – increased illicit drug 
associated with decreased BMI (Volkow, et al., 2008; Volkow & Wise, 2005; Di Chiara & 
Imperato, 1988; MacDonald, et al., 2004). It is important to note that behaviours such as 
cravings, loss of control (Gearhardt, Corbin, & Brownell, 2009) underlie excessive food 
consumption and substance use disorders. Some authors suggest that consequent to deficiencies 
in these neural reward systems, compensating behaviour in the form of increased food or drug 
intake may occur (Trinko, Sears, Guarnieri, & DiLeone, 2007; Johnson & Kenny, 2010). 
Another explanation stem from the fact that substance use disorders increase vulnerability to 
malnutrition which worsens with chronic disruption of eating habits, anorexia, and infections 
(Santolaria-Fernández, et al., 1995). Malnutrition could also occur through neglect of physical 
health, including insufficient calorie intake arising from the adverse effects of substance use 
disorder (McIntyre, et al., 2007; Nazrul Islam, Jahangir, Ahmed, & Ahsan, 2002). This inverse 
relationship found in our study provides further evidence to support the similarities between 
problematic food consumption and addiction (Volkow, Wang, Fowler, & Telang, 2008; 
Gearhardt, Corbin, & Brownell, 2009). 
Major depression was associated with an increased risk of obesity and this was consistent 
with previous studies ( (Pickering, et al., 2011; McLaren, Beck, Patten, Fick, & Adair, 2008). 
Two hypothesized psychosocial models explain this finding. The self-appraisal model where 
stigma following overweight/obesity promotes low self-esteem and negative self-image, 
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resulting in major depression (Puhl & Brownell, 2003). The fitting norms of appearance model is 
a consequence of societal values for thinness (McLaren, Beck, Patten, Fick, & Adair, 2008; 
Paeratakul, White, Williamson, Ryan, & Bray, 2002; Smolak & Striegel Moore, 2002). This 
argues that fitting the norm for weight becomes stressful for the overweight and obese as dieting 
is often unsuccessful resulting in major depression (Pickering, et al., 2011). In addition, our 
finding could reflect emotional overeating linked with suppressed mood (McLaren, Beck, Patten, 
Fick, & Adair, 2008), differential reporting of atypical depression (e.g., increased appetite, 
weight gain) and biological factors such as genetic susceptibility to both overweight and major 
depression (Comings, Gade, MacMurray, Muhlema, & Peters, 1996). 
Inconsistent with a recent study (Gearhardt, Harrison, & McKee, 2012), comorbid SUDs 
(AUD, DUD) with depression compared with no diagnosis increased the risk of obesity in our 
study.  In addition, our study showed a 2-fold associated increase in the risk of obesity in 
comorbid SUD (CUD, DUD) with major depression compared to the SUD (CUD, DUD) only. 
Thus, the inverse relationship between DUD and BMI ceased to exist in the presence of major 
depression in this population. This could be due to major depression mediating the effect on 
BMI. Another possible explanation is the contribution of the subtypes of depression. Atypical 
depression is associated with hypersomnia and weight gain and an increased likelihood of 
substance dependence (Matza, Revicki, Davidson, & Stewart, 2003). Thus, a combined effect 
could occur. Alcohol use disorder was associated with increased risk of overweight/obesity as 
seen in other studies (McLaren, Beck, Patten, Fick, & Adair, 2008). This can be explained by 
one component of substance use, that is, excessive calorie intake due to alcohol consumption 
(McLaren, Beck, Patten, Fick, & Adair, 2008).  
The large sample size being representative of the Canadian population is a major strength of 
this study. Another strong point was that the diagnoses of substance use disorders and major 
depressive episodes were derived from DSM IV criteria.  Other strengths include accounting for 
missing values with multiple imputation and for the complex data structure with survey weights, 
enabling generalizability. Limitations of this study include the cross-sectional study design 
which does not allow for causal inference. Further studies would be required to assess causality. 
Individuals living on reserves and other Aboriginal settlements, in institutions and full-time 
members of the Canadian Forces were excluded from the data. Since these populations account 
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for about 3% of the total population, our study may have underestimated the true strength of 
associations found in these conditions. This study was based on self-reported data, thus could be 
compromised by recall-bias and under-reporting.  
In conclusion, the inverse relationship observed in other studies between substance use 
disorders and obesity ceased to exist in the presence of an underlying common risk factor, major 
depression. It is imperative that health professionals are aware of the associations that exist 
between substance-related behaviors, problematic food intake, and depression. 
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Appendix A. Missing values analysis 
Table A.1 Summary of missing values 
Variables Observed Missing Imputed Total 
Marital status 22824 57 57 22881 
Educational status 22774 107 107 22881 
Race 22787 94 94 22881 
Income 22873 8 8 22881 
Body mass index 22308 573 573 22881 
12-month CUD 22691 190 190 22881 
Lifetime CUD 22686 195 195 22881 
12-month DUD 22622 259 259 22881 
Lifetime DUD 22617 264 264 22881 
12-month AUD 22530 351 351 22881 
Lifetime AUD 22513 368 368 22881 
12-month MDE 22730 151 151 22881 
Lifetime MDE 22727 154 154 22881 
Smoking status 22866 15 15 22881 
Family history of mental illness 22630 251 251 22881 
Personal history of mental illness 22197 684 684 22881 
CUD- cannabis us disorder; AUD- alcohol use disorder; DUD – other drugs (excluding cannabis) use disorder; MDE – major 
depressive episode 
 
 
Test for Missing Completely At Random (MCAR) 
Little's MCAR test: Prob > chi-square   = 0.0000 
Data is not MCAR 
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Table A.2 Association of predictor variables and missingness in Body Mass Index 
Variables Chi square p-value 
Province of residence <0.0001 
Age  0.001 
Sex <0.0001 
Marital status <0.0001 
Educational status <0.0001 
Race 0.08 
Income <0.0001 
12-month CUD 0.05 
Lifetime CUD <0.0001 
12-month DUD 0.04 
Lifetime DUD <0.001 
12-month AUD 0.06 
Lifetime AUD <0.0001 
12-month MDE 0.4 
Lifetime MDE 0.08 
Smoking status 0.008 
Family history of mental illness <0.0001 
Personal history of mental illness <0.0001 
CUD- cannabis us disorder; AUD- alcohol use disorder; DUD – other drugs (excluding cannabis) use disorder; MDE – 
major depressive episode 
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CHAPTER 6. ALCOHOL DEPENDENCE AND THE PERSISTENCE OR 
RECURRENCE OF MAJOR DEPRESSION 
6.1 Introduction 
Alcohol use disorders (AUD) are some of the most prevalent disorders worldwide (Grant, 
et al., 2004b; Kessler, Chiu, Demler, Merikangas, & Walters, 2005) and they frequently co-occur 
at significantly higher levels with major depression (Sullivan, Fiellin, & O'Connor, 2005; 
Swendson & Merikangas, 2000). In the 2016 Global Burden of Disease study, alcohol use was 
estimated to be the 7th-leading risk factor in terms of disability-adjusted life-years (DALYs) 
(GBD 2016 Risk Factors Collaborators, 2017; GBD 2016 Alcohol Collaborators, 2018) while 
major depressive disorder was amongst the five leading causes of years lived with disability 
(YLD) (GBD 2016 Disease and Injury Incidence and Prevalence Collaborators, 2017). Comorbid 
AUD with depression is associated with an earlier onset of alcohol dependence and higher 
prevalence rates of drug dependence (Schuckit, et al., 1997; Brière, Rohde, Seeley, & Daniel 
Klein, 2014), poor outcomes in those entering treatment for drug and alcohol problems (Hasin, et 
al., 2002), and increased relapse rate following AUD treatment (Cornelius J. R., et al., 1995). 
This comorbidity is also associated with an increased likelihood of completed suicides, suicide 
attempts, and severity of suicidality in terms of frequency and duration of suicidal thoughts, 
death wishes and intent to take lethal actions (Preuss, et al., 2002; Britton, et al., 2015; Brière, 
Rohde, Seeley, & Daniel Klein, 2014; Cornelius J. R., et al., 1995).  
Alcohol dependence and major depression occur commonly together (Regier, et al., 1990; 
Grant & Harford, 1995; Brière, Rohde, Seeley, & Daniel Klein, 2014; Grant B. F., et al., 2004a; 
Grant, et al., 2015) and this comorbidity is particularly high in patient samples (Lynskey M. T., 
1998; Britton, et al., 2015). With depression, the risk of alcohol dependence is higher than in the 
general population (Kessler, et al., 1996; Brière, Rohde, Seeley, & Daniel Klein, 2014) and, 
depression is more prevalent with alcohol dependence than without alcohol dependence (Kessler, 
et al., 1997; Britton, et al., 2015). Evidence suggests an increased prevalence of major depression 
among patients seeking treatment for addiction (Miller, Klamen, Hoffman, & Flaherty, 1996; 
Schuckit, et al., 1997; Britton, et al., 2015). For example, the Collaborative Study on the 
Genetics of Alcoholism (COGA) found a lifetime prevalence of major depressive disorder 
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among treatment-seeking alcoholics to be 42.2% while the prevalence prior to alcohol 
dependence was 5.3% and prevalence occurring outside of the context of alcohol dependence 
was 11.5% (Schuckit, et al., 1997).  
Depression was predicted by the World Health Organization (WHO) to be the second most 
important factor influencing the global burden of disease by 2020 and the principal cause in 
developed countries by 2030 (Lépine & Briley, 2011; World Health Organization, 2004). The 
major clinical problems associated with depression resulting in significant personal and public 
health consequences are persistence and recurrence (Judd, 1997; Burcusa & Iacono, 2007). 
About half of those who recover from the first episode of major depression, would have at least 
one additional event in their lifetime and nearly 80% of those with a history of two events will 
have another recurrence (Burcusa & Iacono, 2007; American Psychiatric Association, 2000; 
Kupfer, Frank, & Wamhoff, 1996). The long-term course or persistence and recurrence often 
associated with depression is one of the reasons it is a burden (Balkrishnan, Joish, Yang, 
Jayawant, & Mullins, 2008; Fostick, Silberman, Beckman, Spivak, & Amital, 2010; Judd, et al., 
2000; Burcusa & Iacono, 2007). Previous studies suggest there may be differences in risk 
factors, neurobiological basis and therapeutic response between major depression and recurrent 
or persistent major depression (Holzel, Harter, Reese, & Kriston, 2011; de Maat, Dekker, 
Schoevers, & de Jonghe, 2007; Szádóczky, Fazekas, Rihmer, & Arató, 1994; Burcusa & Iacono, 
2007).  Using the ‘dynamic stress-vulnerability model’ (Ormel & Neeleman, 2000), Spijker et al. 
(2004) classified the many risk factors of persistent major depression identified in the literature 
(Table 6-1) (Spijker, et al., 2004). 
  
 
1
1
5
 
Table 6-1. Potential determinants of the persistence of major depression from literature  
Determinants Results 
Demographic factors 
Age 
 
Gender 
 
Older (Sargeant, Bruce, Florio, & Weismann, 1990); 
Younger (Spijker, Bijl, De Graaf, & Nolen, 2000) 
Female (Sargeant, Bruce, Florio, & Weismann, 1990; Keitner, Ryan, Miller, & Norman, 1992),  
No association (Simpson, Nee, & Endicott, 1997) 
Social Vulnerability factors 
Education 
Social economic status 
Marital status 
 
Low level (Sargeant, Bruce, Florio, & Weismann, 1990) 
Low (Keller, 1994) 
Married (Keller, 1994), no partner (Mueller, et al., 1996) 
Psychobiological vulnerability factors 
Youth experiences 
 
Personality characteristics 
Previous psychiatry illness 
Somatic illness 
 
Childhood adversity (Brown & Moran, 1994; Brown, Harris, Hepworth, & Robinson, 1994) 
High neuroticism (Scott, Eccleston, & Boys, 1992; Keitner, Ryan, Miller, & Norman, 1992) 
low mastery (Spijker, Bijl, De Graaf, & Nolen, 2000) 
Other psychiatry illness (Keller, 1994) 
Presence of somatic illness (Keitner, Ryan, Miller, & Norman, 1992) 
Sustaining factors 
Negative life events 
 
Ongoing difficulties 
Social support 
 
Multiple (Spijker, Bijl, De Graaf, & Nolen, 2000) 
No association (Paykel, Cooper, Ramanda, & Hayhurst, 1996) 
Interpersonal difficulties  (Brown & Moran, 1994; Brown, Harris, Hepworth, & Robinson, 1994) 
Lack of support (Brown, Harris, Hepworth, & Robinson, 1994) 
No association (Paykel, Cooper, Ramanda, & Hayhurst, 1996) 
Illness-related factors 
Severity of depression 
 
Comorbidity 
 
 
 
Previous episodes 
Duration of previous episodes 
 
Severe (Sargeant, Bruce, Florio, & Weismann, 1990; Spijker, Bijl, De Graaf, & Nolen, 2000; Keller, 1994; Mueller, 
et al., 1996; Ramana, et al., 1995; Furukawa, Kiturama, & Takahashi, 2000; Mueller, et al., 1994)  
With dysthymia (Keller, 1994) 
Anxiety disorders (Ormel, Oldehinkel, Brilman, & van den Brink, 1993) 
Alcohol dependence (Mueller, et al., 1994), 
No association (Spijker, et al., 2004; Garcia-Toro, et al., 2013),  
Multiple (Sargeant, Bruce, Florio, & Weismann, 1990), No association (Keller, 1994) 
Long (Sargeant, Bruce, Florio, & Weismann, 1990; Spijker, Bijl, De Graaf, & Nolen, 2000; Scott, Eccleston, & 
Boys, 1992; Ramana, et al., 1995) 
Adapted with permission from: (Spijker, et al., 2004)
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Previous studies suggest the characteristics of the index episode of depression such as the 
severity, duration, comorbidity with other psychiatric disorders and suicidality as the strongest 
predictors of recurrence or persistence (Burcusa & Iacono, 2007; Barkow, et al., 2003; Spijker & 
Nolen, 1998). The review by Burcusa and Iacono (2007) point to severity as an indicator for 
recurrence whether assessed using the International Classification of Disease (ICD) severity, 
Diagnostic and Statistical Manual of Mental Disorders (DSM)  severity, presence of higher 
number of symptoms, higher Becker Depression Inventory (BDI) scores, higher Hamilton rating 
scale scores or the presence of certain symptoms such as suicidality (Burcusa & Iacono, 2007; 
Kessing, 2004). The more severe the first episode, the more likely there would be a recurrence or 
persistence.  
Evidence of  symptom exacerbation, disruptive behaviors, decreased social functioning, 
treatment nonadherence, poor response to conventional treatment, recurrence, increased service 
utilization and hospitalizations (Hobbs, Kushner, Lee, Reardon, & Maurer, 2011; Kushner, et al., 
2005; Grant, et al., 2004b; Petrakis, Gonzalez, Rosenheck, & Krystal, 2002; Gilman & Abraham, 
2001; Salloum & Thase, 2000; Owen, Fischer, Booth, & Cuffel, 1996; Volkow, Baler, Compton, 
& Weiss, 2014; Odlaug, et al., 2016) support the adverse consequences of substance use disorder 
on the course of severe mental illness. However, studies have been inconsistent in showing the 
relationship between alcohol dependence and persistent or recurrent depression. While some 
researchers have found an association between substance use disorders and recurrent depression, 
suggesting a resolution of depressive symptoms and consequent loss of depressive diagnosis with 
abstinence from alcohol, others have not (Garcia-Toro, et al., 2013; Spijker, et al., 2004; Mueller, 
et al., 1994; Barkow, et al., 2003; Alpert, Maddocks, Rosenbaum, & Fava, 1994; Coryell, 
Endicott, & Keller, 1991; Brown & Schuckit, 1988). 
Comorbid alcohol dependence and major depression was found to predict treatment 
seeking (Kaufmann, Chen, Crum, & Mojtabai, 2014; Wu, Kouzis, & Leaf, 1999), and higher 
rates of treatment seeking most likely reflects greater disorder severity (Blanco, et al., 2010; 
Kessler, et al., 1996; Klein, Schwartz, Rose, & Leader, 2000; McFarland & Klein, 2005; Olfson, 
Liu, Grant, & Blanco, 2012; Rush, et al., 2009); therefore, studies based on patient samples may 
overestimate the association between alcohol dependence and major depression in the general 
population due to the inadvertent selection of more severe cases into treatment (Berkson, 1946). 
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To expand current knowledge on this topic, this study was aimed to determine if comorbid 
alcohol dependence predicts the persistence or recurrence of major depression in a cohort sample 
of the general Canadian population.  
6.2  Objectives 
This study aimed to first, determine if concurrent alcohol dependence predicts persistence 
or recurrence of major depression after 6 years and 16 years of follow-up. Second, to 
determine other factors that predict persistent or recurrent major depression after 6 years and 
16  years of follow-up. 
6.3  Methods  
6.3.1 Data Source and study cohort 
Data came from the longitudinal National Population Health Survey (NPHS, 1994/1995-
2010/2011), a nationally representative prospective epidemiologic survey (Statistics Canada, 
2012). Detailed information on the NPHS methodology is available on the Statistics Canada web 
page (Statistics Canada, 2012). Briefly, the participants of the longitudinal NPHS were 
individuals 12 years and older, resident in the ten Canadian provinces in 1994/1995. Criteria for 
exclusion from the survey were living in certain remote areas, institutions, and reserves. In 
addition, full-time members of the Canadian were not included. The population comprised of 
17,276 participants who were re-interviewed every 2 years for 9 cycles (cycles 1 to 9) (Statistics 
Canada, 2012).  
This secondary analysis of the NPHS data included only individuals 18years and older 
who met criteria for a diagnosis of 12-month major depressive episode at baseline (n=908) 
(Figure 6-1). The age restriction was because the structured instrument for the diagnosis of major 
depression, the World Health Organization Composite International Diagnostic Interview Short 
Form (CIDI-SF) based on DSM-III-R criteria, was administered to individuals 18years and older 
(Statistics Canada, 2009). This study focused on cycles 4 (6years from baseline) and 9 (16 years 
from baseline). The follow-up period ended in cycle 9. Cycle 4 was added to this analysis due to 
a significant loss to follow-up in cycle 9 (Figure 6-2). The estimated response rates reported by 
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Statistics Canada were 84.9% and 69.7% for cycles 4 and 9 respectively (Statistics Canada, 
2012). 
Figure 6-1. Cohort sample derivation  
 
*Excluded from the analysis 
NPHS – National Population Health Survey 
Original NPHS cohort at baseline in 1994/95 n=17,276
Eligible individuals for inclusion (18years and older) n=14,713
Cohort sample with complete data on depression and alcohol 
dependence n=13,157
Final cohort at baseline    n=908
Individuals not depressed at baseline n=12,249*
Missing on depression or alcohol dependence variable n=1,556*
Individuals <18 years n=2,563*
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Figure 6-2. Cohort sample follow-up chart  
NPHS- National Population Health Survey 
6.3.2 Measures 
 Major Depressive Episode (MDE) 
Major depressive episode was assessed at baseline (1994/1995) using the World Health 
Organization Composite International Diagnostic Interview Short Form (CIDI-SF) based on 
DSM-III-R criteria (Statistics Canada, 2009).  
The past year MDE was evaluated on the same cohort every 2years. Six-year and 16-year 
persistence or recurrence of major depression were defined as meeting the diagnosis of MDE at 
cycle 4 (2000/2001) and at cycle 9 (2010/2011) respectively. The positive diagnosis of MDE in 
the subsequent cycles represent persistent episodes and, in some instances, recurrence – but it 
was not possible to distinguish between these two possibilities. 
  
NPHS 1994/1995 Baseline (Cycle 1) = 908
1996/1997 (Cycle 2) = 896
1998/1999 (Cycle 3) = 809
2000/2001 (Cycle 4) = 718
2002/2003 (Cycle 5) = 675
2004/2005 (Cycle 6) = 632
2006/2007 (Cycle 7) = 563
2008/2009 (Cycle 8) = 502
2010/2011 (Cycle 9) = 461
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Alcohol dependence  
Alcohol dependence was assessed at cycle 2 (1996/1997) using World Health 
Organization Composite International Diagnostic Interview Short Form (CIDI-SF) based on 
DSM-III-R criteria (Statistics Canada, 2009). Alcohol dependence was not assessed at baseline.  
Other measures 
These were assessed at baseline. These measures are listed in table 6-2 and were 
identified as covariates using the table adopted from (Spijker, et al., 2004)  (Table 6-1). 
Table 6-2. Potential covariates for model building  
Risk factors for persistent 
major depression from the 
literature 
Proxy covariates from the data 
Demographic factors Age 
Gender 
Social Vulnerability factors  Education 
Social economic status (dwelling owned used as proxy)  
Marital status 
Psychobiological 
vulnerability factors 
Youth experiences 
 
 
 
Personality characteristics 
 
Somatic illness 
 
Sustaining factors 
Negative life events 
 
 
Ongoing difficulties 
 
Social support 
 
 
Childhood and adult stress index - this measures the number of traumatic events respondents 
have been exposed to during their childhood, adolescence or adulthood. Higher values 
indicate more stressors/ traumatic events respondent has been exposed to in 
childhood/adolescent (Statistics Canada, 2009) 
Mastery index,  Self-esteem index scores. Higher scores indicate better mastery or self 
esteem (Statistics Canada, 2009) 
Presence of chronic physical illness 
 
 
Recent life events score (the events included in the survey were physical abuse, unwanted 
pregnancy, abortion or miscarriage, major financial difficulties, and serious problems at 
work or in school) (Statistics Canada, 2009). 
Family stress index (the stressors include activity overload, financial difficulties and 
problems with relationships in day-to-day encounters) (Statistics Canada, 2009). 
Perceived social support 
Illness-related factors 
Duration of previous episodes 
 
Number of weeks felt depressed 
 
6.3.3 Statistical analyses 
All statistical analyses were carried out using STATA version 14.0. First, baseline and 
cohort samples were used to describe participants sociodemographic characteristics and risk 
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factors for persistent or recurrent major depression. Second, Modified Poisson models were used 
to fit the data. The Modified Poisson model is an effective way of estimating the Relative Risk 
(RR) of binary data in a cohort (Zou, 2004). 
The RR for the persistence or recurrence of MDE, the main outcome of interest was 
assessed for 6 years (model 1) and 16 years (model 2) of follow-up. The modelling was carried 
out in two stages for each model. First, all covariates were assessed independently as potential 
predictors of persistent or recurrent major depression. In stage two, covariates that were 
independent risk factors or met a significance level of p<0.25 were included in a multivariate 
model. The multivariate Modified Poisson models were built using stepwise analyses with 
backward elimination of covariates. Covariates that were eliminated were assessed for 
confounding and re-entered into the model if found to confound the RR for alcohol dependence. 
Biologically, plausible interactions for gender and alcohol dependence, smoking and alcohol 
dependence were tested for each model but were not significant. Deviance and Pearson 
goodness-of-fit were tested on each model to justify the use of Poisson models. The post-
estimation command ‘fitstat’ in Stata 14 was used to compute other measures of fit and to 
compare models with interaction term and models without the interaction term. Sensitivity 
analysis was done to assess the presence of a difference in the response to major depression 
between those that were lost to follow-up and those that remained in the study (Appendix 1). 
6.4  Results 
6.4.1 Participants characteristics 
At baseline, about half of the cohort sample were aged 25-44years, a third were males 
and married while two-thirds had a chronic condition (Table 6-3). After 6 years (cycle 4) and 
16years (cycle 9), about 20% and 49% of participants were lost to follow-up (Figure 6-2). 
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Table 6-3. Participants characteristics of the NPHS and cohort sample at baseline  
 
Baseline Cohort Sample  
Frequency (%)  
N =908 
Baseline NPHS Sample  
Frequency (%)  
N =14,713 
Age  
18 to 24 years 
25 to 44 years 
45 to 64 years 
65 years and above 
 
149 (16.4) 
442 (48.7) 
231 (25.4) 
86 (9.5) 
 
2258 (15.4) 
5828 (39.6) 
3887 (26.4) 
2740 (18.6) 
Sex 
Male 
Female 
 
288 (31.7) 
620 (68.3) 
 
6733 (45.8) 
7980 (54.2) 
Marital status 
Married 
Common-law/ with a partner 
Widowed 
Divorced or Separated 
Single/ never married 
 
325 (35.8) 
63 (6.9) 
80 (8.8) 
173 (19.1) 
267 (29.4) 
 
7254 (49.3) 
968 (6.6) 
1380 (9.4) 
1445 (9.8) 
3662 (24.9) 
Highest level of education 
<secondary 
Secondary grad 
Some post-secondary 
Post-secondary grad 
 
239 (26.3) 
137 (15.1) 
269 (29.6) 
263 (29.0) 
 
4721 (32.2) 
2184 (14.9) 
3545 (24.2) 
4224 (28.8) 
 Chronic condition 
No 
Yes 
 
279 (30.7) 
629 (69.3) 
 
6215 (42.3) 
8475 (57.7) 
Alcohol dependence 
No 
Yes 
 
879 (96.8) 
29 (3.2) 
 
12,875 (97.9) 
282 (2.1) 
Total household income (CDN$) 
 <15,000 
15,000-29,999 
30,000-49,999 
50,000-79,999 
80,000 or more 
 
220 (24.2) 
247 (27.2) 
210 (23.1) 
160 (17.6) 
71 (7.8) 
 
2646 (18.9) 
3572 (25.5) 
3817 (27.2) 
2762 (19.7) 
1241 (8.8) 
 Dwelling owned by a household member 
No 
Yes 
 
387 (42.6) 
521 (57.4) 
 
4592 (31.2) 
10,115 (68.8) 
Self-esteem index 
Self-esteem index <18 
Self-esteem index = 18 
Self-esteem index 19-22 
Self-esteem index 23-24 
 
299 (32.9) 
190 (20.9) 
266 (29.3) 
153 (16.9) 
 
1826 (13.5) 
3506 (25.8) 
4434 (32.7) 
3804 (28.0) 
Mastery index 
Mastery index <17 
Mastery index 17-19 
Mastery index 20-21 
Mastery index 22-28 
 
407 (44.8) 
212 (23.4) 
157 (17.3) 
132 (14.5) 
 
2960 (21.9) 
3421 (25.3) 
3396 (25.2) 
3728 (27.6) 
Type of smoker 
Never Smoked 
Daily 
Former daily/ Occasionally but former daily 
Always/ former occasional 
 
256 (28.2) 
374 (41.2) 
201 (22.1) 
77 (8.5) 
 
5286 (37.1) 
3851 (27.0) 
3781 (26.5) 
1331 (9.3) 
Recent life events scores 
No recent life events 
<3 recent life events 
3 or more recent life events 
 
397 (43.7) 
400 (44.1) 
111 (12.2) 
 
8738 (66.7) 
3866 (29.5) 
488 (3.7) 
Childhood and adult stress index 
No traumatic events 
<3 traumatic events 
3 or more traumatic events 
 
260 (28.6) 
414 (45.6) 
234 (25.8) 
 
6696 (51.2) 
5060 (38.7) 
1329 (10.2) 
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NPHS- National Population Health Survey 
< Secondary- less than secondary education; Secondary grad- secondary education graduate; Some post sec – some post secondary education; 
Post-secondary grad – post secondary education graduate 
x – All participants in the cohort were depressed at baseline 
6.4.2 Alcohol dependence and 6-year persistence or recurrence of major 
depression 
After 6 years (cycle 4), 718 participants remained in the study (Figure 6-2). A hundred 
and twenty-four (124) participants out of 908 depressed participants at baseline, met the criteria 
for MDE at this time. This accounted for 17.3% of the participants who were still in the study at 
cycle 4. Overall, 13.7% of the baseline cohort continued to have MDE after 6years. The presence 
of alcohol dependence gave a three-fold increase in the risk of having persistent or recurrent 
depression (Table 6-4). Other factors predicting the risk of persistent or recurrent depression 
were being a female, a daily smoker, having pain that prevents activities and experiences of 3 or 
more traumatic life events. A self-esteem index of 23 and above reduced the risk of persistent or 
recurrent depression by 46%. 
  
Perceived social support index 
No social support 
Minimal social support 
Some social support 
Adequate social support 
 
38 (4.2) 
37 (4.1) 
162 (17.8) 
671 (73.9) 
 
133 (1.0) 
256 (1.9) 
1914 (14.2) 
11,234 (83.0) 
Number of weeks felt depressed 
Did not feel depressed 
Felt depressed for <6 weeks 
Felt depressed for 6-52 weeks 
 
x 
418 (46.0) 
490 (54.0) 
 
12,341 (91.1) 
573 (4.2) 
626 (4.6) 
Family stress index 
No stress 
Some stress 
Stress overload  
 
584 (64.3) 
267 (29.4) 
57 (6.3) 
 
9983 (76.3) 
2752 (21.0) 
356 (2.7) 
Activities prevented by pain 
No pain or discomfort 
Pain does not prevent activities 
Pain prevents few activities 
Pain prevents some activities 
Pain prevents most activities 
 
618 (68.1) 
51 (5.6) 
81 (8.9) 
76 (8.4) 
82 (9.0) 
 
11,647 (82.1) 
697 (4.9) 
813 (5.7) 
552 (3.9) 
478 (3.4) 
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Table 6-4. Alcohol dependence, other risk factors for 6-year persistent or recurrent major 
depression  
  
Crude RR 
(95%CI) 
aAdjusted 
RR (95%CI) Statistic (p-value) 
Alcohol dependence 
No 
Yes 
 
1 
2.54 (1.46-4.41)** 
 
1 
3.03 (1.68-5.48)** 
 
Age  
18 to 24 years 
25 to 44 years 
45 to 59 years 
60 years and above 
 
1 
1.33 (0.85-2.08) 
0.79 (0.45-1.38) 
0.59 (0.23-1.49) 
 
1 
1.37 (0.82-2.28) 
0.84 (0.44-1.61) 
0.97 (0.35-2.68) 
0.06 
Sex 
Male 
Female 
 
1 
1.39 (0.95-2.04) 
 
1 
1.53 (1.02-2.29)* 
 
Marital status 
Married 
Common-law/ with a partner 
Widowed 
Divorced or Separated 
Single/ never married 
 
1 
1.29 (0.69-2.40) 
.053 (0.22-1.28) 
1.48 (0.98-2.23) 
1.07 (0.71-1.61) 
 
1 
0.81 (0.41- 1.59) 
0.62 (0.24-1.56) 
1.01 (0.65-1.56) 
0.86 (0.53-1.38) 
 
Highest level of education 
<secondary 
Secondary grad 
Some post-secondary 
Post-secondary grad 
 
1 
0.77 (0.44-1.35) 
0.97 (0.64-1.46) 
0.83 (0.54-1.28) 
 
X 
0.90 
Dwelling owned by a household member 
No 
Yes 
 
1 
0.61 (0.44-0.83)** 
 
1 
0.74 (0.53-1.03) 
 
History of chronic condition 
No 
Yes 
 
1 
1.13 (0.79-1.61) 
 
X 
 
Self-esteem index 
Self-esteem index <18 
Self-esteem index = 18 
Self-esteem index 19-22 
Self-esteem index 23-24 
 
1 
0.56 (0.36-0.87)** 
0.49 (0.32-0.74)** 
0.43 (0.25-0.74)** 
 
1 
0.73 (0.47-1.12) 
0.59 (0.40-0.89)** 
0.54 (0.32-0.92)* 
<0.0001 
Mastery index 
Mastery index <17 
Mastery index 17-19 
Mastery index 20-21 
Mastery index 22-28 
 
1 
0.56 (0.36-0.86)** 
0.64 (0.40-1.01) 
0.43 (0.23-0.77)** 
 
X 
 
Type of smoker 
Never Smoked 
Daily 
Former daily/ Occasionally but former daily 
Always/ former occasional 
 
1 
2.05 (1.34-3.12)** 
1.09 (0.62-1.91) 
1.50 (0.78-2.88) 
 
1 
1.58 (1.03-2.43)* 
1.09 (0.63-1.87) 
1.24 (0.63-2.44) 
0.02 
Recent life events scores 
No recent life events 
<3 recent life events 
3 or more recent life events 
 
1 
1.59 (1.11-2.27)* 
1.47 (0.88-2.47) 
 
1 
1.19 (0.81-1.76) 
0.92 (0.54-1.57) 
0.43 
Childhood and adult stress index 
No traumatic events 
<3 traumatic events 
3 or more traumatic events 
 
1 
1.68 (1.05-2.69)* 
2.67 (1.66-4.28)** 
 
1 
1.38 (0.87-2.19) 
1.72 (1.04-2.83)* 
0.03 
Perceived social support index 
No social support 
Minimal social support 
Some social support 
Adequate social support 
 
1 
0.78 (0.19-3.14) 
1.54 (0.59-4.02) 
1.06 (0.42-2.66) 
 
X 
 
Number of weeks felt depressed 
Felt depressed for <6 weeks 
Felt depressed for 6-52 weeks 
 
1 
1.25 (0.90-1.74) 
 
X 
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a – adjusted in a multivariate model 
x – lost in multivariate analysis 
Significant values are marked in bold print  
*  p-value < =0.05 
** p-value <0.001 
< Secondary- less than secondary education; Secondary grad- secondary education graduate; Some post sec – some post secondary education; 
Post-secondary grad – post secondary education graduate 
6.4.3 16-year persistence or recurrence of major depression 
After 16 years of follow-up (cycle 9), 461 (51%) participants remained in the study 
(Figure 6-2). Seventy-nine of them (17.14%) still met the criteria for MDE, that is 8.7% of the 
baseline cohort of 908 depressed participants continued to have depression after 16 years. 
Alcohol dependence remained a risk factor for the persistence or recurrence of major depression 
with a three-fold increase in the risk compared to those who were not alcohol dependent (Table 
6-5). There was a two-fold increase in the risk of persistent or recurrent depression if participants 
had pain preventing activities compared to no pain or discomfort. After 16years of follow-up, 
being divorced or separated at baseline compared to being married was associated with a 
reduction in the risk of persistent or recurrent depression by 62%. 
  
Family stress index 
No stress 
Some stress 
Stress overload  
 
1 
1.40 (1.01-1.96)* 
1.11 (0.57-2.16) 
 
1 
1.08 (0.76-1.52) 
0.73 (0.37-1.46) 
0.68 
Activities prevented by pain 
No pain or discomfort 
Pain does not prevent activities 
Pain prevents few activities 
Pain prevents some activities 
Pain prevents most activities 
 
1 
1.33 (0.69-2.55) 
1.19 (0.68-2.07) 
1.35 (0.77-2.39) 
2.13 (1.37-3.31)** 
 
1 
0.95 (0.54-1.68) 
0.96 (0.59-1.56) 
1.14 (0.63-2.06) 
1.70 (1.06-2.71)* 
0.03 
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Table 6-5. Alcohol dependence, other risk factors for 16-year persistent or recurrent major 
depression 
 Crude RR (95%CI) aAdjusted 
RR (95%CI) Statistic (p-value) 
Alcohol dependence 
No 
Yes 
 
1 
2.41 (1.09-5.29)* 
 
1 
3.17 (1.15-8.77)* 
 
Age  
18 to 24 years 
25 to 44 years 
45 to 59 years 
60 years and above 
 
1 
1.29 (0.74-2.24) 
0.67 (0.32-1.42) 
0.60 (0.18-1.95) 
 
1 
1.16 (0.64-2.10) 
0.49 (0.22-1.12) 
0.48 (0.13-1.73) 
0.07 
Sex 
Male 
Female 
 
1 
1.23 (0.76-1.97) 
 
1 
1.39 (0.85-2.27) 
 
Marital status 
Married 
Common-law/ with a partner 
Widowed 
Divorced or Separated 
Single/ never married 
 
1 
0.97 (0.41-2.29) 
0.47 (0.12-1.83) 
0.62 (0.32-1.21) 
1.22 (0.79-1.90) 
 
1 
0.86 (0.31-2.37) 
0.63 (0.15-2.85) 
0.38 (0.19-0.74)** 
1.10 (0.66-1.84) 
0.003 
Highest level of education 
<secondary 
Secondary grad 
Some post-secondary 
Post-secondary grad 
 
1 
0.82 (0.34-1.96) 
1.52 (0.82-2.80) 
1.28 (0.69-2.39) 
 
X 
 
Dwelling owned by a household member 
No 
Yes 
 
1 
0.63 (0.42-0.94)* 
 
1 
0.69 (0.44-1.07) 
 
History of chronic condition 
No 
Yes 
 
1 
1.57 (0.98-2.51) 
 
1 
1.32 (0.80-2.18) 
 
Self esteem index 
Self-esteem index <18 
Self-esteem index = 18 
Self-esteem index 19-22 
Self-esteem index 23-24 
 
1 
0.81 (0.46-1.41) 
0.69 (0.41-1.14) 
0.72 (0.40-1.30) 
 
X 
 
Mastery index 
Mastery index <17 
Mastery index 17-19 
Mastery index 20-21 
Mastery index 22-28 
 
1 
0.48 (0.25-0.91)* 
0.66 (0.37-1.16) 
0.73 (0.41-1.28) 
 
1 
0.47 (0.25-0.90)* 
0.68 (0.38-1.25) 
0.82 (0.48-1.40) 
0.01 
Type of smoker 
Never Smoked 
Daily 
Former daily/ Occasionally but former daily 
Always/ former occasional 
 
1 
1.35 (0.83-2.20) 
1.29 (0.74-2.24) 
0.33 (0.08-1.35) 
 
1 
1.15 (0.70-1.89) 
1.28 (0.74-2.22) 
0.23 (0.06-0.95)* 
0.03 
Recent life events scores 
No recent life events 
<3 recent life events 
3 or more recent life events 
 
1 
1.24 (0.79-1.95) 
1.53 (0.86-2.72) 
 
1 
1.09 (0.69-1.72) 
0.90 (0.49-1.66) 
0.51 
Childhood and adult stress index 
No traumatic events 
<3 traumatic events 
3 or more traumatic events 
 
1 
1.18 (0.69-2.00) 
1.86 (1.09-3.19)* 
 
1 
1.30 (0.78-2.19) 
1.32 (0.74-2.37) 
0.58 
Perceived social support index 
No social support 
Minimal social support 
Some social support 
Adequate social support 
 
1 
0.38 (0.08-1.70) 
0.24 (0.08-0.74)* 
0.64 (0.30-1.38) 
 
1 
0.27 (0.05-1.32) 
0.20 (0.07-0.57)* 
0.52 (0.24-1.14) 
0.002 
Number of weeks felt depressed 
Felt depressed for <6 weeks 
Felt depressed for 6-52 weeks 
 
1 
1.12 (0.74-1.68) 
 
X 
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a – adjusted in a multivariate model 
x – lost in multivariate analysis 
Significant values are marked in bold print  
*  p-value < =0.05 
** p-value <0.001 
< Secondary- less than secondary education; Secondary grad- secondary education graduate; Some post sec – some post secondary education; 
Post-secondary grad – post secondary education graduate 
6.5  Discussion 
6.5.1 Alcohol dependence 
This study showed the risk for persistence or recurrence of major depression was three 
times higher with concurrent alcohol dependence. This supports the evidence that comorbidity is 
one of the strongest predictors of persistent or recurrent major depression (Spijker & Nolen, 
1998; Mueller, et al., 1994; Burcusa & Iacono, 2007; Barkow, et al., 2003; Segal, Pearson, & 
Thase, 2003). This also supports the evidence of the adverse effects of substance use disorders 
on the course of severe mental illness (Owen, Fischer, Booth, & Cuffel, 1996; Dixon, McNary, 
& Lehman, 1998; Mueser, Bellack, & Blanchard, 1992; Volkow, Baler, Compton, & Weiss, 
2014; Hobbs, Kushner, Lee, Reardon, & Maurer, 2011). Alcohol dependence could increase the 
risk of persistent or recurrent depression by increasing the likelihood of symptom exacerbation, 
decreased social functioning and treatment nonadherence (Owen, Fischer, Booth, & Cuffel, 
1996; Dixon, McNary, & Lehman, 1998; Mueser, Bellack, & Blanchard, 1992; Burcusa & 
Iacono, 2007).  
Several possible mechanisms postulated for the co-occurrence of alcohol dependence and 
major depression could explain the findings of this study. However, two theories receive more 
recognition: the disorder inducing theory and overlapping predisposition theory. The disorder 
inducing theory believes one disorder causes the other and lends itself to the self-mediation 
theory, where major depression is being treated with alcohol to suppress symptoms (Khantzian, 
1985; Merikangas, et al., 2008; Maremmani, Perugi, Pacini, & Akiskal, 2006; MacDonald, 
Baker, Stewart, & Skinner, 2000). In contrast, in substance-induced mood disorder, major 
Family stress index 
No stress 
Some stress 
Stress overload  
 
1 
1.70 (1.13-2.56)** 
1.00 (0.39-2.58) 
 
1 
1.27 (0.82-1.98) 
0.53 (0.20-1.45) 
0.21 
Activities prevented by pain 
No pain or discomfort 
Pain does not prevent activities 
Pain prevents few activities 
Pain prevents some activities 
Pain prevents most activities 
 
1 
1.02 (0.39-2.64) 
2.70 (1.67-4.39)** 
2.19 (1.15-4.16)* 
1.85 (0.88-3.89) 
 
1 
0.63 (0.22-1.77) 
2.24 (1.39-3.63)** 
1.89 (0.94-3.78) 
2.23 (1.08-4.62)* 
0.001 
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depression becomes a consequence of alcohol dependence (American Psychiatric Association, 
2000). The overlapping predisposition consists of the idea of a common underlying vulnerability 
to alcohol dependence and major depression. This common vulnerability may be genetic and/or 
environmental (Goldman, Orozi, & Ducci, 2005; Kendler, Prescott, Myers, & Neale, 2003) with 
possible predisposition of individuals high in the vulnerability to not only the recurrent major 
depressive episodes, but also to the significant psychosocial risk factors that often accompany 
recurrence or persistence such as the co-occurrence of alcohol dependence (Canadian Centre on 
Substance Abuse, 2009; Edvardsen, et al., 2008; Agrawal & Lynskey, 2014; Li & Burmeister, 
2009; Stewart & Conrod, 2008b; Agrawal & Lynskey, 2008; Burcusa & Iacono, 2007). 
Irrespective of the pathway involved in causing the comorbid occurrence of major 
depression and alcohol dependence, once it is formed, a vicious cycle where one disorder 
maintains or worsens the other, may have been triggered (Stewart & Conrod, 2008; Stewart & 
Conrod, 2008b). In other words, if one were to treat one disorder without addressing the other, 
the risk of relapse, recurrence, or persistence would be very high (Canadian Centre on Substance 
Abuse, 2009; Stewart & O'Connor, 2009; Foa & Kozak, 1986; Forbes, Creamer, Hawthorne, 
Allen, & McHugh, 2003; Bruce, et al., 2005; Kushner, et al., 2005; Driessen, et al., 2001; Book, 
McNeil, & Simpson, 2005)  resulting in increased health care utilization and costs (Willinger, 
Lenzinger, Hornik, Fischer, & Meszaros, 2002). 
6.5.2 Other risk factors 
Childhood and adult stress index was associated with an increased risk for persistent or 
recurrent major depression. This prospective finding which is a measure of the number of 
traumatic events respondents have been exposed to during their childhood, adolescence or 
adulthood, is in line with previous findings (Garcia-Toro, et al., 2013; Johnstone, et al., 2009; 
Klein, et al., 2009; Perez-Fuentes, et al., 2013; Sugaya, et al., 2012). Traumatic events such as 
physical and sexual abuse increase the prevalence, risk, and chronicity of depression (Perez-
Fuentes, et al., 2013; Klein, et al., 2009). Physiologic dysregulation which results from stressful 
events during development also increases the risk of chronic conditions such as depression (Friis, 
Wittchen, Pfister, & Lieb, 2002; Gonzalez, et al., 2012; Choi, DiNitto, Marti, & Choi, 2017; 
Merrick, et al., 2017) and possibly treatment resistance (Klein, et al., 2009; Nemeroff, et al., 
2003; Perez-Fuentes, et al., 2013; Sugaya, et al., 2012). Parental psychopathology, abuse, and the 
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resultant chaotic family environment could interfere with normal childhood development, coping 
mechanisms and self-esteem leading to future and severe psychopathology (Garcia-Toro, et al., 
2013). 
Consistent with previous findings, pain, smoking, lack of social support, low mastery or 
low self-esteem were associated with persistent or recurrent depression (Patten, et al., 2010; 
Bottomley, et al., 2010; Burcusa & Iacono, 2007; Spijker, Bijl, De Graaf, & Nolen, 2000; 
Keitner, Ryan, Miller, & Norman, 1992). Social vulnerability factors such as education and 
socioeconomic status were not associated with persistence or recurrence, consistent with findings 
from the Netherlands (Spijker, et al., 2004), but inconsistent with findings from the USA (Keller, 
1994; Sargeant, Bruce, Florio, & Weismann, 1990; Mueller, et al., 1996). This may reflect the 
income inequality in these countries with the US having more income inequality than the 
Netherlands and Canada (The Conference Board of Canada, 2018).  
 The risk of persistent or recurrent depression was increased in females after 6years of 
follow-up, consistent with previous findings (Sargeant, Bruce, Florio, & Weismann, 1990; 
Keitner, Ryan, Miller, & Norman, 1992) but after 16years of follow-up, gender became a 
confounder. Age was not a determinant of persistent depression contrary to previous findings 
(Spijker, Bijl, De Graaf, & Nolen, 2000; Sargeant, Bruce, Florio, & Weismann, 1990; Spijker, et 
al., 2004) but a confounder. There was no association between the duration of the most recent 
episode (number weeks depressed) and persistent depression. This was consistent with previous 
findings of no associated risk of recurrence with the duration of the index episode (Burcusa & 
Iacono, 2007; Kaminski & Garber, 2002; O'Leary, Costello, Gormley, & Webb, 2000). This 
finding can be explained by the fact that the index episode may not be the first episode and 
results may simply be reflecting treatment response of participants (Gonzales, Lewinsohn, & 
Clarke, 1985). Also, our findings may be affected by recall bias. 
One of the strengths of this study is that this prospective analysis was based on a nationally 
representative sample of the Canadian population giving an inference among individuals 
irrespective of their health-seeking behaviors and severity of their conditions. The diagnoses of 
alcohol dependence and MDE were derived using structured diagnostic instruments based on 
DSM III-R criteria. Limitations of this study include the loss to follow-up. Diagnosis of 
depression and alcohol dependence were interview-based, possibly introducing recall bias. 
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Assessing participants characteristics at baseline as an indication for persistence or recurrence 
over a long time (6 years and 16 years) is a drawback in this analysis. In addition, an important 
determinant of prognosis, the severity of the index MDE, was not assessed in the data.  
6.6  Conclusion 
The significant overlap in the mechanisms leading to alcohol dependence and major 
depression, the adverse effects of dependence on the course of major depression and the 
increased health care utilization caused by this comorbidity, is a public health concern. It is 
therefore of utmost importance to treat both disorders simultaneously to improve treatment 
outcome and reduce health care costs.  
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Appendix A. Loss to follow-up 
Table A.1 Association of predictor variables and missingness in MDE at cycle 4 and 9 
Variables Chi square p-value  
 MDE at cycle 4 MDE at cycle 9 
Province of residence 0.59 0.75 
Age  0.93 0.74 
Sex 0.86 0.98 
Marital status 0.43 0.05 
Educational status 0.79 0.19 
Income 0.53 0.35 
History of chronic disease 0.91 0.29 
Recent life events scores 0.25 0.65 
Childhood and adult stress index 0.05 0.04 
Dwelling owned 0.21 0.29 
Alcohol dependence  0.88 0.25 
Self esteem index 0.36 0.75 
Mastery index 0.96 0.72 
Number of weeks felt depressed 0.11 0.91 
Perceived social support 0.06 0.23 
Type of smoker 0.94 0.52 
Pain preventing activities 0.53 0.42 
Family stress index 0.04 0.22 
MDE – major depressive episode 
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CHAPTER 7. A SYSTEMATIC REVIEW AND META-ANALYSIS OF 
COMORBID SUBSTANCE USE DISORDERS, CANNABIS USE 
DISORDERS WITH MAJOR DEPRESSION 
7.1 Introduction 
Substance use disorders (SUDs) are highly co-morbid with other psychiatric disorders in 
both the general population and in patient populations (Buckley & Brown, 2006; Compton, 
Thomas, Stinson, & Grant, 2007; Conway, Montoya, & Compton, 2007; de Leon & Diaz, 2005; 
Grant, et al., 2004; Jane-LIopis & Matytsina, 2006; Kessler, et al., 2003; Regier, et al., 1990) and 
are usually associated with poor treatment outcomes resulting in severe illnesses and increased 
health service utilization (Kessler, et al., 1994; Kessler R. , 2004; Merikangas & Gelernter, 
1990). Epidemiological patterns of several population-based studies (Grant & Harford, 1995; 
Kessler, et al., 1996a; Kessler, et al., 1997; Kessler, et al., 2001; Regier, et al., 1990; Grant, et al., 
2004; Grant, et al., 2016) consistently found comorbid associations between mental health 
disorders and substance use disorders, and at much higher rates than chance levels.  
Comorbid substance use and psychiatric disorders have been investigated extensively in 
large epidemiological studies: the Epidemiological Catchment Area (ECA) surveys in the United 
States of America  (Regier, et al., 1990), the International Consortium in Psychiatric 
Epidemiology (ICPE) (Kessler, et al., 2001), the US National Comorbidity Survey (NCS) 
(Kessler, et al., 1996a), the Canadian Community Health Survey: Mental Health and Well-Being 
(CCHS 1.2) (Currie, et al., 2005; Rush, Urbanoski, Bassani, Castel, & Wild, 2008), the National 
Longitudinal Alcohol Epidemiologic Survey (NLAES) (Grant B. , 1995), the Netherlands Mental 
Health Survey and Incidence Study (NEMESIS) (Bijl, Ravelli, & Van Zessen, 1998) and the 
National Epidemiologic Survey on Alcohol and Related Conditions (NESARC) (Compton, 
Thomas, Stinson, & Grant, 2007; Hasin, et al., 2016). Even though these surveys have 
demonstrated independently, the prevalence and associations of substance use and psychiatric 
disorders, a meta-analysis of these associations is necessary. 
Comorbidity research has produced a range of prevalence rates (Grant, et al., 2004; 
Kessler, et al., 2003; Currie, et al., 2005; Schuckit, et al., 1997). Although definitive comparisons 
across studies are made impossible by methodological differences, Jane-LIopis & Matytsina 
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(2006) in their review found prevalence estimates overlap of  7% to 45% and 17% to 55% for 
mood or anxiety disorders with alcohol dependence and drug dependence respectively. These 
variations can be explained by the fact that the diagnostic criteria for major depression and 
substance use disorders have changed over the years and the overlap in symptomatology have 
been handled differently in different surveys (Currie, et al., 2005). In addition, a variety of 
instruments and different versions of the same instrument have been used in epidemiological 
surveys (Currie, et al., 2005; Hasin, et al., 1997), with advancements in some of these 
instruments such as the World Health Organization – Composite International Diagnostic 
Interview, WHO-CIDI resulting fewer false positives, hence reduced prevalence of comorbidity 
(Kessler, et al., 2003). In the Collaborative Study on Genetics of Alcoholism (COGA), the 
relationships between Diagnostic and Statistical Manual of Mental Disorders, DSM-IV, DSM-
III-R and International Classification of Diseases, ICD-10 diagnostic criteria were evaluated for 
substance use disorders (Schuckit, et al., 1994). While analyses revealed similarity in the 
proportions of individuals diagnosed with the three systems for substance dependence (kappa 
0.54-0.83), they were largely disparate for substance abuse or harmful alcohol use (kappa rarely 
exceeding 0.1) (Schuckit, et al., 1994).  
Comorbid associations have been postulated to occur either by one disorder inducing the 
other or the individual having a shared vulnerability to both disorders (Canadian Centre on 
Substance Abuse, 2009). Concurrent disorders tend to be more frequent in treatment samples 
than in the general population (Weaver, et al., 2003). Treatment samples are often biased by the 
increased help-seeking behavior of individuals with comorbid, more severe and protracted 
mental health disorders (Berkson, 1946; Regier, et al., 1990; Rounsaville, Dolinsky, Babor, & 
Meyer, 1987). General population-based studies, therefore, provide more robust and 
generalizable estimates of the comorbidity distribution of SUDs and mental health disorders. 
A previous systematic review of comorbid substance use disorders and mental health 
disorders in studies between 1998 and 2005, did not include a meta-analysis (Jane-LIopis & 
Matytsina, 2006). Another systematic review on comorbid substance use and mental health 
disorders had a meta-analysis and was based on studies between 1990 and 2014 included 22 
studies from national epidemiological surveys and community-based samples of predominantly 
large urban centres (Lai, Cleary, Sitharthan, & Hunt, 2015). This may have introduced some 
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form of bias as there are disparities in access to care between rural and urban residents (Loftus, 
Allen, Call, & Everson-Rose, 2018). 
To expand knowledge, our current systematic review with meta-analysis was intended to 
assess the prevalence and strength of associations between comorbid substance use disorders, 
cannabis use disorders with major depression in nationally representative samples. Since 
comorbidity is a significant predictor of treatment seeking (Wu, Kouzis, & Leaf, 1999), 
nationally representative studies where chosen to avoid including studies based on patient 
samples that may overestimate the comorbid associations (Berkson, 1946). In addition, national 
surveys were chosen to avoid population dynamics such as rural versus urban and the influence 
on comorbid treatment access and estimates. Nationally representative studies were defined as 
studies whose original participants were from national surveys capturing both rural and urban 
residents and stated by the authors as nationally representative. Our interest in cannabis stems 
from the fact that it is still the most frequently used controlled substance across the globe (United 
Nations Office on Drugs and Crime, 2016) and a significant political, health and law-
enforcement issue. After alcohol, cannabis is the most consumed substance with several 
countries moving to its legalization and contemplating how its medical uses fit into the equation 
(Canadian Centre on Substance Abuse, 2017; United Nations Office on Drugs and Crime, 2016). 
In Canada, cannabis legalization took place on the 17th of October 2018, and this legalization is 
thought to replace a failed model that increased organized criminal activities and vulnerability to 
children (Tasker, 2018). Evidence of the negative health effects of cannabis appear to be 
inconsistent (Canadian Centre on Substance Abuse, 2017). A systematic review with a pooled 
effect could help to clarify the nature and extent of the relationship between substance use 
disorder, cannabis use disorder and major depression.   
7.2 Objectives 
In this study, we aimed to conduct a systematic review and meta-analyses assessing the 
prevalence and strength of associations between comorbid substance use disorders (alcohol use 
disorders, drug use disorders – all illicit drugs of abuse) with major depressive episodes (MDE), 
comorbid cannabis use disorders (CUDs) with MDE in nationally representative population-
based surveys. 
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7.3  Methods   
The methods were based on the Preferred Reporting Items for Systematic Reviews and 
Meta-analysis (PRISMA) guidelines (Liberati, et al., 2009; Moher, Liberati, Tetzlaff, Altman, & 
Group, 2009). 
7.3.1 Data sources and search strategy 
A computerized search of the following bibliographic databases: MEDLINE, CINAHL, 
PsycINFO and EMBASE was conducted using the following search terms: (co-morbid* or 
comorbid* or co-occur*) OR diagnosis or dual diagnosis(psychiatry), AND (alcohol* or  
cannabis* or marijuana* or drug* or substance* or SUD) OR (mental health  or mental illness or 
bipolar or depress* or mood disorder) AND (epidemiology or prevalence or incidence or 
occurrence), for population surveys of humans in English, published online between January 1st 
1980 and May 31st 2018. Further search of related articles of selected authors (e.g. de Graaf, 
Grant, Kessler, Merikangas, Reiger, Conway and Swendson), the reference list of included 
studies and a previous meta-analysis on comorbid substance use, anxiety and mood disorders 
(Lai, Cleary, Sitharthan, & Hunt, 2015) was done. Gray literature for dissertations, conference 
abstracts, formally unpublished journal articles and books were made. Inclusion criteria were 
publications in English Language, original research, nationally representative samples, and non-
clinical randomly selected adult populations. Studies whose target population were a close 
representation of the national population were assessed as nationally representative.  Exclusion 
criteria were studies done on clinical/ patient samples, restricted geographic area or population of 
a country, children and adolescent. 
7.3.2 Selection criteria 
Two independent raters (Vivian Onaemo and Muzi Li) excluded materials that were 
irrelevant to the review and assessed for risk of bias using the tool developed by Hoy et al 
(2012). The first, second and third rounds of exclusions were based on the articles’ titles, 
abstracts and full texts respectively. If there were any disagreements or uncertainties at the first 
and second rounds, a full text review was done.  Disagreements with full text review were 
resolved by a third rater (Carl D’Arcy). Articles were chosen if they were original research on 
adults, randomly selected national representative surveys. Children and adolescent studies were 
excluded because interviews on them are usually complicated with consent and proxy issues. 
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Studies on subpopulations such as specific cities (e.g. Ontario (Offord, et al., 1996), Munich 
(Wittchen, Essau, von Zerssen, Krieg, & Zaudig, 1992), limited age (e.g. middle-aged), gender-
specific or other specific groups (e.g. veterans), race (Merikangas, et al., 1998), other 
comorbidities (e.g. diabetes), institutionalized, homelessness, specific demographics (e.g. 
students, nurses) were excluded as they were not nationally representative. Studies were also 
screened based on the diagnostic criteria used. All included studies were based on structured 
diagnostic instruments. 
7.3.3 Data abstraction 
The two raters (VO and ML) independently abstracted using a semi-structured form for 
the study characteristics such as the name of study, name of survey, authors, setting (country), 
year survey was conducted, year of publication, journal, sample size, age range, diagnostic 
criteria used, type of SUD and psychiatric disorders (major depression). 
Data abstraction for meta-analysis included the comorbidity prevalence, odds ratios 
(ORs) and 95% confidence intervals of major depression and SUDs (alcohol, drugs), and major 
depression and CUDs. 
7.3.4 Meta-analysis 
STATA version 14 was used to estimate the pooled ORs of selected articles in four 
separate meta-analyses.  
• Substance use disorders2 (SUD) and major depression (MD) 
• Substance abuse3 and MD 
• Substance dependence and MD 
• Cannabis use disorders (CUD) and MD 
                                                 
2 Substance use disorders (alcohol, illicit drugs) refers to substance abuse and /or dependence (American Psychiatric 
Association, 1994). 
3 “Substance abuse refers to the harmful or hazardous use of psychoactive substances (alcohol and illicit drugs) 
while substance dependence is a cluster of behavioural, cognitive, and psychological phenomena (difficulties 
controlling its use or the strong desire to use, persisting in its use despite harmful consequences, higher priority 
given to the drug use than other activities or obligations, increased tolerance, physical withdrawal) that develop 
secondary to repeated use of the substance” (World Health Organization, 2018). 
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In these analyses, substance use disorder is comprised of alcohol use disorders (AUD) 
and illicit drug use disorders (DUD). Substance abuse is comprised of alcohol abuse and illicit 
drug abuse while substance dependence is comprised of alcohol dependence and illicit drug 
dependence. Cannabis use disorder is comprised of cannabis use disorder, cannabis abuse and 
cannabis dependence. All diagnoses were derived using structured diagnostic instruments in the 
primary studies. 
Since the prevalence would likely vary between populations of different nationalities and 
characteristics, we evaluated heterogeneity with DerSimonian and Laird I2 Statistic to determine 
the degree of inconsistency across studies’ results that is due to heterogeneity rather than chance 
(Higgins, Thompson, Deeks, & Altman, 2003). A random effects model was chosen over a fixed 
effects model when the percentage of total variation across studies was found to be significant. 
To avoid duplication, articles reporting odds ratios from the same survey were identified and one 
selected based on quality, estimates reported (lifetime chosen over 12-months) and date of 
publication (most recent chosen). Publication bias was accounted for with Egger’s test and 
impact of study quality with meta-regression. Sensitivity analysis and meta-cumulative analysis 
were done to see the impact of individual studies on the overall estimate. 
7.4  Results  
7.4.1 Search findings 
After removal of duplicates, a total of 2085 titles were identified (Figure 7-1). The two 
independent reviewers (VO and ML) judged 1456 articles as not relevant by title. The reviewers 
examined 629 articles for comorbid associations by abstract and excluded 472 articles. A full 
text review of 157 articles was done and 24 articles from 18 surveys were identified as 
describing comorbid prevalence and associations in nationally representative samples. 
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Figure 7-1. PRISMA flow diagram of search strategies and results. - Comorbid substance use 
disorder with major depression  
  
3011 citations retrieved from 
search
2085 titles reviewed
629 abstracts examined for 
comorbid data 
157 articles examined 
in full text  
24 articles from 18 surveys provided comorbidity data for substance use disorders and 
major depression in nationally representative samples
13 studies included in the comorbid SUD 
with major depression analysis
10 studies included in the comorbid substance abuse 
with major depression analysis
13 studies included in the comorbid substance 
dependence with major depression analysis
6 studies included in the comorbid CUD 
with major depression analysis
133 studies excluded after full text review
• 9 articles described comorbidity in selected communities,not  nationally 
representative  
• 24 described comorbidity in primary care settings 
• 51 described comorbidity in psychiatric patient samples 
• 37 described comorbidity in substance addiction/forensic settings 
• 12 Analyses used same samples 
472 articles excluded after 
abstract review
1456 articles excluded as non relevant by 
two independent reviewers
926 duplicate records 
excluded
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7.4.2 Study characteristics 
The settings, sample sizes and characteristics of respondents for the 24 articles included 
in this review are summarised in Table 7-1. Sample sizes ranged from 1555 in Puerto Rico to 
43,093 in the USA with a total sample size of 300,104 for all 18 surveys included in the analysis. 
Surveys included were from the USA, Canada, Europe (Belgium, France, Germany, Italy, The 
Netherlands, Spain), The Netherlands, Great Britain, Australia, Puerto Rico, South Korea, 
Singapore, Thailand and Taiwan. Some national surveys that were repeated at a different time 
point with different respondents (NSMH&WB 1 and 2 (study ID 12 and 13), NSERC wave I and 
III (study ID 8 and 9), and NCS and NCS-R (study ID 6 and 7) were included as different studies 
while the one that was based on the same respondents (NSERC wave II) from a previous survey 
(NSERC wave I) was excluded.   
The quality of the studies (Appendix 3) and risk for bias were assessed using an 
assessment scale modified from the Newcastle-Ottawa Scale (NOS) (Wells, et al., 2012) and the 
tool developed for prevalence studies by Hoy et al (2012). The assessment was based on the 
external validity (representativeness of the national population, sampling frame a true 
representation of the target population, random selection of participants, likelihood of non-
response minimal) and internal validity ( data collected directly from the subjects not proxy, 
assessment of exposure and outcome, acceptable case definition used in the study, the same 
mode of data collection for all subjects, numerator(s) and denominator(s) for the parameter of 
interest appropriate, appropriate control of confounding) of the studies (Hoy, et al., 2012; Wells, 
et al., 2012). One study (ESEMed) had a medium risk of bias while others were low.   
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Table 7-1. Summary of study characteristics of included studies 
Study 
ID 
Survey name Survey 
year 
Setting First author Sample 
size 
Age range 
(year) 
Psychiatric 
disorders 
SUDs Diagnostic 
criteria 
Risk of bias 
 
1 
Canadian Community 
Health Survey: Mental 
Health and Well-Being 
(CCHS 1.2) 
2002 Canada (Currie, et al., 2005) 36,984 15years and 
older 
Major 
depression 
Harmful alcohol 
use, alcohol 
dependence, 
drug dependence 
WHM-CIDI 
(based on 
DSM-III-R) 
Low; harmful 
alcohol use to 
mean alcohol 
abuse 
2 Epidemiologic Study 
of Puerto Rico 
1984 Puerto Rico (Swendsen, et al., 
1998) 
1551 17-64years Depression AUD DSM-III Low 
3 European Study of the 
Epidemiology of 
mental disorders 
(ESEMed) 
2000 Belgium, 
France, 
Germany, 
Italy, The 
Netherlands
, Spain 
(Alonso, Lepine, & 
Scientific-Committee, 
2007) 
Phase 1 
21,425 
phase 2 
8796 
18years and 
older 
Major 
depression 
Alcohol abuse, 
alcohol 
dependence 
CIDI 3.0 Medium: varied 
response rate 
across regions 
(46-79%), 
combined 
comorbidity 
indices  
4 Korean Epidemiologic 
Catchment Area 
(KECA) study 
2001 South 
Korea 
(Chou, et al., 2012) 7867 18-65years Major 
depression 
Alcohol use 
disorders 
K-CIDI 2.1 Low 
5 Collaborative 
Psychiatric 
Epidemiology Studies 
(CPES) 
2001-
2003 
United 
States 
(Mericle, Ta Park, 
Holck, & Arria, 2012) 
19,729 18years and 
older 
Major 
depressive 
episode 
SUD (AUD and 
DUD) 
WHM-CIDI 
(based on 
DSM-IV) 
Low 
6 National Comorbidity 
Survey (NCS) 
1990-
1992 
United 
States 
(Kessler, et al., 
1996b) 
5,877 15-54years Depression Alcohol, drug, 
abuse, 
dependence, 
SUD 
DSM-III-R Low 
7 National Comorbidity 
Survey Replication 
(NCS-R) 
2001-
2002 
United 
States 
(Kessler, et al., 2003) 5,554 18years and 
older 
Major 
depressive 
ds 
SUD DSM-IV Low 
8a National 
Epidemiologic Survey 
on Alcohol and Related 
Conditions (NSERC)  
2001-
2002 
United 
States 
(Conway, Compton, 
Stinson, & Grant, 
2006) 
43,093 18years and 
older 
Major 
depression 
DUD, abuse, 
dependence; 
CUD, abuse, 
dependence 
AUDADIS-IV 
derived from 
DSM-IV 
Low 
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8b    (Hasin, Goodwin, 
Stinson, & Grant, 
2005) 
43,093 18years and 
older 
Major 
depressive 
ds 
AUD, DUD, 
abuse, 
dependence 
AUDADIS-IV 
derived from 
DSM-IV 
Low 
8c    (Stinson, Ruan, 
Pickering, & Grant, 
2006) 
43,093 18years and 
older 
Major 
depression 
CUD AUDADIS-IV 
derived from 
DSM-IV  
Low 
9a National 
Epidemiological 
Survey on Alcohol and 
Related Conditions 
(NESARC) III 
2012-
2013 
United 
States 
(Grant, et al., 2015) 36,309 18years and 
older 
Major 
depression 
AUD AUDADIS-5 
derived from 
DSM-5 criteria 
 
Low 
9b    (Grant, et al., 2016) 36,309 18years and 
older 
Major 
depression 
DUD AUDADIS-5 
derived from 
DSM-5 criteria 
Low 
9c 
 
 
   (Hasin, et al., 2016) 36, 309 18years and 
older 
Major 
depression 
CUD AUDADIS-5 
derived from 
DSM-5 criteria 
Low 
10 National Household 
Survey on Drug Abuse 
(NHSDA) 
1994, 
1995, 
1996 
United 
States 
 (Kandel, Huang, & 
Davies, 2001) 
39,994 12years and 
older 
Major 
depression 
Alcohol, 
cannabis, drugs 
dependence 
DSM-IV Low 
11a National Longitudinal 
Alcohol Epidemiology 
Survey (NLAES) 
1992 United 
States 
(Grant B. , 1995) 42,862 18years and 
older 
Major 
depression 
DUD, abuse, 
dependence; 
CUD, abuse, 
dependence 
AUDADIS-IV 
derived from 
DSM-IV 
Low 
11b    (Grant & Harford, 
1995) 
42,862 18years and 
older 
Major 
depression 
AUD, abuse, 
dependence 
AUDADIS-IV 
derived from 
DSM-IV 
Low 
12 National Survey of 
Mental Health and 
Well Being 
(NSMH&WB) 
1997 Australia (Burns & Tesson, 
2002) 
10,641 Adults Major 
depression 
AUD CIDI Low 
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13a National Survey on 
Mental Health and 
Well-being 
(NSMH&WB) 
2007 Australia (Teesson, et al., 2010) 8841 16-85years Major 
Depressive 
Disorder 
AUD WMH-CIDI 
derived from 
DSM-IV 
Low 
13b    (Teesson, et al., 2012) 8841 16-85yeasr Major 
depressive 
ds 
CUD WMH-CIDI 
derived from 
DSM-IV 
Low 
14 National Survey of 
Psychiatric 
Comorbidity 
1995 Great 
Britain 
(Farrell, et al., 2001) 10,018 16-64years Depression Alcohol 
dependence, 
drug dependence 
ICD-10 Low 
15 Netherlands Study of 
Depression and 
Anxiety (NESDA) 
2004-
2007 
The 
Netherlands 
(Boschloo, et al., 
2011) 
2981 18-65years Depressive 
ds 
Alcohol abuse, 
alcohol 
dependence 
CIDI Low 
16 Taiwan Psychiatric 
Morbidity Survey 
(TPMS) 
2003-
2005 
Taiwan (Liao, et al., 2012) 10,135 18years and 
older 
Major 
depressive 
disorder 
SUD (AUD and 
DUD) 
WHM-CIDI 
(based on 
DSM-IV) 
Low 
17 Thai National Mental 
Health Survey 
2008 Thailand (Suttajit, 
Kittirattanapaiboon, 
Junsirimongkol, 
Likhitsathian, & 
Srisurapanont, 2012) 
17,140 15 and 
59years 
Major 
depressive 
disorder 
AUD, DUD, 
SUD 
MINI v5.0 
based on 
DSM-IV 
Low 
18 The Singapore Mental 
Health Study 
2009-
2010 
Singapore (Subramaniam, et al., 
2012) 
6,616 18years and 
older 
Major 
depressive 
ds 
AUD WMH-CIDI Low 
AUD, Alcohol use disorders; CUD, Cannabis use disorders; DUD, Drug use disorders; SUD, Substance use disorders; CIDI, Composite International Diagnostic Interview (CIDI); CIDI-SF 
(short form); DIS, diagnostic; WMH-CIDI, World Mental Health-CIDI; DSM, Diagnostic Statistical Manual of Mental Disorders; AUDADIS-IV, Alcohol Use Disorder and 
Associated Disabilities Interview Schedule – DSM-IV version; AUDADIS-5, The Alcohol Use Disorder and Associated Disabilities Interview Schedule-5.  
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7.4.3 Prevalence  
The prevalence of major depression with SUDs, AUD, CUD and DUD are shown in 
Figure 7-2. Prevalence estimates were those of comorbid occurrence of substance use disorders 
with major depression. Comorbid substance use disorders with major depression are highly 
prevalent. Major depression co-occurring with cannabis or drug abuse is more prevalent than 
with cannabis or drug dependence while its co-occurrence with alcohol dependence is more 
prevalent than with alcohol abuse. Comorbid major depression with DUD and CUD are more 
prevalent than with AUD. 
Figure 7-2. Prevalence of comorbid substance use disorder with major depression  
 
AUD, Alcohol use disorders; CUD, Cannabis use disorders, DUD, Drug use disorders, SUD, Substance use disorders  
7.4.4 Meta-analysis 
The forest plot for SUD (AUD, DUD and SUD) and major depression is shown in figure 
7-3. The meta-analysis pooled OR for AUD and major depression was 2.21 (95%CI 1.55-3.14), 
for DUD was 2.63 (95% CI 1.10-2.63) and SUD was 2.30 (95%CI 2.04-2.60). Thirteen studies 
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gave a pooled OR for comorbid major depression with substance use disorder as 2.33 (95%CI 
1.72-3.15), indicating that individuals with SUD are 2 times more likely to have comorbid major 
depression. There was no evidence of publication bias using the Egger’s test (p=0.85). Due to a 
significant DerSimonian and Laird I2 heterogeneity test (p<0.0001), a random effects analysis 
was chosen. 
Figure 7-3. Comorbid substance use disorder with major depression  
 
ES – estimate (OR); AUD - Alcohol use disorders; DUD - Drug use disorders; SUD - Substance use disorders 
Figure 7- 4 shows the forest plot for substance abuse (alcohol abuse, drug abuse) with 
depression. Meta-analysis pooled OR on 10 studies for major depression with substance abuse 
was 1.73 (95% CI 1.34-2.23), for alcohol abuse with depression was 1.42 (95%CI 1.13-1.80) and 
for drug abuse with depression was 2.26 (95%CI 1.57-3.25). Chou et al (2012) in their study on 
the Korean Epidemiologic Catchment Area (KECA) 2001 survey and Boschloo et al (2011) in 
their study on the Netherlands Study of Depression and Anxiety (NESDA) 2004 survey did not 
find associations between comorbid alcohol abuse with major depression. Other studies included 
in the meta-analysis showed significant risk of comorbid depression with substance abuse. There 
NOTE: Weights are from random effects analysis
Overall
Subtotal
Conway et al 2006 (NESARC, 2001-02)
Study
Subtotal
Subtotal
DUD Depression
ID
Kessler et al 1996 (NCS, 1990-92)
Teesson et al 2010 (NSMH&WB, 2007)
Grant & Harford 1995 (NLAES, 1992)
SUD Depression
Grant et al 2016 (NESARC, 2012-13)
Grant 1995 (NLAES, 1992)
Suttajit et al 2012 (Thai-NMHS, 2008)
Hasin et al 2005 (NESARC, 2001-02)
Chou et al 2012 (KECA Study,2001)
Swendson et al 1998 (Epid Study- Puerto Rico, 1984)
Grant et al 2015 (NESARC, 2012-13)
Burns & Teesson 2002 (NSMH&WB, 1997)
AUD Depression
Subramaniam et al 2012 (Singapore-MHS, 2009-10)
2.33 (1.72, 3.15)
2.63 (1.10, 6.29)
2.90 (2.52, 3.33)
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ES (95% CI)
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was no evidence of publication bias with Egger’s test (p=0.37) and random effects analysis 
chosen due to a significant DerSimonian and Laird I2 heterogeneity test (p<0.0001). 
Figure 7-4. Comorbid substance abuse with major depression  
 
ES – estimate (OR); AUD - Alcohol use disorders; DUD - Drug use disorders; SUD - Substance use disorders 
The meta-analysis pooled OR for substance dependence (alcohol dependence, drug 
dependence) with major depression is shown in figure 7-5. The overall pooled estimate for 13 
studies was 3.62 (95%CI 2.82-4.63) while that for alcohol dependence with major depression 
was 3.04 (95%CI 2.29-4.03) and drug dependence with major depression was 4.49 (2.93-6.87). 
This indicates a 3-folds and 4-folds increased risk of comorbid major depression with substance 
dependence and drug dependence respectively. DerSimonian and Laird I2 heterogeneity test was 
significant (p<0.0001) and a random effects analysis was chosen. Egger’s test showed no 
evidence of publication bias (p=0.58).  
  
NOTE: Weights are from random effects analysis
Overall
Grant 1995 (NLAES, 1992)
ID
Alcohol Abuse Depression
Alonso & Lepine 2007 (ESEMed, 2000)
Grant & Harford 1995 (NLAES, 1992)
Subtotal
Kessler et al 1996 (NCS, 1990-92)
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Study
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Figure 7-5. Comorbid substance dependence with major depression  
 
ES – estimate (OR); AUD - Alcohol use disorders; DUD - Drug use disorders; SUD - Substance use disorders 
In figure 7-6, the meta-analysis pooled OR for CUD (Cannabis abuse, cannabis 
dependence, CUD) with major depression was 2.59 (95%CI 1.59-4.23) on 6 studies while the 
pooled OR for cannabis dependence with depression was 5.77 (95%CI 3.8-8.77). In other words, 
individuals with CUD and cannabis dependence are 2 times and 5 times more likely to have 
comorbid major depression respectively. One study, Teesson et al (2012) based on the 2007 
Australian National Survey of Mental Health and WellBeing found a significant reduction in the 
risk of comorbid major depression with cannabis abuse. Other studies in the analysis showed 
increased risk of having comorbid major depression with cannabis use disorders. The 
DerSimonian and Laird I2 test for heterogeneity was significant (p<0.0001) and a random effects 
analysis was chosen. There was no evidence of publication bias with Egger’s test (p=0.97).   
NOTE: Weights are from random effects analysis
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Figure 7-6. Comorbid cannabis use disorder with major depression  
 
ES – estimate (OR); AUD - Alcohol use disorders; DUD - Drug use disorders; SUD - Substance use disorders 
7.5  Discussion 
This systematic review and meta-analysis showed high prevalence and evidence of strong 
associations between substance use disorders (abuse, dependence or both) and major depression, 
irrespective of the type of substance use disorder (alcohol, drug or cannabis). Comorbid major 
depression with CUD and DUD were found to be more prevalent than with AUD. This 
corroborates previous findings of higher rates of comorbid mental health disorders with SUD and 
much higher rates in illicit drug use disorders than AUD (Jane-LIopis & Matytsina, 2006). 
Alcohol dependence was noted to be more prevalent than alcohol abuse unlike in cannabis and 
illicit drug use where the abuse is more prevalent than the dependence. This could be explained 
by the policies on alcohol and drugs. While alcohol is considered a legal substance, illicit drugs 
(and cannabis until recently in some countries including Canada) were not. This may have 
affected participants perception of abuse of these substances with under reporting of abuse 
relating to alcohol. In addition, since dependence is the severe form of the spectrum of alcohol 
NOTE: Weights are from random effects analysis
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use disorder, individuals with alcohol dependence are therefore, more likely to acknowledge the 
problem as opposed to those with alcohol abuse. 
The strongest associations of comorbidity were found between major depression and 
substance dependence (pooled OR, 95%CI - 3.62, 2.82-4.63) and, major depression and 
substance use disorder with pooled OR (95%CI) of 2.33 (1.72-3.15). In sub-analyses, major 
depression had very strong associations with cannabis dependence (OR, 95%CI - 5.77, 3.80-
6.02), drug dependence (OR, 95%CI - 4.49, 2.93-6.87), alcohol dependence (OR, 95%CI - 3.04, 
2.29-4.03), DUD (OR, 95%CI - 2.63, 1.10-6.29) and AUD (OR, 95%CI - 2.21, 1.55-3.14).  
7.5.1 Substance use disorders with major depression 
Major depression is significantly associated with substance use disorder (Figure 7-3) and 
this association was strongest for DUD. A closer inspection of the forest plot showed only one of 
the 13 studies included in the analysis (Teesson, et al., 2010) had a non-significant association 
between substance (alcohol) use disorder and depression (95%CI 0.71-2.03). Substance 
dependence was strongly associated with depression (Figure 7-5) and the strongest association 
was found for drug dependence. Only one of 13 studies did not show this association (Chou, et 
al., 2012) confirming the robustness of this association across countries of different population 
characteristics. These findings are consistent with a previous review finding of significant 
associations of comorbid SUDs with mood disorders across countries (Lai, Cleary, Sitharthan, & 
Hunt, 2015).  
The strength of the association between major depression and substance abuse is weaker 
than that of dependence. This can be explained by the clinical differences and severity of 
substance abuse and substance dependence. Substance dependence which is defined as a cluster 
of behavioural, cognitive, and psychological phenomena is more severe and has a worse outcome 
such as comorbidity associations than substance abuse which is the harmful or hazardous use of 
substances (World Health Organization, 2018). This shows that dependence rather than abuse is 
the major driver in the association between substance use disorders and depression.  
Several mechanisms have been postulated to mediate the co-occurrence of SUD and 
major depression.  However, part of the difficulty in explaining how substance use disorders and 
depression co-occur is that the boundaries between different mood disorders and the variety of 
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substances make research and conclusions in this area quite a challenge (Canadian Centre on 
Substance Abuse, 2009). The onset of either of the disorders is also difficult to define (Canadian 
Centre on Substance Abuse, 2009). Comorbid associations of major depression and SUD are 
difficult to treat as there are several service barriers to overcome (McGovern, Xie, Segal, 
Siembab, & Drake, 2006; Mills, et al., 2012). Having both disorders affects the clinical course of 
both disorders and clinical outcomes, therefore, it is crucial to treat both conditions in an affected 
individual simultaneously (Canadian Centre on Substance Abuse, 2009) . 
7.5.2 Cannabis use disorders with major depression. 
Major depression was strongly associated with cannabis use disorders and this association 
was stronger with cannabis dependence (pooled OR 5.77). A closer inspection of the forest plot 
showed one of six studies found a reduction in the risk of comorbid associations of major 
depression and cannabis abuse (Teesson, et al., 2012). As the most frequently used controlled 
substance globally (United Nations Office on Drugs and Crime, 2016), this meta-analysis, 
confirms the findings from several studies that cannabis, especially the heavy use increases the 
risk of comorbid major depression (Arseneault, et al., 2002; Chen, Wagner, & Anthony, 2002; 
Cheung, et al., 2010; van Laar, van Dorsselaer, Monshouwer, & de Graaf, 2007; Degenhardt, 
Hall, & Lynskey, 2003; Fergusson, Horwood, & Swain-Campbell, 2002; Lynskey, et al., 2004; 
Hayatbakhsh, et al., 2007; Marmorstein & Iacono, 2011; Bovasso, 2001) and negatively affects 
the outcome of pharmacological treatment for depressive symptoms (Bricker, et al., 2007). 
The possibility of several mechanisms leading to the occurrence of comorbid cannabis 
use disorder and major depression has been proposed. First, biological effects where cannabis 
causes multiple effects in brain chemistry, thus increasing the likelihood of depression 
(Degenhardt, Hall, & Lynskey, 2003; Hayatbakhsh, et al., 2007; van Laar, van Dorsselaer, 
Monshouwer, & de Graaf, 2007; Patton, et al., 2002; Dean, Sundram, Bradbury, Scarr, & 
Copolov, 2001). It is also biologically plausible that long-term cannabinoid consumption may 
alter the responsiveness of the serotonin system in ways consistent with depression (Hill, Sun, 
Tse, & Gorzalka, 2006; Tsou, Mackie, Sanudo-Pena, & Walker, 1999; Bhagwager, Rabiner, 
Sargent, Grasby, & Cohen, 2004; Drevets, et al., 1999; Sargeant, Bruce, Florio, & Weismann, 
1990). Another mechanism is through shared vulnerability where common genetic and/or 
environmental vulnerabilities predispose some people to have impaired psychosocial adjustment 
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from which mental health problems could arise (Lynskey, et al., 2004; Degenhardt, Hall, & 
Lynskey, 2003). In addition, the adverse psychological consequences of cannabis use such as 
educational under-achievement, unemployment, and crime exacerbate this association 
(Marmorstein & Iacono, 2011; Lev-Ran, et al., 2014; Degenhardt, Hall, & Lynskey, 2003).  
The results of this meta-analysis further confirm the association between SUDs and major 
depression found in an earlier meta-analysis (Lai, Cleary, Sitharthan, & Hunt, 2015) on alcohol 
use, illicit drug use, and depression. The methods for this meta-analysis differed from Lai et al 
(2015) as we excluded studies from sub-populations within a geographic boundary such as 
community-based epidemiological studies of target cities. Nevertheless, the findings of strong 
associations between substance use disorder and major depression in two meta-analyses 
irrespective of the study question and sample definition do confirm a robust association between 
substance use disorders and major depression.  
7.5.3 Strengths and limitations 
Consistently, strong associations between SUDs and major depression were demonstrated 
by the epidemiological studies used for these analyses. The methods for individual studies were 
relatively consistent, using surveys of face-to-face interviews from random samples of general 
populations at the national level. In addition, studies included used structured diagnostic methods 
to derive the diagnosis of major depression and substance use disorders. Limitations of this study 
include interview-based diagnoses which do not allow for the eliminating of differential 
diagnoses, possibly inflating prevalence and associations. Also, such interviews do not allow for 
detailed history from the respondent nor repeated visits to confirm a diagnosis. Data combined 
were from studies across different geographic regions, cultures with varied response rates. This 
could have introduced some selection bias. Adjustment of prevalence and associations of the 
comorbidity varied across studies. While some studies adjusted for either the demographic or 
socioeconomic factors, others did both. Furthermore, different modifications of different 
versions of the Diagnostic Statistical Manual (DSM) or International Classification of Diseases 
(ICD) diagnostic criteria and the varying depth of the interviews could have contributed to the 
heterogeneity of the study. Finally, the studies did not consider polysubstance use or comorbidity 
clusters of more than two disorders (Rosenthal, Nunes, & Le Fauve, 2012). 
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7.6  Conclusion 
This systematic review of epidemiological studies spanning three decades shows that the 
comorbid association between major depression and substance use disorders is not only strong 
but highly prevalent. This study showed that individuals with substance dependence were three 
times at higher risk for comorbid depression. In light of recent legislative changes around the use 
of cannabis in Canada, the finding of this review that risks of depression increases substantially 
with heavy cannabis use is to be noted as an area of concern. 
Further reviews on prospective studies, comorbidity clusters of polysubstance use would 
be needed to understand the causal relationships and patterns better to help develop better 
preventive strategies and interventions. 
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Appendix A. Search Strategy 
MEDLINE 
1. (((((co-morbid* or comorbid* or co-occur* or diagnosis or dual diagnosis psychiatry,) 
and alcohol*) or cannabis* or marijuana* or drug* or substance* or SUD or mental 
health or mental illness or bipolar or depress* or mood disorder) and epidemiology) or 
prevalence or incidence or occurrence).mp. [mp=title, abstract, original title, name of 
substance word, subject heading word, floating sub-heading word, keyword heading 
word, protocol supplementary concept word, rare disease supplementary concept 
word, unique identifier, synonyms] 
 
  
2. limit 1 to (english language and full text and yr="1980 - 2018") 
 
CINAHL 
1. co-morbid* or comorbid* or co-occur*) OR diagnosis or dual diagnosis(psychiatry), 
AND (alcohol* or cannabis* or marijuana* or drug* or substance* or SUD) OR (mental 
health or mental illness or bipolar or depress* or mood disorder) AND (epidemiology or 
prevalence or incidence or occurrence)  
 
2. Limiters - Full Text; Abstract Available; Published Date: 19800101-20180531; English 
Language; Research Article; Exclude MEDLINE records; Human 
 
3. Search modes - Find all my search terms 
 
EMBASE 
1. (((((co-morbid* or comorbid* or co-occur* or diagnosis or dual diagnosis psychiatry,) 
and alcohol*) or cannabis* or marijuana* or drug* or substance* or SUD or mental 
health or mental illness or bipolar or depress* or mood disorder) and epidemiology) or 
prevalence or incidence or occurrence).mp. [mp=title, abstract, heading word, drug trade 
name, original title, device manufacturer, drug manufacturer, device trade name, 
keyword, floating subheading word, candidate term word] 
 
2. limit 1 to (full text and abstracts and human and Cochrane library and English language 
and yr="1980 - 2018") 
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PsychINFO 
1. (((((co-morbid* or comorbid* or co-occur* or diagnosis or dual diagnosis psychiatry,) 
and alcohol*) or cannabis* or marijuana* or drug* or substance* or SUD or mental 
health or mental illness or bipolar or depress* or mood disorder) and epidemiology) or 
prevalence or incidence or occurrence).mp. [mp=title, abstract, heading word, table of 
contents, key concepts, original title, tests & measures] 
 
2. limit 1 to (human and English language and yr="1980 - 2018" 
 
3. limit 2 to (full text and human and English language and abstracts and yr="1980 - 2018") 
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Appendix C. Assessment of studies quality 
First Author National 
Repres-
entation1 
Close 
representatio
n of target 
population2 
Random 
selection3 
Non-
response 
bias 
minimal
4 
Data 
collection 
from 
subjects5 
Case 
definition6 
Assessment 
of exposure7  
Assessme
nt of 
outcome8 
Data 
collection 
method 
the same9 
Confoundin
g control10 
TOTAL Risk of bias 
Currie, et al., 
2005 
1 1 1 1 1 1 1 1 1 1 10 Low; harmful 
alcohol use to mean 
alcohol abuse 
Swendsen, et 
al., 1998 
1 1 1 1 1 1 1 1 1 1 10 Low 
Alonso, et al., 
2007 
1 1 1 0 1 1 0 0 1 1 7 Medium: varied 
response rate across 
regions (46-79%), 
combined 
comorbidity indices  
Chou, et al., 
2012 
1 1 1 1 1 1 1 1 1 1 10 Low 
Mericle, et al., 
2012 
1 1 1 1 1 1 1 1 1 1 10 Low 
Kessler, et al., 
1996b 
1 1 1 1 1 1 1 1 1 1 10 Low 
Kessler, et al., 
2003 
1 1 1 1 1 1 1 1 1 1 10 Low 
Conway, et 
al., 2006 
1 1 1 1 1 1 1 1 1 1 10 Low 
Hasin, et al., 
2005 
1 1 1 1 1 1 1 1 1 1 10 Low 
Stinson, et al., 
2006 
1 1 1 1 1 1 1 1 1 1 10 Low 
Grant, et al., 
2015 
1 1 1 1 1 1 1 1 1 1 10 Low 
Grant, et al., 
2016 
1 1 1 1 1 1 1 1 1 1 10 Low 
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Hasin, et al., 
2016 
1 1 1 1 1 1 1 1 1 1 10 Low 
 Kandel, et al., 
2001 
1 1 1 1 1 1 1 1 1 1 10 Low 
Grant, 1995 1 1 1 1 1 1 1 1 1 1 10 Low 
Grant & 
Harford, 1995 
1 1 1 1 1 1 1 1 1 1 10 Low 
Burns & 
Tesson, 2002 
1 1 1 1 1 1 1 1 1 1 10 Low 
Teesson, et al., 
2010 
1 1 1 1 1 1 1 1 1 1 10 Low 
Teesson, et al., 
2012 
1 1 1 1 1 1 1 1 1 1 10 Low 
Farrell, et al., 
2001 
1 1 1 1 1 1 1 1 1 1 10 Low 
Boschloo, et 
al., 2011 
1 1 1 1 1 1 1 1 1 1 10 Low 
Liao, et al., 
2012 
1 1 1 1 1 1 1 1 1 1 10 Low 
Suttajit, et al., 
2012 
1 1 1 1 1 1 1 1 1 1 10 Low 
Subramaniam, 
et al., 2012 
1 1 1 1 1 1 1 1 1 1 10 Low 
External validity 
1. Was the study’s target population a close representation of the national population in relation to relevant variables, e.g. age, sex? • 1 -Yes (LOW RISK): The study’s 
target population was a close representation of the national population. • 0 - No (HIGH RISK): The study’s target population was clearly NOT representative of the 
national population. 
2. Was the sampling frame a true or close representation of the target population? • 1-Yes (LOW RISK): The sampling frame was a true or close representation of the target 
population. • 0 - No (HIGH RISK): The sampling frame was NOT a true or close representation of the target population. 
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3. Was some form of random selection used to select the sample, OR, was a census undertaken? • 1-Yes (LOW RISK): A census was undertaken, OR, some form of 
random selection was used to select the sample (e.g. simple random sampling, stratified random sampling, cluster sampling, systematic sampling). •0 - No (HIGH 
RISK): A census was NOT undertaken, AND some form of random selection was NOT used to select the sample. 
4. Was the likelihood of non-response bias minimal? • 1-Yes (LOW RISK): The response rate for the study was >/=75%, OR, an analysis was performed that showed no 
significant difference in relevant demographic characteristics between responders and non-responders • 0 - No (HIGH RISK): The response rate was < 75%, and if any 
analysis comparing responders and non-responders was done, it showed a significant difference in relevant demographic characteristics between responders and non-
responders  
Internal validity 
5. Were data collected directly from the subjects (as opposed to a proxy)? • Yes (LOW RISK): All data were collected directly from the subjects. • No (HIGH RISK): In 
some instances, data were collected from a proxy. 
6. Was an acceptable case definition used in the study? • 1 - Yes (LOW RISK): An acceptable case definition was used. • 0 - No (HIGH RISK): An acceptable case 
definition was NOT used. 
7. Assessment of exposure: use of structured clinical interview derived from structured diagnostic criteria for substance use disorders (DSM-III/IV/V, CIDI)? • 1 - Yes 
(LOW RISK) • 0 - No (HIGH RISK): questions from published health surveys/screening instruments, own system, symptoms described, no system, not specified, or 
self-reported  
8. Assessment of outcome: use of structured clinical interview derived from structured diagnostic criteria for major depression (DSM-III/IV/V, CIDI)? • 1 - Yes (LOW 
RISK) • 0 - No (HIGH RISK): questions from published health surveys/screening instruments, own system, symptoms described, no system, not specified, or self-
reported  
9. Was the same mode of data collection used for all subjects? • 1 - Yes (LOW RISK): The same mode of data collection was used for all subjects. • 0 - No (HIGH RISK): 
The same mode of data collection was NOT used for all subjects 
10. Appropriate methods to control confounding: • 1 - Yes (LOW RISK): multivariable adjusted OR including SES, education in models. • 0 - No (HIGH RISK): univariate 
analysis or controls for age/sex only. 
CIDI - Composite International Diagnostic Interview; DSM- Diagnostic Statistical Manual 
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CHAPTER 8. CONCLUSION: IMPLICATION FOR TREATMENT, 
PREVENTION, POLICY AND RESEARCH 
8.1  Recognizing the interaction between substance use disorders and mental 
health disorders 
Co-occurring substance use disorders and mental health disorders share common 
biological, psychological and social risk factors and affect one another in clinically significant 
ways. They represent a major health challenge and public health concern in Canada and globally. 
They have been recognized by the World Health Organization as one of the major causes of 
disability in most regions of the world (World Health Organization, 2004; GBD 2016 DALYs 
and HALE Collaborators, 2017). And they have been linked to increased treatment seeking, 
health care utilization and social and economic costs (Willinger, Lenzinger, Hornik, Fischer, & 
Meszaros, 2002; Wu, Kouzis, & Leaf, 1999; Hjorthoj, et al., 2015; Kuyper, Hogg, Montaner, 
Schechter, & Wood, 2004; Canadian Substance Use Costs and Harms Scientific Working Group, 
2018; Canadian Institute for Health Information, 2013; Canadian Institute for Health 
Information, 2012; O’Toole, Pollini, Gray, Bigelow, & Ford, 2007). 
An essential first step to overcoming the barrier to effective management of patients with 
comorbid disorders is the recognition of this interaction. Several patients with mental disorders 
receiving treatment in mental health centres are using drugs while a large proportion of those in 
addiction care programs have significant mental health issues for which they receive scanty 
treatment (Canadian Centre on Substance Abuse, 2009; Canadian Institute for Health 
Information, 2012; RachBeisel, Scott, & Dixon, 1999). The interplay of comorbid disorders 
results in marked stress on the at-risk populations through their reduced ability to deal with daily 
hurdles and the shame associated with having a mental disorder. These persons have tendencies 
towards engaging in crime, living on the streets, socially marginalized and committing suicides 
(Canadian Centre on Substance Abuse, 2009).  
This thesis demonstrated the strength of comorbid associations between substance use 
disorders and depression, the effect of concurrent alcohol dependence on the course of major 
depression, and the associated increased risk for suicide and disability in comorbidity. One major 
strength of this thesis is in the use of different epidemiological methods to support existing 
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literature on comorbid substance use disorders with major depression. The data sources were 
nationally representative surveys, robust and very well conducted by a renowned Canadian 
institution with expertise in data collection, Statistics Canada. The diagnosis of substance use 
disorders and major depression in all data sets were derived using structured interviews based on 
the Diagnostical and Statistical Manual of Mental  Disorders (DSM)-IV and III-R criteria, while 
the complex data structures of the surveys were accounted for with survey weights in the 
analyses. The use of multiple imputation to account for missing values in chapters 4 ad 5 were 
important strengths in those chapters. The original studies in the systematic review were based 
on nationally representative, randomly selected samples and the diagnoses of substance use 
disorders and major depression were based on structured diagnostic criteria. Using nationally 
representative high-quality original studies, the systematic review was conducted to avoid 
overestimation of associations related to patient-seeking behaviours or access to health care. 
However, there are some limitations in this thesis. There is a possibility of selection bias with 
underestimation of associations due to the exclusion of some populations in the datasets. The use 
of cross-sectional surveys in some studies did not allow for causal inference of associations. In 
the systematic review, only publications in English language were included giving the potential 
for publication bias and the studies included were highly heterogeneous due to the diverse 
population characteristics, but this was accounted for in the analysis.  
In studying the comorbid association of substance use disorders and major depression, we 
made assumptions that individuals have one SUD with major depression. While this may be true 
for some, it may not be for others. Understanding the nature, extent, and impact of polysubstance 
abuse comorbid with psychiatric illness or vice versa is necessary to manage individuals in these 
highly heterogeneous categories better. Given the significant overlap in comorbid substance use 
disorders and mental health disorders, it is crucial that co-occurring disorders are managed 
proactively and concurrently. A better understanding of these disorders and their interaction is 
essential to developing effective interventions. 
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8.2  Barriers to effective management of co-morbid mental health and 
substance use disorders 
Several practical barriers preventing effective identification and coordination of services to 
achieve holistic care exist within and between systems of care making collaborations difficult. 
Such barriers would include stigma, structural barriers, different etiological and treatment 
conceptions, professional ‘turf’ protection, lack of clear communication, lack of clarity regarding 
roles and responsibilities of various stakeholders, competition between separate services and lack 
of an existing model to follow (Froy, 2009; Marel, et al., 2016; Rosenberg & Hickie, 2013; Muir, 
et al., 2009; Canadian Centre on Substance Abuse, 2009). The stigma associated with mental 
health and addiction particularly in rural settings, poses a major barrier to treatment access 
resulting in late presentation, social marginalization, homelessness and involvement in crime.  
Referral, which is the act of referring a client to a more suitable provider beyond the skills 
and expertise of the clinician (Marsh, O'Toole, Dale, & Willis, 2013) could be a strength and a 
weakness in health service provision. Referring a patient is an ethical practice that ensures the 
appropriate needs of the patient are met (Marsh, O'Toole, Dale, & Willis, 2013);  however, the 
pitfall to this is the potential risk for patients to disappear due to difficulties navigating through 
available services (Kay-Lambkin, Baker, & Lewin, 2004). Therefore, becoming a structural 
barrier. 
Holistic care interventions such as healthy eating, cessation of other addictions (e.g., 
smoking), exercise, medication compliance, and healthy sleep patterns should be emphasized to 
overcome barriers and achieve holistic management of patients. Communication, collaborations 
and assertive follow-up are crucial, particularly with referrals, to ensure services referred to were 
provided (Marel, et al., 2016). 
8.3  A case for integrated management of concurrent disorders 
Four models have been suggested for the treatment of comorbid disorders (Marel, et al., 
2016). In the sequential treatment model, one illness is treated first, then followed by the other 
condition. The choice of which disorder to treat first is mainly dependent on which condition is 
considered primary, severe or in some cases, addiction first (Marel, et al., 2016). Patients in the 
parallel treatment model have both disorders treated simultaneously but provided independently 
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of each other by different providers and/or services. The integrated treatment model comprises 
treatment of both disorders simultaneously by the same treatment provider or service allowing 
for the exploration of the relationship between the patient’s addiction and psychiatric disorder 
(Marel, et al., 2016; Kelly & Daley, 2013; Canadian Centre on Substance Abuse, 2013b; 
Torrens, Rossi, Martinez-Riera, Martinez-Sanvisens, & Balbuena, 2012). In the stepped-care 
treatment model, there is a flexible matching of treatment intensity with case severity. Patients 
are initially started off on the least intensive and expensive treatment and stepped up to a more 
intensive or a different form of treatment, only when the treatment goal is not achieved by the 
less intensive (Marel, et al., 2016). 
Although patients in treatment programs do receive care, the care provided is typically not 
well integrated and does nothing to counteract the course and outcome of the co-occurring 
problem, or the program may also completely exclude the other disorder. Most clients are left 
with significant unmet needs and helplessness, and in some cases, the presenting problem being 
treated, may not be the primary problem (Canadian Centre on Substance Abuse, 2009; Torrens, 
Rossi, Martinez-Riera, Martinez-Sanvisens, & Balbuena, 2012; Canadian Centre on Substance 
Abuse, 2013b; Kavanagh & Mueser, 2007; Mangrum, Spence, & Lopez, 2006). 
The integrated treatment model for comorbid disorders offers superior benefits when 
compared to other treatment options (Marel, et al., 2016; Torrens, Rossi, Martinez-Riera, 
Martinez-Sanvisens, & Balbuena, 2012; Kelly & Daley, 2013; Mangrum, Spence, & Lopez, 
2006; Kavanagh & Mueser, 2007; Canadian Centre on Substance Abuse, 2013b; Drake, Mercer-
McFadden, Mueser, McHugo, & Bond, 1998). The delivery of integrated treatment by a single 
service or provider offers consistency in treatment and helps to ensure a single point of contact is 
established to build trust and avoid falling through the gaps of the system. In addition, the 
relationship between substance use disorders and mental health disorders is explored and 
communication gaps/breakdown between agencies do not interfere with treatment (Kavanagh, 
2008; Marel, et al., 2016). Even though the integrated treatment approach is appealing, there is a 
paucity of research in this area comparing different models of treatment (Australian Institute for 
Primary Care, 2009). While some evidence supports better patient outcomes with the integrated 
model of care (Donald, Dower, & Kavanagh, 2005; Kelly & Daley, 2013; Mangrum, Spence, & 
Lopez, 2006; Torrens, Rossi, Martinez-Riera, Martinez-Sanvisens, & Balbuena, 2012), some 
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support the stepped-care approach (Baker & Dawe, 2005; Baker, et al., 2005; Kay-Lambkin F. J., 
Baker, McKetin, & Lee, 2010). However, the consensus of research evidence and clinical 
expertise is that the treatment of comorbid substance use and mental health disorders is 
insufficient if they are solely psychiatric focused or addiction focused (Kavanagh & Mueser, 
2007; Canadian Centre on Substance Abuse, 2013b; Kelly & Daley, 2013; Torrens, Rossi, 
Martinez-Riera, Martinez-Sanvisens, & Balbuena, 2012). 
In Canada, the existing management systems of addiction and mental health are largely 
independent irrespective of the setting and as such, the trainings, clinical guidelines and 
accreditation standards are separate.  (hospitals, correctional facilities or community health 
services) (Canadian Centre on Substance Abuse, 2009; Canadian Centre on Substance Abuse, 
2013b). The present treatment model is to treat addiction and mental disorders as isolated entities 
even when it is recognized that the most complicated patients with worse outcomes are those 
with co-occurring disorders (Fairbairn, Kerr, Li, Montaner, & Wood, 2007; Fulkerson, Harrison, 
& Beebe, 1999). Due to its fragmented mode of delivery developed to treat either the addiction 
or mental health issue solely as the primary focus, the system is not well prepared to manage 
both disorders concurrently leading to worse patient outcomes (Canadian Centre on Substance 
Abuse, 2009). Education, clinical guidelines and standards for addiction and mental health need 
to be integrated for better outcomes in the treatment and care of patients with comorbid 
disorders.  
8.4  Prevention of comorbid substance use and mental health disorders: A Life 
Course Perspective 
Evidence suggests a developmental course in the onset of comorbid disorders (Canadian 
Centre on Substance Abuse, 2009; Brière, Rohde, Seeley, & Daniel Klein, 2014; Burcusa & 
Iacono, 2007; Lubman, Cheetham, & Yucel, 2015); therefore, the importance of early 
recognition and prevention cannot be ignored. Comorbid disorders have been implicated to have 
common vulnerability factors, i.e. genetic and environmental determinants (Agrawal & Lynskey, 
2014; Kendler, Prescott, Myers, & Neale, 2003; Burcusa & Iacono, 2007; Degenhardt, Hall, & 
Lynskey, 2003a; Lynskey, et al., 2004). Early identification of vulnerable populations could 
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potentially, avert the future emergence of a full-blown concurrent disorder (Canadian Centre on 
Substance Abuse, 2009).  
A life course approach to the prevention of comorbid mental health and substance use 
disorders with a special focus on the developmental stages is recommended. A life course 
approach incorporates, ‘the fetal origins hypothesis’ which links intrauterine exposure and 
conditions to later development of adult chronic disease (Barker, 1998), parenting, infancy, 
childhood, adolescence, and adulthood to aging in prevention efforts. Previous studies suggest 
that the crucial stages of growth when environmental exposures do the most harm to health with 
long-term health consequences are in-utero, early infancy, childhood, and adolescence (Ben-
Shlomo & Kuh, 2002; World Health Organization and International Longevity Centre-UK, 
2000). In addition, in childhood and adolescence are critical developmental phases when 
important cognitive and psychosocial skills are easily obtained (World Health Organization and 
International Longevity Centre-UK, 2000; Ben-Shlomo & Kuh, 2002). Life course trajectories 
with consequences for health in adulthood are greatly impacted by the development of these 
skills and abilities (World Health Organization and International Longevity Centre-UK, 2000).  
Adult health and disease risk are shaped by the socio-economic conditions through-out life 
because, health-damaging exposures, health-enhancing opportunities and individual’s response 
to either are socioeconomically determined (Ben-Shlomo & Kuh, 2002; Kuh & Ben-Shlomo, 
1997). A life course perspective in the prevention of comorbid SUD with major depression helps 
to identify the times of intervention that would be effective and the chains of risk that can be 
broken (World Health Organization and International Longevity Centre-UK, 2000).  
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